<doc>
  <docmeta id="113s959rs">
    <bill congress="113" type="s" number="959" version="rs"/>
    <revision size="308122" annotations="0" status="complete" id="10" commit-time="2014-03-04T23:33:24Z" committer="mbohmer" doc="113s959rs/10.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Reported-in-Senate" dms-id="A1" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 S959 RS: Pharmaceutical Quality, Security, and Accountability Act</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. Senate</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-15</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<calendar>Calendar No. 89</calendar>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 959</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130515">May 15, 2013</action-date>
			<action-desc>
        <sponsor name-id="S172">Mr. Harkin</sponsor> (for himself,
			 <cosponsor name-id="S289">Mr. Alexander</cosponsor>, <cosponsor name-id="S260">Mr. Roberts</cosponsor>, <cosponsor name-id="S332">Mr.
			 Franken</cosponsor>, <cosponsor name-id="S182">Ms. Mikulski</cosponsor>, and
			 <cosponsor name-id="S366">Ms. Warren</cosponsor>) introduced the following
			 bill; which was read twice and referred to the
			 <committee-name added-display-style="italic" committee-id="SSHR00" deleted-display-style="strikethrough">Committee on Health, Education, Labor,
			 and Pensions</committee-name>
      </action-desc>
		</action>
		<action stage="Reported-in-Senate">
			<action-date>June 19, 2013</action-date>
			<action-desc>Reported by <sponsor name-id="S172">Mr. Harkin</sponsor>,
			 with an amendment and an amendment to the title</action-desc>
			<action-instruction>Strike out all after the enacting clause and insert
			 the part printed in italic</action-instruction>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act with
		  respect to compounding drugs.</official-title>
	</form>
	<legis-body>
		<section changed="deleted" committee-id="SSHR00" id="S1" reported-display-style="strikethrough" section-type="section-one">
      <enum>1.</enum>
      <header>Short title; references in
			 Act</header>
			<subsection id="id8ACC258572204D83A85EA1849E53718F">
        <enum>(a)</enum>
        <header>Short
			 title</header>
        <text display-inline="yes-display-inline">This Act may be cited
			 as the <quote>
            <short-title>Pharmaceutical Compounding
			 Quality and Accountability Act</short-title>
          </quote>.</text>
			</subsection>
      <subsection id="id21541D659B854E34B45AF7A32A158413">
        <enum>(b)</enum>
        <header>References in
			 Act</header>
        <text>Except as otherwise specified, amendments made by this Act to
			 a section or other provision of law are amendments to such section or other
			 provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et
			 seq.).</text>
			</subsection>
    </section>
    <section changed="deleted" committee-id="SSHR00" id="id7E19EFA14F4B4868A468C60F026D1740" reported-display-style="strikethrough">
      <enum>2.</enum>
      <header>Regulation of
			 human and animal drug compounding</header>
			<subsection id="id3721FE4A11DE4BC59EDB730C55A347BC">
        <enum>(a)</enum>
        <header>Clarification of
			 new drug and new animal drug status</header>
        <text>For purposes of the Federal
			 Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>), the terms <quote>new
			 drug</quote> (as defined in section 201(p) of such Act) and <quote>new animal
			 drug</quote> (as defined in section 201(v) of such Act) shall include a
			 compounded human drug and a compounded animal drug, respectively.</text>
			</subsection>
      <subsection id="idA9E0FBDB0FBB4DF4A49C2AF54628A533">
        <enum>(b)</enum>
        <header>Regulation of
			 human and animal drug compounding</header>
        <text>Section 503A (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">21 U.S.C. 353a</external-xref>)
			 is amended to read as follows:</text>
				<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="idB47FC16A0245444EA736D7F23B24F1D1" reported-display-style="strikethrough" style="OLC">
					<section id="idE07EB9835DF84C7DAFCF5DC95A117686">
            <enum>503A.</enum>
            <header>Human and
				animal drug compounding</header>
						<subsection id="id124AC6E0C1C04219970442F4C28E98BA">
              <enum>(a)</enum>
              <header>Scope</header>
							<paragraph id="id69BD248E560D4070A2A7680A26813ADE">
                <enum>(1)</enum>
                <header>Compounding</header>
                <text>In
				this section, the terms <term>compounding</term> and
				<term>compound</term>—</text>
								<subparagraph id="idCF793E06B2BE4B3FB31A2D7C6526E526">
                  <enum>(A)</enum>
                  <text>include—</text>
									<clause id="id743AE1FA4C0E42198D7740AC4F2EA2C9">
                    <enum>(i)</enum>
                    <text>the combining,
				admixing, mixing, diluting, reconstituting, or otherwise altering of a marketed
				drug;</text>
									</clause>
                  <clause id="id2CD6F08226F44A0D82CC25E137729990">
                    <enum>(ii)</enum>
                    <text>compounding a
				drug from a bulk drug substance; and</text>
									</clause>
                  <clause id="idA522786264244150859106801D9745FD">
                    <enum>(iii)</enum>
                    <text>repackaging, as
				defined in subsection (b)(5); and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id79E6A4A9124843DEA4E25E62C77D6431">
                  <enum>(B)</enum>
                  <text>exclude mixing,
				reconstituting, or other such acts with respect to a marketed drug that are
				limited to and performed solely in accordance with specific directions for such
				acts contained in approved labeling provided by a drug’s manufacturer, when
				performed upon receipt of a prescription order for an identified individual
				patient.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idDB8DF24CECA14CB1B6558BD84C478822">
                <enum>(2)</enum>
                <header>Dispensing not a
				sale</header>
                <text>In this section, the terms <term>sell</term> or
				<term>resale</term> do not include dispensing to patients, or, in the case of
				animal drugs, to the individual responsible for providing care for the animal
				for which the drug is intended, in accordance with State law, including any fee
				associated with such dispensing.</text>
							</paragraph>
              <paragraph id="idF0ACB41105174CA2B39439C192726FCE">
                <enum>(3)</enum>
                <header>Exemptions</header>
                <text>This
				section shall not apply to—</text>
								<subparagraph id="id677477944B45431999200DB6EE0EFD30">
                  <enum>(A)</enum>
                  <text>medical
				gases;</text>
								</subparagraph>
                <subparagraph id="id4BDBC6F85E404AC08AE5DEB6ED190072">
                  <enum>(B)</enum>
                  <text>animal drugs that
				are subject to regulation as biological products by the Secretary of
				Agriculture under the Act commonly known as the Virus-Serum-Toxin Act;
				or</text>
								</subparagraph>
                <subparagraph id="id3D59E4A42AEB4A058EFF0FA7D542035F">
                  <enum>(C)</enum>
                  <text>human blood and
				blood components for transfusion.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="idDD20BCCAB9664E798DBF7C6632E7F85B">
              <enum>(b)</enum>
              <header>Definitions</header>
              <text>In
				this section:</text>
							<paragraph commented="no" id="id997D23D17191491D89FBFDEC74806287">
                <enum>(1)</enum>
                <header>Compounding
				manufacturer</header>
								<subparagraph commented="no" id="idDDE1701134694C26B76AA2D207CCF86E">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The term <term>compounding manufacturer</term> means a
				facility at one geographic location or address—</text>
									<clause commented="no" id="id6C27B5F97EEE46FD8EEC39A3F21C52DD">
                    <enum>(i)</enum>
                    <text>that compounds any
				sterile drug product without receiving a prescription order for such sterile
				drug product prior to beginning compounding, and distributes or offers to sell
				such compounded sterile drug product in interstate commerce; or</text>
									</clause>
                  <clause commented="no" id="idAB3BAAAA0F7448589213D2825F1A1354">
                    <enum>(ii)</enum>
                    <text>that repackages
				any preservative-free sterile drug product or pools any sterile drug products,
				except as provided in paragraph (7)(B).</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="idAF7B050D7E88489E91892A734C70EB43">
                  <enum>(B)</enum>
                  <header>Excluded
				activities</header>
                  <text>Notwithstanding subparagraph (A)(ii), a facility shall
				not be considered a compounding manufacturer if such facility—</text>
									<clause commented="no" id="id6D8DB87DFE854CB68F6870419C69C15A">
                    <enum>(i)</enum>
                    <text>repackages drugs
				in accordance with section 506F or the final guidance described in section
				506F(d); and</text>
									</clause>
                  <clause commented="no" id="idD9F9FE13577B4CA89808ED5695E9C45A">
                    <enum>(ii)</enum>
                    <text>does not
				otherwise meet the definition of compounding manufacturer under subparagraph
				(A).</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" id="id623299A87E57435B8DEA7B4F245D4D6E">
                <enum>(2)</enum>
                <header>Pooling;
				pools</header>
                <text>The terms <term>pooling</term> and
				<term>pool</term>—</text>
								<subparagraph commented="no" id="id6B2CBCE2FA774D859D9D198AA977298E">
                  <enum>(A)</enum>
                  <text>mean taking a
				single drug approved under section 505 or 512, conditionally approved under
				section 571, included on the index established under section 572(a)(1), or
				licensed under section 351 of the Public Health Service Act from the container
				in which it is distributed by the original manufacturer and combining it with
				the same drug from one or more other containers without or before further
				manipulating the product (such as by diluting it or mixing it with another,
				different drug or drugs);</text>
								</subparagraph>
                <subparagraph commented="no" id="idFC156E6EDE9C43D282048AAFAB965A0B">
                  <enum>(B)</enum>
                  <text>do not include
				combining the drug from two or more separate containers of the same drug when a
				single container of the drug is not sufficient to prepare a single dose for
				administration to an individual patient; and</text>
								</subparagraph>
                <subparagraph commented="no" id="idAA22CDC4EC61454F939C294463A5D191">
                  <enum>(C)</enum>
                  <text>do not include
				combining the drug from two or more separate containers of component products
				of a total parenteral nutrition product, if such pooling, and labeling and use
				of the finished total parenteral nutrition product, comply with State pharmacy
				law.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="id9A507F19BC7144BBBFD05655FCB5E324">
                <enum>(3)</enum>
                <header>Practitioner</header>
                <text>The
				term <term>practitioner</term> includes a physician, veterinarian, or any other
				person that is authorized to prescribe medication under State law.</text>
							</paragraph>
              <paragraph commented="no" id="id1E27EC8457A64DB2B5D1FD1BE3D0BD0A">
                <enum>(4)</enum>
                <header>Prescription;
				prescription order</header>
                <text>The term <term>prescription</term> or
				<term>prescription order</term> means a prescription or prescription order, as
				defined under applicable State law, that complies with requirements applicable
				under such State law.</text>
							</paragraph>
              <paragraph commented="no" id="id21CDB1BA3A8E4F0B8E1CE97AF20459DF">
                <enum>(5)</enum>
                <header>Repackage or
				repackaging</header>
                <text>The term <term>repackage</term> or
				<term>repackaging</term> means taking a drug approved under section 505 or 512,
				conditionally approved under section 571, included on the index established
				under section 572(a)(1), or licensed under section 351 of the Public Health
				Service Act from the container in which it is distributed by the original
				manufacturer and placing it in a different container of the same or smaller
				size without further manipulating the drug (such as by diluting it or mixing it
				with another, different drug or drugs), unless such repackaging is done
				pursuant to a prescription for an identified individual patient.</text>
							</paragraph>
              <paragraph commented="no" id="idCE32000E5D2A4E67A229ACB28ADCE88D">
                <enum>(6)</enum>
                <header>Sterile drug
				product</header>
                <text>The term <term>sterile drug product</term> means a drug
				that is—</text>
								<subparagraph commented="no" id="id2A1A2FFA331B46CBABF4D482B1C297DF">
                  <enum>(A)</enum>
                  <text>intended for
				parenteral administration;</text>
								</subparagraph>
                <subparagraph commented="no" id="idE3172D2848704D31ACA8D2A1E19EA6DF">
                  <enum>(B)</enum>
                  <text>an ophthalmic or
				inhalation drug; or</text>
								</subparagraph>
                <subparagraph commented="no" id="id7419382B9DB64E7CB7B47E497D128C67">
                  <enum>(C)</enum>
                  <text>required to be
				sterile under Federal or State law.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="id410980F3625745EC9972151B917D822F">
                <enum>(7)</enum>
                <header>Traditional
				compounder</header>
								<subparagraph commented="no" id="id3B9501FEA4BB4724AAA3964C932A65E2">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The term <term>traditional compounder</term> means an
				entity—</text>
									<clause id="idfbb004eb9ee14dc29877477b50f3ee6b">
                    <enum>(i)</enum>
                    <text>wherein a drug is
				compounded by—</text>
										<subclause id="idf578b68c17e44a4cb168aae084dbff2b">
                      <enum>(I)</enum>
                      <text>a licensed
				pharmacist, or other pharmacy personnel (to the extent permitted under State
				law), in a State-licensed pharmacy or a Federal facility; or</text>
										</subclause>
                    <subclause id="idc7f9d6b19ed341aeaf87cedf5ac3c9fb">
                      <enum>(II)</enum>
                      <text>a licensed
				physician or licensed veterinarian, to the extent permitted under State
				law;</text>
										</subclause>
                  </clause>
                  <clause id="id72e1ac26cc6244108fb41bf5d84491e7">
                    <enum>(ii)</enum>
                    <text>that—</text>
										<subclause id="idF74B050AC47A4F679665A2245371C6AB">
                      <enum>(I)</enum>
                      <text>compounds a drug
				upon receipt of a prescription order for an identified individual patient;
				or</text>
										</subclause>
                    <subclause commented="no" id="id0922AEE1A8CF4215BE241F78F6DE9B31">
                      <enum>(II)</enum>
                      <text>compounds a drug
				in limited quantities before receipt of a prescription order for an identified
				individual patient, to the extent permitted under State law, if such
				compounding is based on a history of the licensed pharmacist, licensed
				physician, or licensed veterinarian receiving prescription orders for the
				compounding of the drug, which orders have been generated solely within an
				established relationship between the licensed pharmacist, licensed physician,
				or licensed veterinarian and—</text>
											<item commented="no" id="id7B6A562DF5E145A984E0C67A4EABC6D4">
                        <enum>(aa)</enum>
                        <text>such individual
				patient for whom the prescription order will be provided, or, in the case of an
				animal drug, such individual responsible for providing care for the animal for
				which the drug is ordered; or</text>
											</item>
                      <item id="idDF65B5F40E7F4160A479610C15A860F0">
                        <enum>(bb)</enum>
                        <text>the licensed
				physician, licensed veterinarian, or other licensed practitioner who will write
				such prescription order; and</text>
											</item>
                    </subclause>
                  </clause>
                  <clause commented="no" id="idd1bc3823bd5349409d0b0cfe12b07c31">
                    <enum>(iii)</enum>
                    <text>that does not
				meet the definition of a compounding manufacturer under paragraph (1).</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="id4fb5a2b0e8d64003991312ef5c0dba59">
                  <enum>(B)</enum>
                  <header>Exceptions</header>
									<clause commented="no" id="id89348358A8F7472CB12861EC80C931CE">
                    <enum>(i)</enum>
                    <header>Hospitals and
				health systems</header>
										<subclause commented="no" id="id9A9E7AC43A8C42CDA7BB07607861BD83">
                      <enum>(I)</enum>
                      <header>In
				general</header>
                      <text>A pharmacy within a hospital, veterinary hospital, or
				health system that compounds a drug and dispenses such drug (which may include
				interstate shipment) within such hospital or health system or ships such drug
				for dispensing to patients with an established relationship with the hospital
				or health system (which may include interstate shipment), or that repackages
				preservative-free sterile drug product or pools sterile drug products, shall be
				considered a traditional compounder if such pharmacy otherwise meets the
				definition under subparagraph (A).</text>
										</subclause>
                    <subclause commented="no" id="idC873139368D648A191D90864BA539C83">
                      <enum>(II)</enum>
                      <header>Health system
				defined</header>
                      <text>For purposes of this subparagraph, the term <term>health
				system</term> means two or more hospitals or veterinary hospitals that are
				owned and operated by the same entity and that share access to databases with
				drug order information for patients or animals, as applicable. A health system
				includes both the inpatient and outpatient facilities of hospitals within the
				health system.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="id4254BC5B2EB944BC9E494758DE8B7E11">
                    <enum>(ii)</enum>
                    <header>PET and
				radiopharmaceuticals</header>
                    <text>A pharmacy that compounds positron emission
				tomography drugs or radiopharmaceuticals shall be considered a traditional
				compounder if it does not compound other drugs that would cause it to be a
				compounding manufacturer described in paragraph (1)(A).</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="id68E8D19962D245109458F8997CCEADAB">
              <enum>(c)</enum>
              <header>Exemptions from
				certain requirements</header>
							<paragraph id="idD5C461E3CF364B4FA82EEEA954D5CE0E">
                <enum>(1)</enum>
                <header>Drugs compounded
				by traditional compounders</header>
                <text>
                  Sections 501(a)(2)(B),
				502(f)(1), 505 (in the case of a human drug), section 512 (in the case of an
				animal drug), and section 351 of the Public Health Service Act (in the case of
				a biological product) shall not apply to a compounded drug if such drug—</text>
								<subparagraph id="idAFE6CF4A1E854AB08A028FDBDEC7CBF9">
                  <enum>(A)</enum>
                  <text>is compounded by a
				traditional compounder that is in compliance with this section; and</text>
								</subparagraph>
                <subparagraph id="id93126E8B6795458996584A7EC608C561">
                  <enum>(B)</enum>
                  <text>meets the
				requirements of this section applicable to drugs compounded by traditional
				compounders.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id2C92B90EEF024CE694E5F0E8AB8B934B">
                <enum>(2)</enum>
                <header>Drugs compounded
				by compounding manufacturers</header>
                <text>
                  Sections 502(f)(1), 505
				(in the case of a human drug), section 512 (in the case of an animal drug), and
				section 351 of the Public Health Service Act (in the case of a biological
				product) shall not apply to a compounded prescription drug if such drug—</text>
								<subparagraph id="id9A4FD255941449C88F9C2D7F2CF75685">
                  <enum>(A)</enum>
                  <text>is compounded by a
				compounding manufacturer—</text>
									<clause id="id4287B01B938B4B3094779C200B1BCD45">
                    <enum>(i)</enum>
                    <text>that is not
				licensed as a pharmacy in any State; and</text>
									</clause>
                  <clause id="idFF97E921A2494C9D9D7ECAB12246A1C9">
                    <enum>(ii)</enum>
                    <text>that is in
				compliance with this section; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id876394A169354A2BB99BCC233B6CB079">
                  <enum>(B)</enum>
                  <text>meets the
				requirements of this section applicable to drugs compounded by compounding
				manufacturers.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="id9D65C932308C4CA1A4DAE9CED5164DDD">
              <enum>(d)</enum>
              <header>Drugs that may
				not be compounded</header>
							<paragraph id="id9BAE43418C2041569D9B65180E2D8ED1">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>The following drugs may not be compounded, except under
				conditions specified by the Secretary:</text>
								<subparagraph id="id683580DDC0B746479134E18F294DE5FE">
                  <enum>(A)</enum>
                  <header>Drugs that are
				demonstrably difficult to compound</header>
                  <text>A drug or category of drugs
				that presents demonstrable difficulties for compounding, which may include a
				complex dosage form or biological product, as designated by the Secretary
				pursuant to paragraph (2).</text>
								</subparagraph>
                <subparagraph id="id42958634B4D8402C9295EEB6A18290F9">
                  <enum>(B)</enum>
                  <header>Marketed
				drugs</header>
                  <text>A drug, other than a biological product, that is a copy of
				a marketed drug approved under 505 or 512, conditionally approved under section
				571, or included on the index established under section 572(a)(1), except as
				provided in paragraph (3).</text>
								</subparagraph>
                <subparagraph id="idC888A8C0E6114B4C836C49FE65180E1F">
                  <enum>(C)</enum>
                  <header>Biological
				products</header>
                  <text>A drug that is a biological product, except as provided
				in paragraph (4).</text>
								</subparagraph>
                <subparagraph commented="no" id="ID4D0BE8B4A67348F5A3C1B494894DFDB7">
                  <enum>(D)</enum>
                  <header>Drugs removed
				for safety and efficacy</header>
                  <text>A drug that appears on a list published
				by the Secretary in the Federal Register of drugs that have been withdrawn or
				removed from the market because such drug or components of such drug have been
				found to be unsafe or not effective, subject to paragraph (5).</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="idB80B609678C84FF58C631D50C00C9092">
                <enum>(2)</enum>
                <header>Drugs that are
				demonstrably difficult to compound</header>
								<subparagraph commented="no" id="id108691FE8F4B4B638FEF8C42FB4C0BB5">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The Secretary may promulgate a regulation that designates
				drugs or categories of drugs that are demonstrably difficult to compound that
				may not be compounded, or that may be compounded only under conditions
				specified by the Secretary. Such regulation—</text>
									<clause commented="no" id="idD4E81B03C4BE4C709A42E3B096EFB256">
                    <enum>(i)</enum>
                    <text>may include the
				designation of drugs or categories of drugs that are complex dosage forms or
				biological products, such as extended release products, metered dose inhalers,
				transdermal patches, and sterile liposomal products; and</text>
									</clause>
                  <clause commented="no" id="id8C0EDC081E6E483FB8BC7D0B798A115A">
                    <enum>(ii)</enum>
                    <text>shall specify,
				for each drug included on the list, whether the prohibition or condition
				applies to the use of the drug in humans, animals, or both.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="id884A5FC134954D8381624206B78E550C">
                  <enum>(B)</enum>
                  <header>Interim
				list</header>
									<clause commented="no" id="idDBAA2EAA2749495195AA75DBA6DB6833">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Before the effective date of the regulation promulgated
				under subparagraph (A), the Secretary may designate drugs that are complex
				dosage forms or biological products that cannot be compounded by—</text>
										<subclause commented="no" id="id3F0ECA26028B42EEA4DD3ED993479558">
                      <enum>(I)</enum>
                      <text>publishing a
				notice of such drugs proposed for designation, including the rationale for such
				designation, in the Federal Register;</text>
										</subclause>
                    <subclause commented="no" id="idEC67BA0BFA74424ABC8EDF1684DD438A">
                      <enum>(II)</enum>
                      <text>providing a
				period of not less than 60 days for comment on the notice; and</text>
										</subclause>
                    <subclause commented="no" id="idEED32EC05C2D45259957852FBBBE330F">
                      <enum>(III)</enum>
                      <text>publishing a
				notice in the Federal Register designating the drugs that are complex dosage
				forms and biological products that cannot be compounded.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="id4AB88029E0A94DF6897B85CBE6478F90">
                    <enum>(ii)</enum>
                    <header>Sunset</header>
                    <text>Any
				notice provided under clause (i) shall cease to have force or effect on the
				date that is 5 years after the date of enactment of the
				<short-title>Pharmaceutical Compounding Quality and
				Accountability Act</short-title> or on the effective date of the final
				regulation under subparagraph (A), whichever is earlier.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" id="idAE5F6C00E48644F6AF3D98B7DC3034CB">
                <enum>(3)</enum>
                <header>Exceptions
				regarding marketed drugs</header>
								<subparagraph commented="no" id="id1435EC34580D4AA79D435DB4E6E3CA18">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>A drug (other than a biological product) that is a copy
				of a marketed drug approved under 505 or 512, conditionally approved under
				section 571, or included on the index established under section 572(a)(1),
				including variations of such drug compounded from bulk substances, may be
				compounded only if—</text>
									<clause commented="no" id="id481F27E7F74145ED9732CA16C2E3069B">
                    <enum>(i)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="idBC4050AD48EA4A99AD05B7BE5481B076">
                      <enum>(I)</enum>
                      <text>the compounded
				variation produces for the patient a clinical difference between the compounded
				drug and such marketed drug, as determined by the prescribing practitioner,
				and, prior to beginning compounding a variation of such drug, the facility
				compounding the variation receives a prescription order specifying that the
				variation may be compounded; or</text>
										</subclause>
                    <subclause changed="deleted" commented="no" committee-id="SSHR00" id="idA5585ADD81B9464E8DC17B3B2A50D6D5" indent="up1" reported-display-style="strikethrough">
                      <enum>(II)</enum>
                      <item commented="no" display-inline="yes-display-inline" id="idDA7D6A8A77A04D5391073F9EDAE633AE">
                        <enum>(aa)</enum>
                        <text>such marketed drug, at
				the time of compounding a copy of such drug and at the time of distribution of
				the compounded drug, is on the drug shortage list under section 506E (in the
				case of a human drug), on the Current Drug Shortages list for veterinary
				products maintained on the Internet Web site of the Food and Drug
				Administration (in the case of an animal drug), or in the Secretary’s sole
				discretion, has otherwise been identified by the Secretary as in shortage such
				as in a specific region or on a drug shortage list maintained by a private
				party; and</text>
											</item>
                      <item changed="deleted" commented="no" committee-id="SSHR00" id="idCBCA5C0C21904F548F02972A8B4CA9C1" indent="up1" reported-display-style="strikethrough">
                        <enum>(bb)</enum>
                        <text>the traditional compounder or the
				compounding manufacturer notifies the Secretary not later than 3 calendar days
				after beginning the compounding, unless the Secretary waives the notice
				requirement; and</text>
											</item>
                    </subclause>
                  </clause>
                  <clause commented="no" id="idC78F9D091AA04B5EA408C799FF79D653">
                    <enum>(ii)</enum>
                    <text>in the case of a
				marketed drug approved under section 505 that is subject to a risk evaluation
				and mitigation strategy approved with elements to assure safe use pursuant to
				section 505–1, the entity compounding the drug demonstrates to the Secretary
				that the entity will utilize controls that are comparable to the controls
				applicable under the relevant risk evaluation and mitigation strategy.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="idC9CE09412EC446449DE4AC47C5FECC91">
                  <enum>(B)</enum>
                  <header>Exclusion</header>
                  <text>For
				purposes of this paragraph, repackaging a marketed drug approved under section
				505, 512, conditionally approved under section 571, or included on the index
				established under section 572(a)(1), does not make the repackaged drug a copy
				of such marketed drug.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="idD1CEF9DC91C844BC9ACA915D926723E4">
                <enum>(4)</enum>
                <header>Exceptions
				regarding biological products</header>
                <text>A drug that is a biological product
				may be compounded only if—</text>
								<subparagraph id="id2A859AB582984865A8F33131508CBB0E">
                  <enum>(A)</enum>
                  <text>such drug is
				compounded from a licensed biological product and the compounding does not
				involve combining or mixing the licensed biological product with—</text>
									<clause id="id3C591B4C264C425DAC97D914AB727286">
                    <enum>(i)</enum>
                    <text>a bulk drug
				substance; or</text>
									</clause>
                  <clause id="idA7F5A1287AD04E7DAF054323B2341831">
                    <enum>(ii)</enum>
                    <text>another,
				different drug or drugs approved under 505 or 512, conditionally approved under
				section 571, included on the index established under section 572(a)(1), or
				licensed under section 351 of the Public Health Service Act, unless the
				compounding is limited to the combining, mixing, or diluting of licensed
				allergenic products; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id86A28F6A8F054D1E906D7A2950ED88BD">
                  <enum>(B)</enum>
                  <clause commented="no" display-inline="yes-display-inline" id="id5A8EC86B74A74A318890D21DB356524B">
                    <enum>(i)</enum>
                    <text>with respect to a
				traditional compounder, the compounded biological product produces for the
				patient a clinical difference between the compounded drug and the licensed
				biological product, as determined by the prescribing practitioner, and, prior
				to beginning compounding such drug, the facility compounding the variation
				receives a prescription order specifying that the biological product may be
				compounded;</text>
									</clause>
                  <clause changed="deleted" committee-id="SSHR00" id="id74F93AC177524B08AC8CE4FC00E8F06A" indent="up1" reported-display-style="strikethrough">
                    <enum>(ii)</enum>
                    <text>with respect to a
				compounding manufacturer, the compounded variation biological product produces
				for the patient a clinical difference between the compounded drug and the
				licensed biological product, as determined by a licensed practitioner
				responsible for the patient’s care in a health care entity that provides
				medical services through licensed prescribers directly to patients, and, prior
				to beginning compounding such drug, the compounding manufacturer receives a
				duly authorized medical order from a hospital or health system specifying that
				the biological product may be compounded; or</text>
									</clause>
                  <clause changed="deleted" committee-id="SSHR00" id="id96F80EB163844D9DB6740CA1C6E171FE" indent="up1" reported-display-style="strikethrough">
                    <enum>(iii)</enum>
                    <text>the compounded
				biological product is an allergenic product.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" id="id1E712E3DB5BC4E65B65A6DE69E770416">
                <enum>(5)</enum>
                <header>Requirement
				regarding drugs removed for safety or efficacy</header>
                <text>The list published
				by the Secretary in the Federal Register of drugs that have been withdrawn or
				removed from the market, as described in paragraph (1)(D), shall specify
				whether a human drug on such list may, notwithstanding the inclusion on such
				list, be compounded for use in animals. The Secretary shall update the lists
				described in subparagraphs (D) and (E) of subsection (e)(2), as appropriate, to
				conform with the list described in paragraph (1)(D).</text>
							</paragraph>
            </subsection>
            <subsection id="idA26C9E119AB94D0E9C4EF67BEF7A6D47">
              <enum>(e)</enum>
              <header>Quality of drug
				ingredients</header>
							<paragraph id="idA3C6AB0C1CA54DA3BEB491EDDDD3B666">
                <enum>(1)</enum>
                <header>Human
				drugs</header>
                <text>A traditional compounder or a compounding manufacturer
				shall—</text>
								<subparagraph id="ID9C11ECEE5FA74D05A77BAAAEA173503E">
                  <enum>(A)</enum>
                  <text>compound a human
				drug using only bulk drug substances (as defined in regulations of the
				Secretary published at <external-xref legal-doc="usc" parsable-cite="usc/21/207">section 207.3(a)(4)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulations))—</text>
									<clause id="IDF12B697D3B224CCBA5BEF3D5BE77E849">
                    <enum>(i)</enum>
                    <text>that—</text>
										<subclause id="IDE6DB70F8D2A54DC1952C2CDBBA04AF4A">
                      <enum>(I)</enum>
                      <text>comply with the
				standards of an applicable United States Pharmacopoeia or National Formulary
				monograph, if a monograph exists and has not been identified under paragraph
				(6), and the United States Pharmacopoeia chapters on pharmacy
				compounding;</text>
										</subclause>
                    <subclause id="ID1EBD4FC4F6EF429AA3F850E0891BB835">
                      <enum>(II)</enum>
                      <text>if such a
				monograph does not exist, are drug substances that are components of drugs
				approved by the Secretary; or</text>
										</subclause>
                    <subclause id="IDFF52C6DC676C4B57A3258D1CFF2A40F8">
                      <enum>(III)</enum>
                      <text>if such a
				monograph does not exist and the drug substance is not a component of a drug
				approved by the Secretary, that appear on a list developed by the Secretary
				through regulations issued by the Secretary;</text>
										</subclause>
                  </clause>
                  <clause id="IDA448CA33D2F74776B6E3669191AB75F5">
                    <enum>(ii)</enum>
                    <text>that are
				manufactured by an establishment that is registered under section 510
				(including a foreign establishment that is registered under section 510(i));
				and</text>
									</clause>
                  <clause id="ID4305EDCEBF7244C0885A94C2253A43EA">
                    <enum>(iii)</enum>
                    <text>that are
				accompanied by valid certificates of analysis for each specific lot of bulk
				drug substance; and</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="IDA7E2C87F84C7458B92DF996A79E56BCE">
                  <enum>(B)</enum>
                  <text>use ingredients
				(other than bulk drug substances) that comply with the standards of an
				applicable United States Pharmacopoeia or National Formulary monograph, if a
				monograph exists and has not been identified under paragraph (6), and with the
				United States Pharmacopoeia chapter on pharmacy compounding.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="id62D837E76DF74F37864249856A72A773">
                <enum>(2)</enum>
                <header>Animal
				drugs</header>
                <text>A traditional compounder or a compounding manufacturer
				shall—</text>
								<subparagraph id="ide98f91f0616f40bcac33fe596184c29e">
                  <enum>(A)</enum>
                  <text>compound an animal
				drug using only bulk drug substances (as defined in regulations of the
				Secretary published at <external-xref legal-doc="usc" parsable-cite="usc/21/207">section 207.3(a)(4)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulations)) that—</text>
									<clause id="id5e47029fde46483395e9bde38852695d">
                    <enum>(i)</enum>
                    <text>are manufactured
				by an establishment that is registered under section 510 (including a foreign
				establishment that is registered under section 510(i)); and</text>
									</clause>
                  <clause id="idbb3e48471d20427d94a0e9af96fefbb6">
                    <enum>(ii)</enum>
                    <text>are accompanied
				by valid certificates of analysis for each specific lot of bulk drug
				substance;</text>
									</clause>
                </subparagraph>
                <subparagraph id="idA7F55762CD6D44D19C91579496485B85">
                  <enum>(B)</enum>
                  <text>use ingredients
				(other than bulk drug substances) that comply with the standards of an
				applicable United States Pharmacopoeia or National Formulary monograph, if a
				monograph exists and has not been identified under paragraph (6), and with the
				United States Pharmacopoeia chapters on pharmacy compounding;</text>
								</subparagraph>
                <subparagraph id="id7627130DE7A04EF5B9669617BB4EEC67">
                  <enum>(C)</enum>
                  <text>in the case of a
				compounded animal drug for use in non-food-producing minor species, use bulk
				substances that—</text>
									<clause id="idbc72f4ddd9ae497e8eac1cc6faba8d2c">
                    <enum>(i)</enum>
                    <text>comply with the
				standards of an applicable United States Pharmacopoeia or National Formulary
				monograph, if a monograph exists and has not been identified under paragraph
				(6), and with the United States Pharmacopoeia chapters on pharmacy
				compounding;</text>
									</clause>
                  <clause id="id44b69f6dc5ba49a08d5bcecdb00cbdcd">
                    <enum>(ii)</enum>
                    <text>if such a
				monograph does not exist, are drug substances that are components of drugs
				approved by the Secretary; or</text>
									</clause>
                  <clause id="id10227604a6e34c768e005a8dc8521eee">
                    <enum>(iii)</enum>
                    <text>if such a
				monograph does not exist and the drug substance is not a component of a drug
				approved by the Secretary, that appear on a list developed by the Secretary
				through regulations issued by the Secretary;</text>
									</clause>
                </subparagraph>
                <subparagraph id="idA3E265515E3E4430B6C2AF2A8534FF0B">
                  <enum>(D)</enum>
                  <text>in the case of a
				compounded animal drug for use in non-food-producing major species, beginning
				on the date of publication of the list established in accordance with paragraph
				(3)(A), shall use bulk substances that are included on such list, subject to
				paragraph (3)(C); and</text>
								</subparagraph>
                <subparagraph id="id7D5ECD0B44E546DFBEC16F5684AEAD70">
                  <enum>(E)</enum>
                  <text>in the case of a
				compounded animal drug for use in food-producing major and minor species, shall
				use bulk substances that are included on a list established by the Secretary of
				bulk substances acceptable for use in compounding a drug for one or more such
				species, in accordance with paragraph (4).</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id673AA966C9BF4178B96C4BDE470F64BF">
                <enum>(3)</enum>
                <header>Non-food-producing
				major species listing procedure</header>
								<subparagraph id="id004D2BC59D9844C98CC8B27705FCD8A5">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Not later than 30 days after the effective date of the
				<short-title>Pharmaceutical Compounding Quality and
				Accountability Act</short-title>, the Secretary shall establish a list of bulk
				substances acceptable for compounding a drug for use in non-food-producing
				major species, and any conditions applicable to such use, and may also identify
				bulk substances that the Secretary has determined not acceptable for
				compounding with respect to a drug for use in such species.</text>
								</subparagraph>
                <subparagraph id="id7F9E5FD1328D43F3857518F907299572">
                  <enum>(B)</enum>
                  <header>Procedure</header>
                  <text>In
				developing and updating the list under subparagraph (A), the Secretary
				shall—</text>
									<clause id="idd12c0692831a4c50a37301967fc92f57">
                    <enum>(i)</enum>
                    <text>publish a notice
				in the Federal Register identifying bulk substances proposed as acceptable and
				any bulk substance determine to be unacceptable, and the rationale for such
				proposed designations;</text>
									</clause>
                  <clause id="id44af568875364a04a4b47e785f8a588b">
                    <enum>(ii)</enum>
                    <text>provide a period
				of not less than 30 days for comment on the notice; and</text>
									</clause>
                  <clause id="idad200469d99a40ea929c39c041b17f6a">
                    <enum>(iii)</enum>
                    <text>publish a notice
				in the Federal Register designating the bulk substances acceptable, and any
				bulk substances determined to be unacceptable, and the rationale for such
				designations and determinations.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id622C237CC1C74E51AB1A95F4183B7E3F">
                  <enum>(C)</enum>
                  <header>Notification</header>
                  <text>Upon
				initial publication of the list under subparagraph (B)(iii), any traditional
				compounder or compounding manufacturer that has received and filled a
				prescription in the 60 days prior to such publication for a compounded drug for
				a non-food-producing major species from a bulk substance not addressed in the
				notice (either as acceptable or unacceptable), and that reasonably expect to
				receive and fill another prescription for such a drug for such species within
				60 days after such publication, may notify the Secretary of such bulk substance
				within 30 days of such publication, in a manner to be determined by the
				Secretary and published in the Federal Register on or before publication of the
				list under subparagraph (B)(iii). A traditional compounder or compounding
				manufacturer that provides such notice shall not be subject to the restriction
				in paragraph (2)(D) until such time as the Secretary designates such bulk
				substance as acceptable or determines it to be unacceptable pursuant to the
				process described in subparagraph (B)(iii).</text>
								</subparagraph>
                <subparagraph id="id4DE045D882034AB78D3FA14A8A43C5DB">
                  <enum>(D)</enum>
                  <header>Modification of
				list</header>
                  <text>The Secretary may amend the list at any time, in accordance
				with process described in subparagraph (B).</text>
								</subparagraph>
                <subparagraph id="idDBDE253FC8EC413D87062F90BC8F8900">
                  <enum>(E)</enum>
                  <header>Criteria</header>
                  <text>In
				evaluating bulk substances for purposes of subparagraph (B), the Secretary
				shall consider, among other factors—</text>
									<clause id="idF11E00CC063543EFA45AF5E0E1E29753">
                    <enum>(i)</enum>
                    <text>the safety of the
				bulk substance;</text>
									</clause>
                  <clause id="idF041EFC729D04D29B6228C51720B58BD">
                    <enum>(ii)</enum>
                    <text>historical use of
				the substance in pharmacy compounding;</text>
									</clause>
                  <clause id="id8FEB07A930924B1782608F7334DE464C">
                    <enum>(iii)</enum>
                    <text>evidence of the
				effectiveness of the bulk substance or lack of effectiveness;</text>
									</clause>
                  <clause id="idC88B6BD87AB24B829C906E5A64B2B46F">
                    <enum>(iv)</enum>
                    <text>whether any drug
				approved under section 505 or 512, conditionally approved under section 571, or
				included on the index established under section 572(a)(1), can be used on
				label, or any drug approved under section 505 or 512 can be used in an
				extralabel manner in accordance with section paragraphs (4) and (5) of section
				512(a), to treat the applicable condition in the identified species; and</text>
									</clause>
                  <clause id="idF8DDA96C109042E6BEECCB640FB72059">
                    <enum>(v)</enum>
                    <text>whether a
				compounded drug appropriate to treat the applicable condition in the identified
				species could be obtained by manipulating a drug approved under 505 or 512,
				conditionally approved under section 571, or included on the index established
				under section 572(a)(1).</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="id18519C3B3CBB40ECA5017CC7DC8FB05C">
                <enum>(4)</enum>
                <header>Food-producing
				animals listing procedure</header>
                <text>In establishing a list of designated
				bulk substances acceptable for use in compounding a drug for use in
				food-producing major and minor species under paragraph (2), and any conditions
				applicable to such use, the Secretary shall—</text>
								<subparagraph id="idb45c14775a4c4b6e8a44217c2f3281f2">
                  <enum>(A)</enum>
                  <text>publish a notice
				in the Federal Register identifying bulk substances proposed as acceptable and
				any bulk substance determine to be unacceptable, and the rationale for such
				designations;</text>
								</subparagraph>
                <subparagraph id="idbae007c8dd8f4136a816e0ced5e7015e">
                  <enum>(B)</enum>
                  <text>provide a period
				of not less than 30 days for comment on the notice; and</text>
								</subparagraph>
                <subparagraph id="id699a226e70714e8ba780994437cf0464">
                  <enum>(C)</enum>
                  <text>publish a notice
				in the Federal Register designating the bulk substances acceptable for use in
				compounding a drug for use in food-producing major and minor species, and the
				rationale for such designations.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id5311468C28574984811043E6FE21D981">
                <enum>(5)</enum>
                <header>Withdrawal
				periods</header>
                <text>The requirements for establishing substantially extended
				withdrawal periods in accordance with <external-xref legal-doc="usc" parsable-cite="usc/21/530">section 530.20</external-xref> of title 21, Code of
				Federal Regulations (or any successor regulations) shall apply to compounded
				animal drugs for use in food-producing animals that are compounded using bulk
				substances.</text>
							</paragraph>
              <paragraph id="idC87C9E923A764B03B72468AF698F91A0">
                <enum>(6)</enum>
                <header>Identification
				by Secretary</header>
								<subparagraph id="idA27167AA14C344389AAA91A445F0E19E">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Notwithstanding the existence of an applicable monograph
				under subparagraph (A)(i)(I) or (B) of paragraph (1) or subparagraph (B) or
				(C)(i) of paragraph (2), the Secretary may identify bulk substances that the
				Secretary determines, based on public health concerns, may not be used in
				compounding a drug.</text>
								</subparagraph>
                <subparagraph id="id4ECF80E150574AFE82373EAE986918E8">
                  <enum>(B)</enum>
                  <header>Procedure</header>
                  <text>In
				identifying the bulk substances that may not be used in compounding, the
				Secretary shall—</text>
									<clause commented="no" id="id4F4212AF65034BB0ABE1A10C7FB4AD36">
                    <enum>(i)</enum>
                    <text>publish a notice
				of such bulk substances proposed for identification in the Federal
				Register;</text>
									</clause>
                  <clause commented="no" id="idC6F3633DF918423CB0628ED6B990E737">
                    <enum>(ii)</enum>
                    <text>provide a period
				of not less than 60 days for comment on the notice;</text>
									</clause>
                  <clause commented="no" id="id771C4790F4684DB1988022FBB5E8AD05">
                    <enum>(iii)</enum>
                    <text>publish a notice
				in the Federal Register identifying the bulk substances that may not be used in
				compounding a drug; and</text>
									</clause>
                  <clause commented="no" id="id08A3C0901DF4453498566126140B5AA3">
                    <enum>(iv)</enum>
                    <text>state whether the
				bulk is not suitable for compounding of human drugs, animal drugs, or
				both.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="id833A2EC3FBFE468B8D50C90196E09D5E">
              <enum>(f)</enum>
              <header>Requirements
				regarding wholesaling and labeling applicable to traditional compounders and
				compounding manufacturers</header>
							<paragraph id="id8667B99A4DA343CEA0421944645963DD">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>A compounded drug—</text>
								<subparagraph id="id9F80D551B3A9442CAF67B62CDF7A5B60">
                  <enum>(A)</enum>
                  <text>may not be sold by
				an entity other than the compounding manufacturer or traditional compounder
				that compounded the drug;</text>
								</subparagraph>
                <subparagraph id="id1454cdb6d39d480c880ae4f5aaae5834">
                  <enum>(B)</enum>
                  <text>compounded by a
				compounding manufacturer may not be sold to an entity other than a health care
				entity that provides medical services through licensed prescribers directly to
				patients or animals, or a network of such providers, except that a compounding
				manufacturer may transfer without profit a compounded sterile drug to a
				licensed pharmacy if—</text>
									<clause id="id32ED1352EB75411FB553D462098CC8C8">
                    <enum>(i)</enum>
                    <text>the licensed
				pharmacy falls under the same corporate ownership as the compounding
				manufacturer;</text>
									</clause>
                  <clause id="id7611569AED0E4920B40A1786D70876CC">
                    <enum>(ii)</enum>
                    <text>the transfer of
				such compounded sterile drug is solely for the purpose of dispensing the
				compounded sterile drug to the end user, who has been instructed by the
				prescribing physician to self-administer such compounded sterile drug;</text>
									</clause>
                  <clause id="idBE87C394F3DE4C9BBC4698CD7F3B54F2">
                    <enum>(iii)</enum>
                    <text>as of the date
				of enactment of the <short-title>Pharmaceutical
				Compounding Quality and Accountability Act</short-title>, the compounding
				manufacturer is an entity that provides pharmacy benefits management services
				on behalf of a health benefits plan;</text>
									</clause>
                  <clause id="ide819637ff124446ab94e9f5b32db9405">
                    <enum>(iv)</enum>
                    <text>the compounding
				manufacturer identifies itself to the Secretary upon registering under
				subsection (g)(2) as an entity that qualifies for the exemption under this
				subparagraph, and provides documentation of the compounding of such drugs as of
				the date of enactment of the <short-title>Pharmaceutical
				Compounding Quality and Accountability Act</short-title>, in a manner described
				by the Secretary; and</text>
									</clause>
                  <clause id="id35a232a12b4042a8ba02f85b53dc5a5e">
                    <enum>(v)</enum>
                    <text>the compounding
				manufacturer receives confirmation from the Secretary that the compounding
				manufacturer qualifies for the exemption under this subparagraph and the
				sterile drug or drugs for which the exemption applies; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id007EBD3399A5440F8659169170BC4216">
                  <enum>(C)</enum>
                  <text>in the case of a
				compounded drug sold to a health care entity described in subparagraph (B),
				shall be labeled <quote>not for resale</quote>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id72B54F427E5B4FF690CCA027A388E2DE">
                <enum>(2)</enum>
                <header>Advertising and
				promotion</header>
                <text>The advertising and promotion of compounded drugs shall
				not be false or misleading in any particular.</text>
							</paragraph>
            </subsection>
            <subsection id="idA1CF6C69CC38432C8CE3FB744EF3A80B">
              <enum>(g)</enum>
              <header>Other
				requirements applicable to compounding manufacturers</header>
							<paragraph id="idC2C2F2F332384A32B1F3F961DCA27047">
                <enum>(1)</enum>
                <header>Licensed
				pharmacist oversight</header>
                <text>A compounding manufacturer shall ensure that
				a pharmacist licensed in the State where the compounding manufacturer is
				located exercises direct supervision over the operations of the compounding
				manufacturer.</text>
							</paragraph>
              <paragraph id="id66BFC03B77664C5BA2C3C84B37514540">
                <enum>(2)</enum>
                <header>Registration of
				compounding manufacturers and reporting of drugs</header>
								<subparagraph id="id421F01E533DE4C6495C4A8BB825D3957">
                  <enum>(A)</enum>
                  <header>Registration of
				compounding manufacturers</header>
									<clause id="id55D2A2BD15664785B3156A02208583E0">
                    <enum>(i)</enum>
                    <header>Annual
				registration</header>
                    <text>During the period beginning on October 1 and ending
				on December 31 each year, each compounding manufacturer shall register with the
				Secretary its name, place of business, and unique facility identifier (which
				shall conform to the requirements for the unique facility identifier
				established under section 510), and a point of contact e-mail address.</text>
									</clause>
                  <clause id="id4D1E5A1E60F84FCC9BB2069CA196916D">
                    <enum>(ii)</enum>
                    <header>New compounding
				manufacturers</header>
                    <text>Each compounding manufacturer, upon first engaging
				in the operations described in subsection (b)(1), shall immediately register
				with the Secretary and provide the information described under clause (i). The
				Secretary shall establish a timeline for registration for the first year
				following the effective date of the <short-title>Pharmaceutical Compounding Quality and Accountability
				Act</short-title>. In no case may registration be required until at least 60
				days following publication of the timeline in the Federal Register.</text>
									</clause>
                  <clause id="idF12E4B8D32A34B56ADDA893692F47877">
                    <enum>(iii)</enum>
                    <header>Additional
				facilities</header>
                    <text>Each compounding manufacturer duly registered in
				accordance with clauses (i) and (ii) shall immediately identify to the
				Secretary any additional facility that engages in the activities described in
				subsection (b)(1) and that is owned or operated in any State by the person that
				owns or operates the compounding manufacturer.</text>
									</clause>
                  <clause id="idE6108384DC254E90AF11B6F2A04A5B9E">
                    <enum>(iv)</enum>
                    <header>Availability of
				registration for inspection</header>
                    <text>The Secretary shall make available
				for inspection, to any person so requesting, any registration filed pursuant to
				this subparagraph, except that any drug reporting information submitted
				pursuant to this subparagraph and the information accompanying such reporting
				shall be exempt from such inspection, unless the Secretary finds that such an
				exemption would be inconsistent with the protection of the public
				health.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id2BDD2002550E4AEF8E20F578EBCFD917">
                  <enum>(B)</enum>
                  <header>Drug reporting
				by compounding manufacturers</header>
									<clause id="id79D78C95B30443CD97CCF7889C7A1704">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Each com­pound­ing manufacturer who registers with the
				Secretary under subparagraph (A) shall submit to the Secretary, once during the
				month of June of each year and once during the month of December of each year,
				a report—</text>
										<subclause id="id4E491B24598F408F97A107C169C65C20">
                      <enum>(I)</enum>
                      <text>identifying the
				drugs compounded by such compounding manufacturer during the previous 6-month
				period; and</text>
										</subclause>
                    <subclause id="id9E178B7CEB35439B8523C2F5EDF28D60">
                      <enum>(II)</enum>
                      <text>with respect to
				each drug identified under subclause (I), providing the active ingredient, the
				source of such active ingredient, the National Drug Code number of the source
				drug or bulk active ingredient, the strength of the active ingredient per unit,
				the dosage form and route of administration, the package description, the
				number of individual units produced, the National Drug Code number of the final
				product, and which conforms to other applicable requirements identified by the
				Secretary in accordance with clause (ii).</text>
										</subclause>
                  </clause>
                  <clause id="idF983F6DC1A4241C998F39FCDE54F619C">
                    <enum>(ii)</enum>
                    <header>Form</header>
                    <text>Each
				report under clause (i) shall be prepared in such form and manner as the
				Secretary may prescribe by regulation or guidance.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id76AA4E93AED944B88336D10189BE2A80">
                  <enum>(C)</enum>
                  <header>Electronic
				registration and reporting</header>
                  <text>Registrations and drug reporting under
				this paragraph (including the submission of updated information) shall be
				submitted to the Secretary by electronic means unless the Secretary grants a
				request for waiver of such requirement because use of electronic means is not
				reasonable for the person requesting waiver.</text>
								</subparagraph>
                <subparagraph id="id1A157CED2E5E4E738F515EB1065B7CE0">
                  <enum>(D)</enum>
                  <header>Risk-based
				inspection frequency</header>
									<clause id="id6A6A6D7936F44888910435CA0A2AB587">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Compounding manufacturers shall be subject to inspection
				pursuant to section 704.</text>
									</clause>
                  <clause id="id95FC98A78AD34CCBAF3BE86B12A0DB0B">
                    <enum>(ii)</enum>
                    <header>Risk-based
				schedule</header>
                    <text>The Secretary, acting through one or more officers or
				employees duly designated by the Secretary, shall inspect compounding
				manufacturers described in clause (i) in accordance with a risk-based schedule
				established by the Secretary.</text>
									</clause>
                  <clause id="id0A044EC7F35A42B8B438B9F7F2950F87">
                    <enum>(iii)</enum>
                    <header>Risk
				factors</header>
                    <text>In establishing the risk-based schedule under clause
				(ii), the Secretary shall inspect compounding manufacturers according to the
				known safety risks of such compounding manufacturers, which shall be based on
				the following factors:</text>
										<subclause id="iddf7ad7d8bca24352a6c54bda15d6b340">
                      <enum>(I)</enum>
                      <text>The compliance
				history of the compounding manufacturer.</text>
										</subclause>
                    <subclause id="id669be2a27d274711abde0fd3d7fa5925">
                      <enum>(II)</enum>
                      <text>The record,
				history, and nature of recalls linked to the compounding manufacturer.</text>
										</subclause>
                    <subclause id="ideee744146b644e7faf6bf099a7f18545">
                      <enum>(III)</enum>
                      <text>The inherent
				risk of the drug compounded at the compounding manufacturer.</text>
										</subclause>
                    <subclause id="id5333a41d04664e27bcc45d90140e353b">
                      <enum>(IV)</enum>
                      <text>The inspection
				frequency and history of the compounding manufacturer, including whether the
				compounding manufacturer has been inspected pursuant to section 704 within the
				last 4 years.</text>
										</subclause>
                    <subclause id="idfff4cdba7e524939a1f5515718d1a032">
                      <enum>(V)</enum>
                      <text>Any other criteria
				deemed necessary and appropriate by the Secretary for purposes of allocating
				inspection resources.</text>
										</subclause>
                  </clause>
                </subparagraph>
              </paragraph>
              <paragraph id="id9537AC2124CD44C99DE9A3E16EF9CD9B">
                <enum>(3)</enum>
                <header>Adverse event
				reporting</header>
								<subparagraph id="idB9E1BC71ACC04D8BB89AC89AF587F7A2">
                  <enum>(A)</enum>
                  <header>Definitions</header>
                  <text>In
				this paragraph:</text>
									<clause id="idD6C72C0E69244B5C80B2ADA097A5ACD2">
                    <enum>(i)</enum>
                    <header>Adverse
				event</header>
                    <text>The term <term>adverse event</term> means any
				health-related event associated with the use of a compounded drug that is
				adverse, including—</text>
										<subclause id="idBDF4A3435B704D018BED4DD4D018DF82">
                      <enum>(I)</enum>
                      <text>an event occurring
				in the course of the use of the drug in professional practice;</text>
										</subclause>
                    <subclause id="idF1290E15DB084AF0958FDE6E547CAF28">
                      <enum>(II)</enum>
                      <text>an event
				occurring from an overdose of the drug, whether accidental or
				intentional;</text>
										</subclause>
                    <subclause id="idB5E137513FF845BA83B442E3D90E7B3F">
                      <enum>(III)</enum>
                      <text>an event
				occurring from abuse of the drug;</text>
										</subclause>
                    <subclause id="id0EDE3AE2211F45C7A4DEA30C4744231F">
                      <enum>(IV)</enum>
                      <text>an event
				occurring from withdrawal of the drug; and</text>
										</subclause>
                    <subclause id="id6CB54B1422254B769A931A8B0C53B3AF">
                      <enum>(V)</enum>
                      <text>any failure of
				expected pharmacological action of the drug.</text>
										</subclause>
                  </clause>
                  <clause id="id709065EB47584C41AE8C186A1A0B2E1F">
                    <enum>(ii)</enum>
                    <header>Serious adverse
				event</header>
                    <text>The term <term>serious adverse event</term> means an
				adverse event that—</text>
										<subclause id="idC27D838102D545148AA12428BFCDDE59">
                      <enum>(I)</enum>
                      <text>results in—</text>
											<item id="id707F247BC508464498B73C16CBEF99C7">
                        <enum>(aa)</enum>
                        <text>death;</text>
											</item>
                      <item id="id67D5890F9EE440FF94259B5DBAA8D596">
                        <enum>(bb)</enum>
                        <text>an adverse drug
				event that places the patient at immediate risk of death from the adverse drug
				event as it occurred (not including an adverse drug event that might have
				caused death had it occurred in a more severe form);</text>
											</item>
                      <item id="idFD5AA951FD1549E090DF2ECF24838530">
                        <enum>(cc)</enum>
                        <text>inpatient
				hospitalization or prolongation of existing hospitalization;</text>
											</item>
                      <item id="id7502DCE8F78647CE973914EE20D4A85A">
                        <enum>(dd)</enum>
                        <text>a persistent or
				significant incapacity or substantial disruption of the ability to conduct
				normal life functions; or</text>
											</item>
                      <item id="id7BF02EF5275841AABC502E9BC101331C">
                        <enum>(ee)</enum>
                        <text>a congenital
				anomaly or birth defect; or</text>
											</item>
                    </subclause>
                    <subclause id="id9A4C9B9A971046D0B70BE7F59BF3E854">
                      <enum>(II)</enum>
                      <text>based on
				appropriate medical judgment, may jeopardize the patient and may require a
				medical or surgical intervention to prevent an outcome described in subclause
				(I).</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="id0C33697C3DA74047B5F12E0E1AA3FC13">
                  <enum>(B)</enum>
                  <header>Reports</header>
									<clause id="id67869B18A5034A44A677FC89C2B0C6CF">
                    <enum>(i)</enum>
                    <header>Adverse event
				reporting requirement</header>
										<subclause id="idA887D231F05345EC90B0D51406572265">
                      <enum>(I)</enum>
                      <header>15-day
				report</header>
                      <text>If a compounding manufacturer becomes aware of any serious
				adverse event, such manufacturer shall submit reports of each instance to the
				Secretary as soon as practicable, but in no case later than 15 calendar days
				after the initial receipt of the applicable information. Such manufacturer
				shall investigate and submit to the Secretary followup reports for each such
				instance not later than 15 calendar days after receipt of new information or as
				requested by the Secretary. Unless and until the Secretary establishes the
				content and format of adverse event reports by guidance or regulation, reports
				shall be submitted in accordance with the content and format requirements under
				<external-xref legal-doc="regulation" parsable-cite="cfr/21/310.305">section 310.305</external-xref> of title 21, Code of Federal Regulations (or any successor
				regulations) (in the case of human drugs), <external-xref legal-doc="usc" parsable-cite="usc/21/600">section 600.80</external-xref> of title 21, Code of
				Federal Regulations (or any successor regulations) (in the case of biological
				products), or <external-xref legal-doc="regulation" parsable-cite="cfr/21/514.80">section 514.80</external-xref> of title 21, Code of Federal Regulations (or any
				successor regulations) (in the case of animal drugs).</text>
										</subclause>
                    <subclause id="id9B633185565A4948A6368D616B7887C3">
                      <enum>(II)</enum>
                      <header>Annual
				report</header>
                      <text>Compounding manufacturers that report serious adverse
				events shall submit in December of each year a narrative summary of any
				analysis of each report submitted under subclause (I), including a history of
				actions taken during the year because of each report, using the content,
				format, and manner established by the Secretary by guidance or regulation.
				Until such time as the Secretary publishes such guidance or regulation, each
				compounding manufacturer shall retain such summaries as part of the records to
				be maintained in accordance with subparagraph (C).</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="id6D321165B54A4077BDFA7E5A6604A8C6">
                    <enum>(ii)</enum>
                    <header>Product quality
				reporting requirement</header>
                    <text>Not later than 3 calendar days after the
				compounding manufacturer becomes aware of information pertaining to sterility,
				stability, or other product quality concerns that could result in serious
				adverse events, the compounding manufacturer shall submit to the Secretary a
				product quality report, in a form and manner established by the Secretary by
				guidance or regulation.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id44536B0037694181B0485E6C23AB0067">
                  <enum>(C)</enum>
                  <header>Maintenance of
				records</header>
                  <text>A compounding manufacturer shall maintain for a period of
				10 years records of all serious adverse drug events known to the compound
				manufacturer in accordance with <external-xref legal-doc="usc" parsable-cite="usc/21/314">section 314.80(i)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulation), or as otherwise directed by the
				Secretary in regulations.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id0AA77FC0E39444BAB5F72E640E31C6A5">
                <enum>(4)</enum>
                <header>Labeling of
				drugs</header>
								<subparagraph id="id4160257BA70E4DB09C183EB7536E8BD5">
                  <enum>(A)</enum>
                  <header>Label</header>
                  <text>The
				label of a drug compounded by a compounding manufacturer shall include—</text>
									<clause id="idF9E7F797F950465EB7274D7887D5F8E3">
                    <enum>(i)</enum>
                    <text>the statement
				<quote>This is a compounded drug.</quote> or a reasonable comparable
				alternative statement (as specified by the Secretary) that identifies the drug
				as a compounded drug;</text>
									</clause>
                  <clause id="idEB7899A57B684FA79D17102976B10755">
                    <enum>(ii)</enum>
                    <text>the name,
				address, and phone number of the applicable compounding manufacturer;
				and</text>
									</clause>
                  <clause id="idDA79C079705C49D680CB5D5A73939C49">
                    <enum>(iii)</enum>
                    <text>with respect to
				the compounded drug—</text>
										<subclause id="id62F76063D1DC4B87B46BD6271B486168">
                      <enum>(I)</enum>
                      <text>the lot or batch
				number;</text>
										</subclause>
                    <subclause id="idC016A9A56CF541FCAADB648774474679">
                      <enum>(II)</enum>
                      <text>the established
				name of the medication;</text>
										</subclause>
                    <subclause id="idD549A01C9C7D4090B1928597960B4E53">
                      <enum>(III)</enum>
                      <text>the dosage form
				and strength;</text>
										</subclause>
                    <subclause id="id35006F734B9A4EFE993F5315480589B6">
                      <enum>(IV)</enum>
                      <text>the statement of
				quantity or volume, as appropriate;</text>
										</subclause>
                    <subclause commented="no" id="idF155FE2DFFC943C8A890E6AECF0A334C">
                      <enum>(V)</enum>
                      <text>in the case of a
				drug intended for use in a food-producing animal, the withdrawal period
				established pursuant to subsection (e)(5) to ensure that no residues from the
				compounded drug can be detected in edible tissues of the treated animal;</text>
										</subclause>
                    <subclause id="id9A4E22B47FF24DA58509C5A3AC0C3043">
                      <enum>(VI)</enum>
                      <text>the date that the
				drug was compounded;</text>
										</subclause>
                    <subclause id="idBA6A6BA1F5224E48BA527F9C9FA10EB3">
                      <enum>(VII)</enum>
                      <text>the expiration
				date;</text>
										</subclause>
                    <subclause id="id00ED99928063475198FD493712A63AD0">
                      <enum>(VIII)</enum>
                      <text>storage and
				handling instructions;</text>
										</subclause>
                    <subclause id="id89912486FA3E4795AC229EC8799C8346">
                      <enum>(IX)</enum>
                      <text>the National Drug
				Code number, if available;</text>
										</subclause>
                    <subclause id="id16D3AEFC29F849E9910F7BFC4F8F6706">
                      <enum>(X)</enum>
                      <text>the <quote>not
				for resale</quote> statement required as required by subsection (f)(1)(C);
				and</text>
										</subclause>
                    <subclause id="id4A5481B063E242438C52367809D2F800">
                      <enum>(XI)</enum>
                      <text>subject to
				subparagraph (B)(i), a list of active and inactive ingredients, identified by
				established name and the quantity or proportion of each ingredient.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="idBF9D24476221410DB739170EA4A20223">
                  <enum>(B)</enum>
                  <header>Container</header>
                  <text>The
				container from which the individual units of a drug compounded by a compounding
				manufacturer are removed for dispensing or for administration (such as a
				plastic bag containing individual product syringes) shall include—</text>
									<clause id="id1D3436D0D1964BAEBD418037FA980897">
                    <enum>(i)</enum>
                    <text>the information
				described under subparagraph (A)(iii)(XI), if there is not space on the label
				for such information;</text>
									</clause>
                  <clause id="idF2AD1B75764C47BA8843EF9FF7C35F09">
                    <enum>(ii)</enum>
                    <text>the following
				information to facilitate adverse event reporting: www.fda.gov/medwatch and
				1–800–FDA–1088; and</text>
									</clause>
                  <clause id="id402E5EEB89C74CD9BE1FD41ACA0510BD">
                    <enum>(iii)</enum>
                    <text>the directions
				for use, including dosage and administration, as appropriate.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id2E2F356AB737472DADCF85AC0772A43B">
                  <enum>(C)</enum>
                  <header>Additional
				information</header>
                  <text>The label and labeling of a drug compounded by a
				compounding manufacturer shall include any other information as determined
				necessary and specified in regulations promulgated by the Secretary.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="idD8FB9353725F4B0CAF2CD7C4B706210C">
              <enum>(h)</enum>
              <header>Compounding
				manufacturer establishment and reinspection fees</header>
							<paragraph id="idFBE027F0B55B435B8358609AD0D8B6F1">
                <enum>(1)</enum>
                <header>Definitions</header>
                <text>In
				this subsection—</text>
								<subparagraph id="id0E812543AC0C4B628D41944F106355F2">
                  <enum>(A)</enum>
                  <text>the term
				<term>affiliate</term> has the meaning given such term in section
				735(11);</text>
								</subparagraph>
                <subparagraph id="id05593E120B514D3EAB554172E2A92A80">
                  <enum>(B)</enum>
                  <text>the term
				<term>gross annual sales</term> means the total worldwide gross annual sales,
				in United States dollars, for a compounding manufacturer, including the sales
				of all the affiliates of the compounding manufacturer; and</text>
								</subparagraph>
                <subparagraph id="id1BBD8AD567AE484A8660B9D434340031">
                  <enum>(C)</enum>
                  <text>the term
				<term>reinspection</term> means, with respect to a compounding manufacturer,
				one or more inspections conducted under section 704 subsequent to an inspection
				conducted under such provision which identified noncompliance materially
				related to an applicable requirement of this Act, specifically to determine
				whether compliance has been achieved to the Secretary's satisfaction.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id0AC78BF864B945B4B9A7296026CE7BF1">
                <enum>(2)</enum>
                <header>Establishment
				and reinspection fees</header>
                <text>For fiscal year 2015 and each subsequent
				fiscal year, the Secretary shall, in accordance with this subsection, assess
				and collect—</text>
								<subparagraph id="idD0B43E623D4F4E5DA9978793DFCB5966">
                  <enum>(A)</enum>
                  <text>an annual
				establishment fee from each compounding manufacturer to cover
				inspection-related costs relating to inspections of drug compounders for such
				year; and</text>
								</subparagraph>
                <subparagraph id="id9EDA004698854CF885E6476F8590800E">
                  <enum>(B)</enum>
                  <text>a reinspection fee
				from each compounding manufacturer subject to a reinspection in such fiscal
				year.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id6719D59CBC3643459A8CDBCA43374558">
                <enum>(3)</enum>
                <header>Establishment
				and reinspection fee setting</header>
                <text>The Secretary shall establish the
				establishment and reinspection fee to be collected under this subsection for
				each fiscal year, based on the methodology described in paragraph (4) and shall
				publish such fee in a Federal Register notice not later than 60 days before the
				start of each such year.</text>
							</paragraph>
              <paragraph id="id1054C35293E94A20A55797AD35A5B63E">
                <enum>(4)</enum>
                <header>Amount of
				establishment and reinspection fee</header>
								<subparagraph id="idC23EA184F02D4C9EA1EE4FCBAF700759">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Except as provided in subparagraph (D), the amount of the
				annual establishment fee and the reinspection fee (if applicable) under
				paragraph (2) for each compounding manufacturer in a fiscal year shall be equal
				to the sum of—</text>
									<clause id="idD20AB76C5BC04657BE997C28041CF09F">
                    <enum>(i)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="id1C21232DACE6477BBC689ECFEB746A81">
                      <enum>(I)</enum>
                      <text>$15,000 per compounding
				manufacturer, multiplied by</text>
										</subclause>
                    <subclause changed="deleted" committee-id="SSHR00" id="id5DABEF08D4EF48C0A72803614A4D5FF3" indent="up1" reported-display-style="strikethrough">
                      <enum>(II)</enum>
                      <text>the inflation adjustment factor
				described in subparagraph (B); plus</text>
										</subclause>
                  </clause>
                  <clause id="id188D198538E946DFA112125CA3D09F50">
                    <enum>(ii)</enum>
                    <text>the small
				business adjustment factor described in subparagraph (C).</text>
									</clause>
                </subparagraph>
                <subparagraph id="idDE58CF307A464477992F58B17836C296">
                  <enum>(B)</enum>
                  <header>Inflation
				adjustment factor</header>
									<clause id="ID6E333A3737EA4C18B5D81B506A2CD4E5">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>For fiscal year 2015 and subsequent fiscal years, the
				revenues established in subparagraph (A) shall be adjusted by the Secretary by
				notice, published in the Federal Register, for a fiscal year by the amount
				equal to the sum of—</text>
										<subclause id="ID86599264058A44F785C46FEAB22F3EFA">
                      <enum>(I)</enum>
                      <text>one;</text>
										</subclause>
                    <subclause id="ID71524C26EF4E4DAFB92C29E93D94BDC6">
                      <enum>(II)</enum>
                      <text>the average
				annual percent change in the cost, per full-time equivalent position of the
				Food and Drug Administration, of all personnel compensation and benefits paid
				with respect to such positions for the first 3 years of the preceding 4 fiscal
				years, multiplied by the proportion of personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the Food
				and Drug Administration for the first 3 years of the preceding 4 fiscal years,
				and</text>
										</subclause>
                    <subclause id="IDA60B05E9F00446FCA95561C70192E769">
                      <enum>(III)</enum>
                      <text>the average
				annual percent change that occurred in the Consumer Price Index for urban
				consumers (U.S. City Average; Not Seasonally Adjusted; All items; Annual Index)
				for the first 3 years of the preceding 4 years of available data multiplied by
				the proportion of all costs other than personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the Food
				and Drug Administration for the first 3 years of the preceding 4 fiscal
				years.</text>
										</subclause>
                  </clause>
                  <clause id="ID8C4991E0CD3042B693EB4CACB0D9E9B6">
                    <enum>(ii)</enum>
                    <header>Compounded
				basis</header>
                    <text>The adjustment made each fiscal year under clause (i) shall
				be added on a compounded basis to the sum of all adjustments made each fiscal
				year after fiscal year 2014 under clause (i).</text>
									</clause>
                </subparagraph>
                <subparagraph id="id8D2CB783774947D7A168BAB953D107C0">
                  <enum>(C)</enum>
                  <header>Small business
				adjustment factor</header>
                  <text>The small business adjustment factor described
				in subparagraph (A)(ii) shall be an amount established by the Secretary for
				each fiscal year based on the Secretary’s estimate of—</text>
									<clause id="idf96d564b5bc14f51b89b2c6a6b5be5af">
                    <enum>(i)</enum>
                    <text>the number of
				small businesses that will pay a reduced establishment fee for such fiscal
				year; and</text>
									</clause>
                  <clause id="id32d67b5fe01f44bc8b28926f847eead9">
                    <enum>(ii)</enum>
                    <text>the adjustment to
				the establishment fee necessary to achieve total fees equaling the total fees
				that the Secretary would have collected if no entity qualified for the small
				business exception in subparagraph (D).</text>
									</clause>
                </subparagraph>
                <subparagraph id="id29BAF1FF035D4E6688AEF1AEE562F685">
                  <enum>(D)</enum>
                  <header>Exception for
				small businesses</header>
									<clause id="id5BF05A8C2F5B43A4A7F08623C2952E5D">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>In the case of a compounding manufacturer with gross
				annual sales of $1,000,000 or less in the 12 months ending June 1 of the fiscal
				year immediately preceding the fiscal year in which the fees under this
				subsection are assessed, the amount of the establishment fee and reinspection
				fee under paragraph (2) for a fiscal year shall be equal to
				<fraction>1/3</fraction> of the amount calculated under subparagraph (A)(i) in
				such fiscal year.</text>
									</clause>
                  <clause id="idABD9ACED9D2E443C9D9082AFCD35903D">
                    <enum>(ii)</enum>
                    <header>Application</header>
                    <text>The
				Secretary may require a small business to apply for the exception under this
				subparagraph by certifying its gross annual sales for the 12 months ending June
				1 of the fiscal year immediately preceding the fiscal year in which fees under
				this subsection are assessed. Any such application must be submitted to the
				Secretary prior to August 1 for the following fiscal year. Any statement or
				representation made to the Secretary shall be subject to section 1001 of title
				18, United States Code.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id802D70D4249C48E6BA41B241D9774888">
                  <enum>(E)</enum>
                  <header>Crediting of
				fees</header>
                  <text>In establishing the small business adjustment factor under
				subparagraph (C) for a fiscal year, the Secretary shall provide for the
				crediting of fees from the previous year to the next year if the Secretary
				overestimated the amount of the small business adjustment factor for such
				previous fiscal year, and consider the need to account for any adjustment of
				fees and such other factors as the Secretary determines appropriate.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id00B30E856F5F4EDCA8C17944D67BB9A5">
                <enum>(5)</enum>
                <header>Use of
				fees</header>
                <text>The Secretary shall make all of the fees collected pursuant
				to subparagraph (A) and (B) of paragraph (2) available solely to pay for the
				inspection-related costs (including re-inspection) for the oversight of drug
				compounding.</text>
							</paragraph>
              <paragraph id="ide5364325e8034b1a86c67e90f8af77e6">
                <enum>(6)</enum>
                <header>Supplement not
				supplant</header>
                <text>Funds received by the Secretary pursuant to this
				subsection shall be used to supplement and not supplant any other Federal funds
				available to carry out the activities described in this subsection.</text>
							</paragraph>
              <paragraph id="ID7A6A9D0587AC4CBE986A2BE6AC3FFE74">
                <enum>(7)</enum>
                <header>Crediting and
				availability of fees</header>
                <text>Fees authorized under this subsection shall
				be collected and available for obligation only to the extent and in the amount
				provided in advance in appropriations Acts. Such fees are authorized to remain
				available until expended. Such sums as may be necessary may be transferred from
				the Food and Drug Administration salaries and expenses appropriation account
				without fiscal year limitation to such appropriation account for salaries and
				expenses with such fiscal year limitation. The sums transferred shall be
				available solely for the purpose of paying the inspection-related costs
				(including reinspection) for the oversight of drug compounding.</text>
							</paragraph>
              <paragraph id="ID84BCEC0EE2534EC0AAFFF080FC3C8F77">
                <enum>(8)</enum>
                <header>Collection of
				fees</header>
								<subparagraph id="idE1E8407602FD43A3BDB112066558EF95">
                  <enum>(A)</enum>
                  <header>Establishment
				fee</header>
                  <text>A compounding manufacturer shall remit the establishment fee
				due under this subsection in a fiscal year when submitting a registration
				pursuant to subsection (g) for such fiscal year.</text>
								</subparagraph>
                <subparagraph id="ID5C0310B27F7E4602A1DD22A717221E39">
                  <enum>(B)</enum>
                  <header>Reinspection
				fee</header>
                  <text>The Secretary shall specify in the Federal Register notice
				described in paragraph (3) the manner in which reinspection fees assessed under
				this subsection shall be collected and the timeline for payment of such fees.
				Such a fee shall be collected after the Secretary has conducted a reinspection
				of the compounding manufacturer involved.</text>
								</subparagraph>
                <subparagraph id="idCA36C67CD9A94D7593B21209A1F1199B">
                  <enum>(C)</enum>
                  <header>Effect of
				failure to pay fees</header>
									<clause id="id4721DF18986A44648676921A6864255A">
                    <enum>(i)</enum>
                    <header>Registration</header>
                    <text>A
				compounding manufacturer shall not be considered registered under subsection
				(g) in a fiscal year until the date that the compounding manufacturer remits
				the establishment fee under this subsection for such fiscal year.</text>
									</clause>
                  <clause id="id0EAB03EFFE334F0FB4CEAA0DAA05F667">
                    <enum>(ii)</enum>
                    <header>Misbranding</header>
                    <text>All
				drugs compounded by a compounding manufacturer for which any establishment fee
				or reinspection fee has not been paid as required by this subsection shall be
				deemed misbranded under section 502(cc) until the fees owed for such
				compounding manufacturer under this subsection have been paid.</text>
									</clause>
                </subparagraph>
                <subparagraph id="IDD835A99A591A4272B9C3554ED59B5A64">
                  <enum>(D)</enum>
                  <header>Collection of
				unpaid fees</header>
                  <text>In any case where the Secretary does not receive
				payment of a fee assessed under this subsection within 30 days after it is due,
				such fee shall be treated as a claim of the United States Government subject to
				provisions of subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States
				Code.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="ID0A6668F2D1AC43238BF35D57E3032C90">
                <enum>(9)</enum>
                <header>Annual report to
				congress</header>
                <text>Not later than 120 days after each fiscal year in
				which fees are assessed and collected under this subsection, the Secretary
				shall submit a report to the Committee on Health, Education, Labor, and
				Pensions of the Senate and the Committee on Energy and Commerce of the House of
				Representatives, to include a description of fees assessed and collected for
				each year, a summary description of entities paying the fees, and the number of
				inspections and reinspections of such entities performed each year.</text>
							</paragraph>
              <paragraph id="ID00940E566BAF4BCAA03683F6C010BBF9">
                <enum>(10)</enum>
                <header>Authorization
				of appropriations</header>
                <text>For fiscal year 2015 and each subsequent fiscal
				year, there is authorized to be appropriated for fees under this subsection an
				amount equivalent to the total amount of fees assessed for such fiscal year
				under this subsection.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" id="id0fd8d114d3264442917d796b95fe9936">
              <enum>(i)</enum>
              <header>Action by
				Secretary regarding complaints from State boards of pharmacy</header>
							<paragraph id="id8d3d69653815448f9c07e50fe468179f">
                <enum>(1)</enum>
                <header>Designation</header>
                <text>The
				Secretary shall designate a point of contact and establish a format and
				procedure for a State Board of Pharmacy to notify the Secretary if it appears
				to a State Board of Pharmacy that an entity licensed by a State as a pharmacy
				is required to be registered with the Secretary as a compounding
				manufacturer.</text>
							</paragraph>
              <paragraph id="ide7fc305dcedd4b96ab0f8908ab885d23">
                <enum>(2)</enum>
                <header>Determination</header>
                <text>If
				the Secretary determines that such an entity described in paragraph (1) is
				required to be registered with the Secretary as a compounding manufacturer, the
				Secretary shall transmit such determination to the State Board of Pharmacy in
				the State in which the entity is located, and to the State Board of Pharmacy in
				the notifying State, if different, within 15 days of such determination.</text>
							</paragraph>
              <paragraph id="idd1e3de8f0c724857988f1c04046e2b6d">
                <enum>(3)</enum>
                <header>Effect</header>
                <text>The
				Secretary shall encourage direct communications between States regarding
				traditional compounders. Nothing in this subsection shall expand the
				Secretary’s authority over or responsibility for traditional
				compounding.</text>
							</paragraph>
            </subsection>
            <subsection id="idBC94F52C9BC041CD9D70142EA0CBB338">
              <enum>(j)</enum>
              <header>Prescription
				order reference</header>
              <text>For purposes of this section, reference to a
				prescription order for an identified individual patient includes, in the case
				of animal drugs, a prescription order for a specific herd or flock (or other
				identified group) of
				animals.</text>
						</subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="idB3D5A38BF4604BD2910BDDC6E0ADEA18">
        <enum>(c)</enum>
        <header>Prohibited
			 act</header>
        <text>Section 301 (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>) is amended—</text>
				<paragraph id="id7A14832EB8C1435489E8DD9F70C2E396">
          <enum>(1)</enum>
          <text>in subsection (e),
			 by striking <quote>417, 416, 504</quote> and inserting <quote>417, 416,
			 503A(g), 504</quote>; and</text>
				</paragraph>
        <paragraph id="id4F611AF35DB04390893F9E21D418EF10">
          <enum>(2)</enum>
          <text>by adding at the
			 end the following:</text>
					<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="idBAF5A9A10D1742DB9F1C8AFCBB8A1D23" reported-display-style="strikethrough" style="OLC">
						<subsection id="id05F3DE114692403E955BC88352C2CA87">
              <enum>(ccc)</enum>
              <text>The resale of a
				compounded drug that is labeled <quote>not for resale</quote> as required by
				section
				503A.</text>
						</subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="idF2B2954B49D24184A34078B8D8D700C7">
        <enum>(d)</enum>
        <header>Report by
			 GAO</header>
        <text>Not later than November 1, 2016, the Comptroller General of
			 the United States shall conduct study and submit to Congress a report regarding
			 the impact of this Act (and the amendments made by this Act) on the safety of
			 animal drug compounding and the availability of safe and effective drugs for
			 animals.</text>
			</subsection>
    </section>
    <section changed="deleted" committee-id="SSHR00" id="id7198612A26904983A02CEDBD7F6F812C" reported-display-style="strikethrough">
      <enum>3.</enum>
      <header>Other
			 requirements relating to compounding manufacturers</header>
			<subsection id="id66EB604B5AD848C0B9CF6B6B22E2CE9E">
        <enum>(a)</enum>
        <header>Labeling</header>
        <text display-inline="yes-display-inline">Section 502 (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended by
			 adding at the end the following:</text>
				<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="id763EF671E5794D229D0C570CB18BF934" reported-display-style="strikethrough" style="OLC">
					<subsection id="idF96D8B759C15433EB5C85A511CC5F631">
            <enum>(bb)</enum>
            <text>If it is a
				compounded drug and the labeling does not include the information as required
				by subsections (f)(1)(C) and (g)(4) of section 503A, as applicable.</text>
					</subsection>
          <subsection id="id15EF37DE857C4A019473B0B540DF25A6">
            <enum>(cc)</enum>
            <text>If it is a drug,
				and it was compounded by a compounding manufacturer for which fees have not
				been paid as required by section
				503A(g).</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="id8A1FF9E1E4354A3196B3516BC7A5431A">
        <enum>(b)</enum>
        <header>Application of
			 inspection requirements to compounding manufacturers</header>
        <text>Section
			 704(a)(2) (<external-xref legal-doc="usc" parsable-cite="usc/21/374">21 U.S.C. 374(a)(2)</external-xref>) is amended by adding at the end the following
			 flush text:</text>
				<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="idD905BE9E04294D2FAF4510F9751D906A" reported-display-style="strikethrough" style="OLC">
					<quoted-block-continuation-text changed="deleted" committee-id="SSHR00" quoted-block-continuation-text-level="subsection" reported-display-style="strikethrough">The exemption in subparagraph (A)
				does not apply with respect to compounding manufacturers (as such term is
				defined in section
				503A).</quoted-block-continuation-text>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="id6C4CD85E10E040ACB3F6EADBDEC5670B">
        <enum>(c)</enum>
        <header>Adulteration of
			 compounded animal drugs containing drug residues</header>
        <text>
          Section
			 402(a)(2)(C) is amended by striking <quote>
            512;</quote> and inserting
			 <quote>
            512; or (iii) any residue from a compounded animal drug;</quote>.</text>
			</subsection>
    </section>
    <section changed="deleted" committee-id="SSHR00" id="id310111ED2A9245A3BED7174E7D1C2811" reported-display-style="strikethrough">
      <enum>4.</enum>
      <header>Implementation</header>
      <text display-inline="no-display-inline">In promulgating any regulations to implement
			 this Act (and the amendments made by this Act), the Secretary of Health and
			 Human Services shall—</text>
			<paragraph id="idfaa21d2a856d46b7b3b3c81f9530e1cd">
        <enum>(1)</enum>
        <text>issue a notice of
			 proposed rulemaking that includes the proposed regulation;</text>
			</paragraph>
      <paragraph id="idb08c95274883468194c989ad5d9cbe72">
        <enum>(2)</enum>
        <text>provide a period
			 of not less than 60 days for comments on the proposed regulation; and</text>
			</paragraph>
      <paragraph commented="no" display-inline="no-display-inline" id="idaecff12bfa6548d79f9f852978b98d21">
        <enum>(3)</enum>
        <text>publish the final
			 regulation not more than 18 months following publication of the proposed rule
			 and not less than 30 days before the effective date of such final
			 regulation.</text>
			</paragraph>
    </section>
    <section changed="deleted" commented="no" committee-id="SSHR00" display-inline="no-display-inline" id="idA41E64A175CA4A088F1F8B1EFFE7F414" reported-display-style="strikethrough">
      <enum>5.</enum>
      <header>Effective
			 date</header>
      <text display-inline="no-display-inline">This Act (and the
			 amendments made by this Act) shall take effect on the date that is 1 year after
			 the date of enactment of this Act.</text>
		</section>
  </legis-body>
	<legis-body display-enacting-clause="no-display-enacting-clause">
		<section changed="added" committee-id="SSHR00" id="idfd343c50-6731-42ce-8353-f90f70b87aae" reported-display-style="italic" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act" proposed="true">Pharmaceutical Quality, Security, and Accountability Act</cato:entity-ref>
        </quote>.</text>
		</section>
    <section changed="added" committee-id="SSHR00" id="id03DB57E1CB21492D8E239D090FC9D3F3" reported-display-style="italic">
      <enum>2.</enum>
      <header>References in Act; table
			 of contents</header>
			<subsection id="ide801a56b-b7a2-4675-bfc0-a19cb9942497">
        <enum>(a)</enum>
        <header>References in
			 Act</header>
        <text>Except as otherwise specified, amendments made by this Act to
			 a section or other provision of law are amendments to such section or other
			 provision of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et
			 seq.</cato:entity-ref>)</cato:entity>.</text>
			</subsection>
      <subsection id="idF1F015C5DDD6418D87FD482CD1CBF5D8">
        <enum>(b)</enum>
        <header>Table of
			 contents</header>
        <text>The table of contents of this Act is as follows:</text>
				<toc changed="added" committee-id="SSHR00" reported-display-style="italic">
					<toc-entry idref="S1" level="section">Sec. 1. Short
				title.</toc-entry>
					<toc-entry idref="id03DB57E1CB21492D8E239D090FC9D3F3" level="section">Sec. 2. References in Act; table of
				contents.</toc-entry>
					<toc-entry idref="idEB894060157D477FA065F99E8E3BF89C" level="title">TITLE I—Human drug
				compounding</toc-entry>
					<toc-entry idref="idADC92DCF496143B5A177CE0EC4852745" level="section">Sec. 101. Short title.</toc-entry>
					<toc-entry idref="idd84bc06e0d654f88a98b823dcd2bddd9" level="section">Sec. 102. Regulation of human drug
				compounding.</toc-entry>
					<toc-entry idref="idad2964bbb9084e169acf987e8c5c6734" level="section">Sec. 103. Other requirements.</toc-entry>
					<toc-entry idref="ide6ee348803ae4fb8bc4c5a7c5e75897d" level="section">Sec. 104. Implementation.</toc-entry>
					<toc-entry idref="id8e3448708e0a42a8a3391b881e33f907" level="section">Sec. 105. Effective date.</toc-entry>
					<toc-entry idref="idA6D5B3EFFDD347388F74014AC6650496" level="title">TITLE II—Drug Supply Chain
				Security</toc-entry>
					<toc-entry idref="id564FD637D4154F21AC4047FDB1025B55" level="section">Sec. 201. Short title.</toc-entry>
					<toc-entry idref="id152ccba45d2d4c529aa71d3141e42f5d" level="section">Sec. 202. Pharmaceutical distribution supply
				chain.</toc-entry>
					<toc-entry idref="id78139f99bfa44fd6bfe76849e3b3d206" level="section">Sec. 203. Enhanced drug distribution
				security.</toc-entry>
					<toc-entry idref="id789f8b5aea394bc2b27455cbec46e78f" level="section">Sec. 204. National licensure standards for
				prescription drug wholesale distributors.</toc-entry>
					<toc-entry idref="idd67351dddf004eff9e0b4ae9d0e45e95" level="section">Sec. 205. National licensure standards for
				third-party logistics providers; uniform national policy.</toc-entry>
					<toc-entry idref="idbc50988f765742969ebc9251bee48e0c" level="section">Sec. 206. Penalties.</toc-entry>
					<toc-entry idref="id919BAF362748462F8C1AB792EDD7E534" level="section">Sec. 207. Conforming amendment.</toc-entry>
					<toc-entry idref="id5374815F273F423C980ED14B747BC243" level="section">Sec. 208. Savings clause.</toc-entry>
				</toc>
			</subsection>
    </section>
    <title changed="added" committee-id="SSHR00" id="idEB894060157D477FA065F99E8E3BF89C" reported-display-style="italic">
      <enum>I</enum>
      <header>Human drug
			 compounding</header>
			<section id="idADC92DCF496143B5A177CE0EC4852745">
        <enum>101.</enum>
        <header>Short
			 title</header>
        <text display-inline="no-display-inline">This title may be cited
			 as the <quote>
            <short-title>Pharmaceutical Compounding
			 Quality and Accountability Act</short-title>
          </quote>.</text>
			</section>
      <section id="idd84bc06e0d654f88a98b823dcd2bddd9">
        <enum>102.</enum>
        <header>Regulation of human
			 drug compounding</header>
				<subsection id="id6d80bc9ae8e84881b154d68c9e0adf46">
          <enum>(a)</enum>
          <header>Clarification of new
			 drug status</header>
          <text>For purposes of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/301">
                <cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et seq.</cato:entity-ref>
              </external-xref>)</cato:entity>, the term <term>new drug</term> (as defined in
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:201/ss:p">section 201(p) of such Act</cato:entity-ref>) shall include a compounded human drug.</text>
				</subsection>
        <subsection id="ida5655f6e37844fb0ab2856c0fbae689d">
          <enum>(b)</enum>
          <header>Regulation of human
			 drug compounding</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A">Section 503A</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">
                <cato:entity-ref entity-type="uscode" value="usc/21/353a">21 U.S.C. 353a</cato:entity-ref>
              </external-xref>)</cato:entity> is amended to read
			 as follows:</text>
					<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id83856A282B5F4F7C859969D3931ECFD2" reported-display-style="italic" style="OLC">
						<section id="id8994ab4e162a418d9ee81cfd07186b84">
              <enum>503A.</enum>
              <header>Human drug
				compounding</header>
							<subsection id="id5c6e98bef3c8476d8ee400d366a5527e">
                <enum>(a)</enum>
                <header>Scope</header>
								<paragraph id="id248f81f546c94aa6936a37ea86995f9f">
                  <enum>(1)</enum>
                  <header>Compounding</header>
                  <text>In
				this section, the terms <quote>compounding</quote> and
				<quote>compound</quote>—</text>
									<subparagraph id="ida6876edb4a9b4ba79e834a12e6962371">
                    <enum>(A)</enum>
                    <text>include—</text>
										<clause id="id6b8875ed4c5a4802a85401f51647c8de">
                      <enum>(i)</enum>
                      <text>the combining, admixing,
				mixing, diluting, reconstituting, or otherwise altering of a marketed
				drug;</text>
										</clause>
                    <clause id="id4a1dd7e14480419eb88e680e6c3370a4">
                      <enum>(ii)</enum>
                      <text>compounding a drug from
				a bulk drug substance; and</text>
										</clause>
                    <clause id="idede6bff275ca406f8a3bb88ef8aa2b47">
                      <enum>(iii)</enum>
                      <text>repackaging; and</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idc9113f54c0c04dbaad7cf5fb78e8c936">
                    <enum>(B)</enum>
                    <text>exclude mixing,
				reconstituting, or other such acts with respect to a marketed drug that are
				limited to and performed in accordance with specific directions for such acts
				contained in approved labeling provided by a drug’s manufacturer, when
				performed based upon a prescription order for an identified individual
				patient.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id1d127b4c86f8499f909ec93cde281dd0">
                  <enum>(2)</enum>
                  <header>Administration and
				dispensing not a sale</header>
                  <text>In this section, the terms
				<term>sell</term> or <term>resale</term> do not include—</text>
									<subparagraph id="id7E1F1259559A457D90F6654E508BB9A5">
                    <enum>(A)</enum>
                    <text>circumstances in which
				drug is administered to a patient or provided to a patient who has been
				instructed to self-administer the drug;</text>
									</subparagraph>
                  <subparagraph id="id6930C0290E944FFB947EA027B859F8D4">
                    <enum>(B)</enum>
                    <text>the dispensing of a drug
				pursuant to a prescription executed in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>;
				or</text>
									</subparagraph>
                  <subparagraph id="id4F878AE3C179402A9698948B76E54958">
                    <enum>(C)</enum>
                    <text>any fee associated with
				such administration, provision, or dispensing of the drug.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="ide53af4caeb3c43cea2a167536f295401">
                  <enum>(3)</enum>
                  <header>Inapplicability to
				certain drugs</header>
									<subparagraph id="idbf3ba2b5988b438182bb6f1bf2fac039">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>For purposes of this section, the activities described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall not be considered <quote>compounding</quote> if such
				activities are conducted in whole or in part with respect to a drug described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A" proposed="true">subparagraph (B)</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="id1fabd82341224ac3862ad5737010837e">
                    <enum>(B)</enum>
                    <header>Excluded
				drugs</header>
                    <text>The drugs described in this subparagraph are the
				following:</text>
										<clause id="id0f54bb7c03414e5a97dbf174652e4996">
                      <enum>(i)</enum>
                      <text>Blood and blood
				components for transfusion.</text>
										</clause>
                    <clause id="ide98906dc5c2a49d5bd85bc77a73d053c">
                      <enum>(ii)</enum>
                      <text>Medical gases, as
				defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:575">section 575</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                </paragraph>
                <paragraph commented="no" id="idcfb7a1b94be84a2aacc1d0bd38831312">
                  <enum>(4)</enum>
                  <header>Animal drugs for human
				use</header>
                  <text>Nothing in this section shall be construed to permit the use
				of animal drugs in compounding a drug for human use.</text>
								</paragraph>
              </subsection>
              <subsection id="id9bbc65aa703a481687844e8cc7631595">
                <enum>(b)</enum>
                <header>Definitions</header>
                <text>In
				this section:</text>
								<paragraph id="id42d184d4e9b54d068b4bf41499cc6108">
                  <enum>(1)</enum>
                  <header>Compounding
				manufacturer</header>
									<subparagraph id="id4829ac0aef914ea1a45ca64e1d1d7af2">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>The term <term>compounding manufacturer</term> means a
				facility at one geographic location or address—</text>
										<clause id="ide4a590a596de42e4a8ed509107a9d838">
                      <enum>(i)</enum>
                      <text>that compounds any
				sterile drug without receiving a prescription order for an identified
				individual patient for such sterile drug prior to beginning compounding, and
				distributes or offers to sell such compounded sterile drug in interstate
				commerce; or</text>
										</clause>
                    <clause id="idfbfeb9d75d4a4883bccae5f4078f4bd7">
                      <enum>(ii)</enum>
                      <text>that repackages any
				preservative-free sterile drug or engages in sterile pooling.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id40f31fc5f49e47b1bcbeb064be303096">
                    <enum>(B)</enum>
                    <header>Exclusions</header>
										<clause id="idB0315F425DD34328BB43898878CBB4E8">
                      <enum>(i)</enum>
                      <header>Excluded
				activities</header>
                      <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, a facility shall
				not be considered a compounding manufacturer if such facility—</text>
											<subclause id="id35d415f944be4a89abacb5f3e7b7d366">
                        <enum>(I)</enum>
                        <text>repackages drugs in
				accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506F">section 506F</cato:entity-ref> or the final guidance described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506F/ss:d">section 506F(d)</cato:entity-ref>
				once the final guidance is published; and</text>
											</subclause>
                      <subclause id="id5ffaea0fe7e24cfda8ce0ffcaf69c681">
                        <enum>(II)</enum>
                        <text>does not otherwise meet
				the definition of compounding manufacturer under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
											</subclause>
                    </clause>
                    <clause id="id447B308C6706472E96B2BEB41AD4368C">
                      <enum>(ii)</enum>
                      <header>Compounding nuclear
				pharmacy</header>
                      <text>The term <term>compounding manufacturer</term> shall not
				include a compounding nuclear pharmacy.</text>
										</clause>
                  </subparagraph>
                </paragraph>
                <paragraph id="idd491c6fb4f2d47ad87d611b1fd73f679">
                  <enum>(2)</enum>
                  <header>Compounding nuclear
				pharmacy</header>
                  <text>The term <term>compounding nuclear pharmacy</term> means
				an entity that—</text>
									<subparagraph id="ide3640b7ac7b34017907f3b4e18e54b01">
                    <enum>(A)</enum>
                    <text>is a State-licensed
				pharmacy or a Federal facility;</text>
									</subparagraph>
                  <subparagraph id="id36c0533ab50648179afdf0adbe9d1280">
                    <enum>(B)</enum>
                    <text>holds a license currently
				in effect from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3100">Nuclear Regulatory Commission</cato:entity-ref> or from a State pursuant to an
				agreement with such commission under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Atomic Energy Act of 1954/s:274">section 274 of the Atomic Energy Act of
				1954</cato:entity-ref>; and</text>
									</subparagraph>
                  <subparagraph id="id6f546b4757bd48729ab4c6213dc8e9a3">
                    <enum>(C)</enum>
                    <text>does not compound
				non-radioactive drugs that would cause the entity to be a compounding
				manufacturer described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:A" proposed="true">paragraph (1)(A)</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id7ec5ba6b75dd431ea9c405ed13cc1697">
                  <enum>(3)</enum>
                  <header>Copy</header>
                  <text>The
				term <term>copy</term> means an identical or nearly identical version of a
				drug.</text>
								</paragraph>
                <paragraph id="id190ba7fcd4394acf928e186ff62ab2de">
                  <enum>(4)</enum>
                  <header>Practitioner</header>
                  <text>The
				term <term>practitioner</term> includes a physician or any other person that is
				authorized to prescribe medication under State law.</text>
								</paragraph>
                <paragraph id="idf6acf19aa2ce45ae807ab49a0ed97e22">
                  <enum>(5)</enum>
                  <header>Radioactive
				drug</header>
                  <text>The term <term>radioactive drug</term>—</text>
									<subparagraph id="idF1C72F34521E4DF5BA5E7ECE5966AFE4">
                    <enum>(A)</enum>
                    <text>means any substance
				defined as a drug in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:201/ss:g/p:1">section 201(g)(1)</cato:entity-ref> that exhibits spontaneous disintegration
				of unstable nuclei with the emission of nuclear particles or photons and
				includes any nonradioactive reagent kit or nuclide regenerator which is
				intended to be used in the preparation of any such substance but does not
				include drugs such as carbon-containing compounds or potassium-containing salts
				which contain trace quantities of naturally occurring radionuclides; and</text>
									</subparagraph>
                  <subparagraph id="id6CA4777C2A6F4B4CA2D44BC2DEE15781">
                    <enum>(B)</enum>
                    <text>includes a
				<quote>radioactive biological product,</quote> which means a biological product
				which is labeled with a radionuclide or intended solely to be labeled with a
				radionuclide.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id09d8a34c84f740989d3aadd252a683ee">
                  <enum>(6)</enum>
                  <header>Repackage or
				repackaging</header>
                  <text>The term <term>repackage</term> or
				<quote>repackaging</quote>—</text>
									<subparagraph id="id20775FC52DD34BF8868C189974BA4A9A">
                    <enum>(A)</enum>
                    <text>means taking a drug
				approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health
				Service Act</cato:entity-ref> from the container in which it is distributed by the original
				manufacturer and placing it in a different container of the same or smaller
				size without further manipulating the drug (such as by diluting it or mixing it
				with another, different drug or drugs); and</text>
									</subparagraph>
                  <subparagraph id="id1BC1FBAF22894C45BFA4DD832BCFA494">
                    <enum>(B)</enum>
                    <text>does not include removing
				the drug from its original container for immediate administration to an
				identified individual patient, such as withdrawing a drug into a syringe for
				immediate injection or filling a cassette for immediate use within a drug
				delivery device.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="idc96e2f9a66b84d2bb958d162fdad07e9">
                  <enum>(7)</enum>
                  <header>Sterile
				drug</header>
                  <text>The term <term>sterile drug</term> means a drug that
				is—</text>
									<subparagraph id="ida408cc330ed64322b5aec51486373997">
                    <enum>(A)</enum>
                    <text>intended for parenteral
				administration;</text>
									</subparagraph>
                  <subparagraph id="idd2fe1dcfc6504cde8a681aeba15f5f66">
                    <enum>(B)</enum>
                    <text>an ophthalmic or oral
				inhalation drug in aqueous format; or</text>
									</subparagraph>
                  <subparagraph id="id44dcac841a414e17a11dee1e403f7b4e">
                    <enum>(C)</enum>
                    <text>required to be sterile
				under Federal or State law.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="idd0c5f81f83334bac9e0a4e9117a8d72d">
                  <enum>(8)</enum>
                  <header>Sterile
				pooling</header>
                  <text>The term <term>sterile pooling</term>—</text>
									<subparagraph id="id6b23d50349b74d3286503dbd573a5fe0">
                    <enum>(A)</enum>
                    <text>means taking a single
				sterile drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> from the container in which it is
				distributed by the original manufacturer and combining it with the same sterile
				drug from one or more other containers without or before further manipulating
				the product (such as by diluting it or mixing it with another, different drug
				or drugs);</text>
									</subparagraph>
                  <subparagraph id="id85fd21c9164f4888b09f6e191a02b71b">
                    <enum>(B)</enum>
                    <text>does not include
				combining the drug from two or more separate containers of the same drug when a
				single container of the drug is not sufficient to prepare a single dose for
				administration to an individual patient; and</text>
									</subparagraph>
                  <subparagraph id="ide34c4923513e4009ab4882994f821c7c">
                    <enum>(C)</enum>
                    <text>does not include
				combining a single drug from two or more separate containers of component
				products of a parenteral nutrition product, if such pooling, labeling, and use
				of the finished parenteral nutrition product, comply with State pharmacy
				law.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="iddebbe6278097492f913e8457bd8dd23b">
                  <enum>(9)</enum>
                  <header>Traditional
				compounder</header>
									<subparagraph id="ida1090d1e201c4a40bdad79f105e04ff2">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>The term <term>traditional compounder</term> means a
				facility operating pursuant to State law—</text>
										<clause id="idee6811e9b2b54fde8c91428fb0de9d04">
                      <enum>(i)</enum>
                      <text>wherein a drug is
				compounded by—</text>
											<subclause id="ided4500beaba04edeb4873068a1b20211">
                        <enum>(I)</enum>
                        <text>a licensed pharmacist in
				a State-licensed pharmacy or a licensed Federal facility; or</text>
											</subclause>
                      <subclause id="id71ab1eefa192452b98e712b16a6b9a77">
                        <enum>(II)</enum>
                        <text>a licensed
				physician;</text>
											</subclause>
                    </clause>
                    <clause id="id770166ec362843b9b4c2f6ca28823393">
                      <enum>(ii)</enum>
                      <text>that—</text>
											<subclause id="id5220c85b24aa4c76b2fab1e0e2ff0a37">
                        <enum>(I)</enum>
                        <text>compounds a drug upon
				receipt of a prescription order for an identified individual patient; or</text>
											</subclause>
                      <subclause id="idc2fc8e149d544104a6e39f3a2a29533d">
                        <enum>(II)</enum>
                        <text>compounds a drug in
				limited quantities before receipt of a prescription order for an identified
				individual patient, if such compounding is based on a history of the licensed
				pharmacist or licensed physician receiving prescription orders for the
				compounding of the drug, which orders have been generated solely within an
				established relationship between the licensed pharmacist or licensed physician
				and—</text>
												<item id="id3c22672ea34c4c7d97f41a3f753e74c4">
                          <enum>(aa)</enum>
                          <text>such individual patient
				for whom the prescription order will be provided; or</text>
												</item>
                        <item id="ide2b262f8399e4515bc4391d13c8c79b2">
                          <enum>(bb)</enum>
                          <text>the licensed physician
				or other licensed practitioner who will write such prescription order;
				and</text>
												</item>
                      </subclause>
                    </clause>
                    <clause id="idca439322284c42af892fa95e6b2c094b">
                      <enum>(iii)</enum>
                      <text>that does not meet the
				definition of a compounding manufacturer under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id98ec826369e147838aa1a5e0b2790329">
                    <enum>(B)</enum>
                    <header>Exceptions</header>
										<clause id="id0c5f161985e6447c93d5bb985d68cfff">
                      <enum>(i)</enum>
                      <header>Hospitals and health
				systems</header>
                      <text>A pharmacy within a hospital or health system shall be
				considered a traditional compounder if such pharmacy otherwise meets the
				definition under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:9/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> and if, with respect to a drug compounded by
				such pharmacy, the only activity conducted by the pharmacy is to dispense or
				administer such drug (which may include interstate shipment) solely to a
				patient of such hospital or health system.</text>
										</clause>
                    <clause id="id3ac0c14631314838839cfebe0f52fb36">
                      <enum>(ii)</enum>
                      <header>Health system
				defined</header>
                      <text>The term <term>health system</term>—</text>
											<subclause id="idf54bb5a3699746f188ea6b666708efba">
                        <enum>(I)</enum>
                        <text>means an entity that owns
				and operates—</text>
												<item id="ide16990bb39744cc69a6bba7ad4c54b0a">
                          <enum>(aa)</enum>
                          <text>one hospital; or</text>
												</item>
                        <item id="idf66581aeaaaa472ab6f5312ed50da21e">
                          <enum>(bb)</enum>
                          <text>two or more hospitals
				that have common access to databases with drug order information for patients;
				and</text>
												</item>
                      </subclause>
                      <subclause id="id1511769193ad4afe8ab243cf6b94445d">
                        <enum>(II)</enum>
                        <text>includes only the
				inpatient, outpatient, and ambulatory facilities wholly owned and operated by
				such entity, and accredited by a national accreditation body recognized by the
				Secretary.</text>
											</subclause>
                    </clause>
                  </subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id7dfee572a9d44cc28df55a70779903bd">
                <enum>(c)</enum>
                <header>Exemptions from certain
				requirements</header>
								<paragraph id="idCA029320C26848A6BC7155D174E5353F">
                  <enum>(1)</enum>
                  <header>In
				general</header>
                  <text>Except as otherwise provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:2" proposed="true">paragraphs (2)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:3" proposed="true">(3)</cato:entity-ref>, and
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:4" proposed="true">(4)</cato:entity-ref>, a compounded drug shall be subject to all the requirements of this Act
				applicable to new drugs.</text>
								</paragraph>
                <paragraph id="idb6614206708641fca03bf9b0597f003e">
                  <enum>(2)</enum>
                  <header>Drugs compounded by
				traditional compounders</header>
                  <text>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:501/ss:a/p:2/sp:B">Sections 501(a)(2)(B)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">502(f)(1)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505
				of this Act</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> shall not apply to
				a compounded drug if such drug—</text>
									<subparagraph id="id0790785a38fa4809a1d52a4e19b69c91">
                    <enum>(A)</enum>
                    <text>is compounded by a
				traditional compounder that is in compliance with this section; and</text>
									</subparagraph>
                  <subparagraph id="ida1dbfaf8693c4c1896555097a8adb363">
                    <enum>(B)</enum>
                    <text>meets the requirements of
				this section applicable to drugs compounded by traditional compounders.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id16c1d2aade6544a6b6f5e31b2beda801">
                  <enum>(3)</enum>
                  <header>Drugs compounded by
				compounding manufacturers</header>
                  <text>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">Sections 502(f)(1)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505 of this Act</cato:entity-ref>
				and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> shall not apply to a
				compounded prescription drug, if such prescription drug—</text>
									<subparagraph id="id211e86c27eea46eba6a70aa0cd15db7b">
                    <enum>(A)</enum>
                    <text>is compounded by a
				compounding manufacturer—</text>
										<clause id="idad18355715fc498ca0e9ee014bf68466">
                      <enum>(i)</enum>
                      <text>that is not licensed as a
				pharmacy in any State; and</text>
										</clause>
                    <clause id="id823f3139d516434486a4782ea3fd8f60">
                      <enum>(ii)</enum>
                      <text>that is in compliance
				with this section; and</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id31109c98c4d24ad7bddd716d919dd0ba">
                    <enum>(B)</enum>
                    <text>meets the requirements of
				this section applicable to drugs compounded by compounding
				manufacturers.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="idc0e31fca5e19411898798dc552756211">
                  <enum>(4)</enum>
                  <header>Drugs compounded by
				compounding nuclear pharmacies</header>
                  <text>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:501/ss:a/p:2/sp:B">Sections 501(a)(2)(B)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">502(f)(1)</cato:entity-ref>,
				and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505 of this Act</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> shall not
				apply to a compounded radioactive drug if such drug is compounded—</text>
									<subparagraph id="id5bb94e478047487eac478e220122f950">
                    <enum>(A)</enum>
                    <text>by a licensed pharmacist
				in a compounding nuclear pharmacy;</text>
									</subparagraph>
                  <subparagraph id="ida380b0a6854f403ea661cef8ceb33a21">
                    <enum>(B)</enum>
                    <text>solely using a
				radioactive drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of
				the Public Health Service Act</cato:entity-ref>, and one or more ingredients in compliance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:1/sp:B" proposed="true">subsection (e)(1)(B)</cato:entity-ref>; and</text>
									</subparagraph>
                  <subparagraph id="iddca52e0080604599a0503205b7ef8b5c">
                    <enum>(C)</enum>
                    <text>in compliance with the
				United States Pharmacopoeia chapters on pharmacy compounding.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id3200f66925994377a05838e49f32c75d">
                <enum>(d)</enum>
                <header>Drugs that may not be
				compounded</header>
								<paragraph id="idd6a45c5982dc4006bb278729c637627e">
                  <enum>(1)</enum>
                  <header>In
				general</header>
                  <text>The following drugs may not be compounded:</text>
									<subparagraph id="id23dd8126b8d94a119a823461fd3e4552">
                    <enum>(A)</enum>
                    <header>Drugs that are
				demonstrably difficult to compound</header>
                    <text>A drug or category of drugs
				that presents demonstrable difficulties for compounding, which may include a
				complex dosage form or biological product, as designated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2" proposed="true">paragraph (2)</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="idb11c615852f44cf190e6020ae87a74e0">
                    <enum>(B)</enum>
                    <header>Marketed
				drugs</header>
                    <text>A drug (other than a biological product) that is a copy of
				a marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref> or a variation of such drug compounded from
				bulk drug substances, except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:3" proposed="true">paragraph (3)</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="id80cc9c97b1df4c918525aaef6e530a97">
                    <enum>(C)</enum>
                    <header>Biological
				products</header>
                    <text>A drug that is a biological product, except as provided
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="id1995b2cdf5c64621b6ca8351648d6018">
                    <enum>(D)</enum>
                    <header>Drugs subject to risk
				evaluation and mitigation strategy</header>
                    <text>A copy or variation of a drug
				approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health
				Service Act</cato:entity-ref> that is the subject of a risk evaluation and mitigation strategy
				approved with elements to assure safe use pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1">section 505–1</cato:entity-ref>, except
				provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:5" proposed="true">paragraph (5)</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="id087efa7978074fbe847fd32700533708">
                    <enum>(E)</enum>
                    <header>Drugs removed for
				safety and efficacy</header>
                    <text>A drug that appears on a list published by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the Federal Register of drugs that have been withdrawn or
				removed from the market because such drug or components of such drug have been
				found to be unsafe or not effective.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id054af55fb7ee46a1a57937a5bc1d1f32">
                  <enum>(2)</enum>
                  <header>Drugs that are
				demonstrably difficult to compound</header>
									<subparagraph id="ida6f284e3ff164864b3f44b4cbcd6b5a9">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may promulgate a regulation that designates
				drugs or categories of drugs that are demonstrably difficult to compound that
				may not be compounded, or that may be compounded only under conditions
				specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>. Such regulation may include the designation of
				drugs or categories of drugs that are complex dosage forms or biological
				products, such as extended release products, metered dose inhalers, transdermal
				patches, and sterile liposomal products.</text>
									</subparagraph>
                  <subparagraph id="id857fb482a99445a382e1b448b7616966">
                    <enum>(B)</enum>
                    <header>Interim list</header>
										<clause id="idde33dcc2dbd240f3a42d14bf4e0d7e71">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Before the effective date of the regulation promulgated
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may designate drugs or categories of
				drugs that present demonstrable difficulties for compounding, which may include
				complex dosage forms or biological products that cannot be compounded, except
				under conditions specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, by—</text>
											<subclause id="id937d75fb6eca43c2926a8e5531b39394">
                        <enum>(I)</enum>
                        <text>publishing a notice of
				such drugs or categories of drugs proposed for designation, including the
				rationale for such designation, in the Federal Register;</text>
											</subclause>
                      <subclause id="idfef330b254f14740a722824e729803d6">
                        <enum>(II)</enum>
                        <text>providing a period of
				not less than 60 calendar days for comment on the notice; and</text>
											</subclause>
                      <subclause id="id09d9141c5eac401386a9d709b7617824">
                        <enum>(III)</enum>
                        <text>publishing a notice in
				the Federal Register designating such drugs or categories of drugs that cannot
				be compounded, including the rationale for such designation.</text>
											</subclause>
                    </clause>
                    <clause id="idc6ab921a581647cb95a441e1d9f9b3e6">
                      <enum>(ii)</enum>
                      <header>Sunset</header>
                      <text>Any
				notice provided under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref> shall cease to have force or effect on the
				date that is 5 years after the date of enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical
				Compounding Quality and Accountability Act</cato:entity-ref> or on the effective date of the
				final regulation under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, whichever is earlier.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id1a1dd1452f844b87b184ac64f21893be">
                    <enum>(C)</enum>
                    <header>Consultation with
				stakeholders</header>
                    <text>Prior to establishing the lists described in this
				paragraph, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consult with relevant stakeholders including
				pharmacists, professional associations, patient and public health advocacy
				groups, manufacturers and physicians about the need for the compounded drugs to
				be included or excluded from the lists.</text>
									</subparagraph>
                  <subparagraph id="id10f65d42f4cd419f8c6e099d676d77fb">
                    <enum>(D)</enum>
                    <header>Updates to difficult to
				compound list</header>
                    <text>Five years after the effective date of the
				regulation described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, and every 5 years thereafter, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish a Federal Register notice seeking public input about
				the need for the compounded drugs to be included or excluded from the list
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>. Nothing in the previous sentence prohibits
				notifications or submissions before or during any 5-year period described under
				such sentence regarding the need for the compounded drugs to be included or
				excluded from the list.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id85eeb0bd2a2246a1a01f7f19d245886e">
                  <enum>(3)</enum>
                  <header>Exceptions regarding
				marketed drugs</header>
									<subparagraph id="id48ce58d049e844d98fc26b52608b7901">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>A drug (other than a biological product) that is a copy
				of a marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref>, including variations of such drug
				compounded from bulk drug substances, may be compounded only if—</text>
										<clause id="id89bbcbd525a54ed187072bf18b422cc5">
                      <enum>(i)</enum>
                      <text>the compounded variation
				produces for the individually identified patient a clinical difference between
				the compounded drug and such marketed drug, as determined by the prescribing
				practitioner, and, prior to beginning compounding such variation, the
				traditional compounder compounding the variation receives a prescription order
				for an identified individual patient specifying that the variation may be
				compounded; or</text>
										</clause>
                    <clause id="id173fb265cd8e48789e0d7c9b5a8c1552">
                      <enum>(ii)</enum>
                      <subclause commented="no" display-inline="yes-display-inline" id="idD2FFEB745E3E4B2B92B1C977029456DA">
                        <enum>(I)</enum>
                        <text>such marketed drug, at
				the time of compounding a copy of such drug and at the time of distribution of
				the compounded drug, is on the drug shortage list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506E">section 506E</cato:entity-ref>, or has
				otherwise been identified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary's</cato:entity-ref> sole discretion,
				as in shortage, such as in a specific region or on a drug shortage list
				maintained by a private party;</text>
											</subclause>
                      <subclause changed="added" committee-id="SSHR00" id="idD0ABC165DF514AFE8488826CF2977DA2" indent="up1" reported-display-style="italic">
                        <enum>(II)</enum>
                        <text>the facility compounding
				the drug notifies the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than 3 calendar days after beginning
				the compounding; and</text>
											</subclause>
                      <subclause changed="added" committee-id="SSHR00" id="id964C029CEBCD4CE28C3D98B0EE3ADDD9" indent="up1" reported-display-style="italic">
                        <enum>(III)</enum>
                        <text>in the case of a
				compounding manufacturer, the compounding manufacturer has registered under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2" proposed="true">subsection (g)(2)</cato:entity-ref> as an entity that intends to compound pursuant to this
				paragraph and notifies the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> at least 14 calendar days prior to
				beginning the compounding.</text>
											</subclause>
                    </clause>
                  </subparagraph>
                  <subparagraph id="idB8912E95056C4ABF95A8269CBA44E547">
                    <enum>(B)</enum>
                    <header>Notice
				waiver</header>
                    <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may waive a notice required under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:3/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="ided4b8423a9f04593b6a33062ae76d607">
                    <enum>(C)</enum>
                    <header>Exclusion</header>
                    <text>For
				purposes of this paragraph, repackaging a marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section
				505</cato:entity-ref> does not make the repackaged drug a copy of such marketed drug, unless the
				repackaged drug is also a marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="idf917426ef9df422d847c5d3f81166de3">
                  <enum>(4)</enum>
                  <header>Exceptions regarding
				biological products</header>
									<subparagraph id="idD25E8A840BC741CBBD07D48831EB9CAA">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>A drug that is a variation of a licensed biological
				product may be compounded only if—</text>
										<clause id="id05c196c2866d43f799f94b5deaa7bf4c">
                      <enum>(i)</enum>
                      <subclause commented="no" display-inline="yes-display-inline" id="id3F32CF0D65D6427E9BE994DCA10D1977">
                        <enum>(I)</enum>
                        <text>such compounded
				variation is compounded solely using a licensed biological product, or solely
				using a licensed biological product and one or more ingredients in compliance
				with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:1/sp:B" proposed="true">subsection (e)(1)(B)</cato:entity-ref>; or</text>
											</subclause>
                      <subclause changed="added" committee-id="SSHR00" id="id13E93487B20D4783A857EA7B6F4A0C95" indent="up1" reported-display-style="italic">
                        <enum>(II)</enum>
                        <text>in the case of a
				licensed allergenic product, such variation is compounded solely using one or
				more licensed allergenic products, or solely using one or more licensed
				allergenic products and one or more ingredients in compliance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:1/sp:B" proposed="true">subsection
				(e)(1)(B)</cato:entity-ref>;</text>
											</subclause>
                    </clause>
                    <clause id="idfd8d02ebc57d40a99ea0c7675f428101">
                      <enum>(ii)</enum>
                      <text>such compounded
				variation produces for the patient a clinical difference between such
				compounded variation and the licensed biological product, as determined
				by—</text>
											<subclause id="idEB9BCF3A9F774508B3BC39FB540B9C8D">
                        <enum>(I)</enum>
                        <text>the prescribing
				practitioner (in the case of a variation compounded by a traditional
				compounder); or</text>
											</subclause>
                      <subclause id="id03BC78E0140F4ABD9C656746BF61FC84">
                        <enum>(II)</enum>
                        <text>a licensed practitioner
				responsible for the patient’s care in a health care entity that provides
				medical services through licensed practitioners directly to patients (in the
				case of a variation compounded by a compounding manufacturer);</text>
											</subclause>
                    </clause>
                    <clause id="idD6C38DE007754B95A27984A6908D7B94">
                      <enum>(iii)</enum>
                      <text>prior to beginning
				compounding—</text>
											<subclause id="id1B584E1DD76D4AC3A092747FAC6C9C76">
                        <enum>(I)</enum>
                        <text>except as provided in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>, the traditional compounder receives a prescription order for
				an identified individual patient specifying that the biological product may be
				compounded for an identified individual patient; or</text>
											</subclause>
                      <subclause id="idBD8162769FB048B59602EA16045A43B1">
                        <enum>(II)</enum>
                        <text>the compounding
				manufacturer receives a duly authorized medical order from a health care entity
				that provides medical services through licensed practitioners directly to
				patients, specifying that the biological product may be compounded based on
				such order for an identified patient or patients; and</text>
											</subclause>
                    </clause>
                    <clause id="id82E68B79309C438096896A28F7072C6A">
                      <enum>(iv)</enum>
                      <text>in the case of a
				radioactive biological product, the compounded variation is compounded by a
				compounding nuclear pharmacy in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:2" proposed="true">subsection (b)(2)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idAC036299F1A34A68BBB46593B0A620B2">
                    <enum>(B)</enum>
                    <header>Special rule for
				pediatric uses</header>
                    <text>A traditional compounder that is a hospital or
				health system may begin compounding a drug that is a variation of a licensed
				biological product prior to receiving a prescription order as required under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4/sp:A/cl:iii" proposed="true">subparagraph (A)(iii)</cato:entity-ref> if—</text>
										<clause id="idD810729E76404E92B6D5DC1001F69812">
                      <enum>(i)</enum>
                      <text>such compounded variation
				is a diluted or repackaged variation of the licensed biological product for
				emergent use in pediatric patients; and</text>
										</clause>
                    <clause id="idA7B39A2E31D04FAD875AA3E98B158299">
                      <enum>(ii)</enum>
                      <text>such compounded
				variation produces for the patient a clinical difference between such
				compounded variation and the licensed biological product, as determined by a
				licensed practitioner responsible for the patient’s care in the hospital or
				health system.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id075B92157F8248B795157668B9C83B18">
                    <enum>(C)</enum>
                    <header>Inapplicability</header>
                    <text>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4/sp:A/cl:ii" proposed="true">Clauses
				(ii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4/sp:A/cl:iii" proposed="true">(iii) of subparagraph (A)</cato:entity-ref> shall not apply to a compounded allergenic
				product.</text>
									</subparagraph>
                  <subparagraph commented="no" id="idB1331ACC2E5C48D6B38BA6D041F82F43">
                    <enum>(D)</enum>
                    <header>Pooling</header>
                    <text>Notwithstanding
				any other provision of this section, sterile pooling of a biological product is
				not permitted.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="ida9706c7561874d1da01ed745430bc97e">
                  <enum>(5)</enum>
                  <header>Requirement for drugs
				that have risk evaluation and mitigation strategies</header>
									<subparagraph id="id6c1d04b28606410db986d67aeb2d06cb">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>A copy or variation of a drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref>
				or biological product licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service
				Act</cato:entity-ref> that is the subject of a risk evaluation and mitigation strategy approved
				with elements to assure safe use pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1">section 505–1</cato:entity-ref>, may be compounded
				only if—</text>
										<clause id="id7b5a0d4b28714965ad03a9776b238d26">
                      <enum>(i)</enum>
                      <text>the entity compounding
				the copy or variation receives a prescription order for an identified
				individual patient specifying that the drug or biological product may be
				compounded; and</text>
										</clause>
                    <clause id="id19911b9ff40c45478a1da629b0ca3d18">
                      <enum>(ii)</enum>
                      <text>the entity compounding
				the copy or variation demonstrates to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, prior to beginning
				compounding, that the entity will utilize controls that are comparable to the
				controls applicable under the relevant risk evaluation and mitigation strategy
				for the approved drug or licensed biological product.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id2c49b0e22a7448978eb0f537a7596a76">
                    <enum>(B)</enum>
                    <header>Effect</header>
                    <text>Nothing
				in this paragraph shall be construed to permit compounding a copy or variation
				of a drug other than as permitted in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:3" proposed="true">paragraphs (3)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4" proposed="true">(4)</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id778390f20710418bae343dad97fc8a0b">
                <enum>(e)</enum>
                <header>Quality of drug
				ingredients</header>
								<paragraph id="id0d31e70c68d849ab81627459b97d4723">
                  <enum>(1)</enum>
                  <header>Human
				drugs</header>
                  <text>A traditional compounder or a compounding manufacturer
				shall—</text>
									<subparagraph id="id85000cfddb884e789a4f03c4bbe8ebc9">
                    <enum>(A)</enum>
                    <text>if compounding a drug
				from bulk drug substances (as defined in regulations of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> published
				at <external-xref legal-doc="regulation" parsable-cite="cfr/21/207.3">section 207.3(a)(4)</external-xref> of title 21, Code of Federal Regulations (or any
				successor regulations)), use only bulk substances—</text>
										<clause id="id353f0340182141fa9a6ce34fd8af295f">
                      <enum>(i)</enum>
                      <text>that—</text>
											<subclause id="id21c1c998f0e94f7099b3267b162efa9d">
                        <enum>(I)</enum>
                        <text>comply with the standards
				of an applicable United States Pharmacopoeia or National Formulary monograph,
				if a monograph exists and has not been identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2" proposed="true">paragraph (2)</cato:entity-ref>;</text>
											</subclause>
                      <subclause id="id00491a0d2318484eb340278250b00ba1">
                        <enum>(II)</enum>
                        <text>if such a monograph does
				not exist, are drug substances that are components of drugs approved by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>; or</text>
											</subclause>
                      <subclause id="id6bc17c0030274da691981b0ec34ed461">
                        <enum>(III)</enum>
                        <text>if such a monograph
				does not exist and the drug substance is not a component of a drug approved by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that appear on a list developed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> through
				regulations issued by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>;</text>
											</subclause>
                    </clause>
                    <clause id="id2221835463884c3e9297c2372466dcb1">
                      <enum>(ii)</enum>
                      <text>that are manufactured by
				an establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> (including a foreign
				establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:i">section 510(i)</cato:entity-ref>); and</text>
										</clause>
                    <clause id="idee4cd281994d40789673af6f415a7eda">
                      <enum>(iii)</enum>
                      <text>that are accompanied by
				valid certificates of analysis for each specific lot of bulk drug
				substance;</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idd26b55f3cd984d31bdcb7c0eb83a4f2b">
                    <enum>(B)</enum>
                    <text>use ingredients (other
				than bulk drug substances) that comply with the standards of an applicable
				United States Pharmacopoeia or National Formulary monograph, if a monograph
				exists and has not been identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2" proposed="true">paragraph (2)</cato:entity-ref>; and</text>
									</subparagraph>
                  <subparagraph id="idEB1DC1F6D20B4B95BC4609B7CF1A3235">
                    <enum>(C)</enum>
                    <text>in the case of a
				traditional compounder, comply with the standards of the United States
				Pharmacopoeia chapters on pharmacy compounding.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="ide5bcc7ba758b4ec9b7c84199994f43ed">
                  <enum>(2)</enum>
                  <header>Identification by
				secretary</header>
									<subparagraph id="id87bfd3df5e44475d953a64c51365c556">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>Notwithstanding the existence of an applicable monograph
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:1/sp:A/cl:i/scl:I" proposed="true">subparagraph (A)(i)(I)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:1/sp:B" proposed="true">(B) of paragraph (1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may
				identify bulk substances that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines, based on public health
				concerns, may not be used in compounding a drug.</text>
									</subparagraph>
                  <subparagraph id="id87371d0d71a940d0b8f60063252e7af8">
                    <enum>(B)</enum>
                    <header>Procedure</header>
                    <text>In
				identifying the bulk substances that may not be used in compounding, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
										<clause id="id636a576ee33e4dbbad61506fdd934c04">
                      <enum>(i)</enum>
                      <text>publish a notice of such
				bulk substances proposed for identification in the Federal Register, including
				the rationale for such proposal;</text>
										</clause>
                    <clause id="id0a9e74fa4a9449f1be4090ec7e0fc105">
                      <enum>(ii)</enum>
                      <text>provide a period of not
				less than 60 calendar days for comment on the notice; and</text>
										</clause>
                    <clause id="id530a03893f6d4163a8792a7a3ba9bd30">
                      <enum>(iii)</enum>
                      <text>publish a notice in the
				Federal Register identifying the bulk substances that may not be used in
				compounding a drug.</text>
										</clause>
                  </subparagraph>
                </paragraph>
              </subsection>
              <subsection id="ida0ad46ae2c724b59a439e494394fe9b6">
                <enum>(f)</enum>
                <header>Requirements regarding
				wholesaling and labeling applicable to traditional compounders and compounding
				manufacturers</header>
                <text>A compounded drug—</text>
								<paragraph id="idef88a52d64a848b9a5f41630d9fc2ae6">
                  <enum>(1)</enum>
                  <text>may not be sold by an
				entity other than the compounding manufacturer or traditional compounder that
				compounded the drug;</text>
								</paragraph>
                <paragraph id="idbc004dff5ae34e2591f9923671879a32">
                  <enum>(2)</enum>
                  <text>compounded by a
				compounding manufacturer may not be sold or transferred to an entity other than
				a health care entity that provides medical services through licensed
				practitioners directly to patients, or a network of such providers, except that
				a compounding manufacturer may transfer without profit a compounded sterile
				drug to a licensed pharmacy if—</text>
									<subparagraph id="id6e5eeca71a434b26b480d6b83fb66092">
                    <enum>(A)</enum>
                    <text>as of the date of
				enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical Compounding Quality and Accountability Act</cato:entity-ref>, and
				at the time of such transfer, the licensed pharmacy falls under the same
				corporate ownership as the compounding manufacturer;</text>
									</subparagraph>
                  <subparagraph id="idd251ea9d60204b138f29c4eb1cf47d87">
                    <enum>(B)</enum>
                    <text>the transfer of such
				compounded sterile drug is solely for the purpose of dispensing the compounded
				sterile drug to the end user, who has been instructed by the prescribing
				physician to self-administer such compounded sterile drug;</text>
									</subparagraph>
                  <subparagraph id="id37183a7328324c42b3b64d310bfbb577">
                    <enum>(C)</enum>
                    <text>as of the date of
				enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical Compounding Quality and Accountability Act</cato:entity-ref>, and
				at the time of such transfer, the compounding manufacturer is an entity wholly
				owned by an entity that provides pharmacy benefits management services on
				behalf of a health benefits plan;</text>
									</subparagraph>
                  <subparagraph id="id8faa6b57a7c741268944a7b13437266b">
                    <enum>(D)</enum>
                    <text>the compounding
				manufacturer identifies itself to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> upon registering under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2" proposed="true">subsection (g)(2)</cato:entity-ref> as an entity that qualifies for the exception under this
				paragraph, and provides documentation of the compounding of such drugs as of
				the date of enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical Compounding Quality and
				Accountability Act</cato:entity-ref>, in a manner described by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>; and</text>
									</subparagraph>
                  <subparagraph id="ida93b8f9434674e7da68002d9c5041842">
                    <enum>(E)</enum>
                    <text>the compounding
				manufacturer receives confirmation from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that the compounding
				manufacturer qualifies for the exception under this paragraph and the sterile
				drug or drugs for which the exemption applies; and</text>
									</subparagraph>
                </paragraph>
                <paragraph id="ide2c24370cff54ae6a14d24a479f17892">
                  <enum>(3)</enum>
                  <text>in the case of a
				compounded drug offered for sale, shall be labeled <quote>not for
				resale</quote>.</text>
								</paragraph>
              </subsection>
              <subsection id="id3e8c8a6dea9e49f5b362978fc472e067">
                <enum>(g)</enum>
                <header>Other requirements
				applicable to compounding manufacturers</header>
								<paragraph id="ide43c5f039b7043e0a01f3b2caca8b3a3">
                  <enum>(1)</enum>
                  <header>Licensed pharmacist
				oversight</header>
                  <text>A compounding manufacturer shall ensure that a
				pharmacist licensed in the State where the compounding manufacturer is located
				exercises direct supervision over the operations of the compounding
				manufacturer.</text>
								</paragraph>
                <paragraph id="idbf6b203779854262b4d0f4344413896a">
                  <enum>(2)</enum>
                  <header>Registration of
				compounding manufacturers and reporting of drugs</header>
									<subparagraph id="idbe8f3efbad2f4bd1ac995131857262f0">
                    <enum>(A)</enum>
                    <header>Registration of
				compounding manufacturers</header>
										<clause id="idba6ce7dbaee64711b0e39c45006cc985">
                      <enum>(i)</enum>
                      <header>Annual
				registration</header>
                      <text>During the period beginning on October 1 and ending
				on December 31 each year, each compounding manufacturer shall register with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> its name, place of business, and unique facility identifier (which
				shall conform to the requirements for the unique facility identifier
				established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:510">section 510</cato:entity-ref>), and a point of contact e-mail address, and
				shall indicate whether the compounding manufacturer intends to compound drug in
				shortage pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:d/p:3/sp:A/cl:ii" proposed="true">subsection (d)(3)(A)(ii)</cato:entity-ref>.</text>
										</clause>
                    <clause id="id27a0f8b72f994d4a9cf6f621db53fe03">
                      <enum>(ii)</enum>
                      <header>New compounding
				manufacturers</header>
                      <text>Each compounding manufacturer, upon first engaging
				in the operations described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:b/p:1" proposed="true">subsection (b)(1)</cato:entity-ref>, shall immediately register
				with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and provide the information described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref>. The
				Secretary shall establish a timeline for registration for the first year
				following the effective date of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical Compounding Quality and
				Accountability Act</cato:entity-ref>. In no case may registration be required until at least 60
				calendar days following publication of the timeline in the Federal
				Register.</text>
										</clause>
                    <clause id="id0e55c097e7664826b3875ca09c0eb62a">
                      <enum>(iii)</enum>
                      <header>Availability of
				registration for inspection</header>
                      <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make available
				for inspection, to any person so requesting, any registration filed pursuant to
				this subparagraph.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id93373ff8b90045b3a84dcd2fd38d7361">
                    <enum>(B)</enum>
                    <header>Drug reporting by
				compounding manufacturers</header>
										<clause id="id3decbc45d57f4d4083e4928f722c72ee">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Each compounding manufacturer who registers with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, once during the
				month of June of each year and once during the month of December of each year,
				a report—</text>
											<subclause id="id2927a2dcd85641a9b117def3bed8fa99">
                        <enum>(I)</enum>
                        <text>identifying the drugs
				compounded by such compounding manufacturer during the previous 6-month period;
				and</text>
											</subclause>
                      <subclause id="idbca12792019a46ec91ab9748f058f066">
                        <enum>(II)</enum>
                        <text>with respect to each
				drug identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2/sp:B/cl:i/scl:I" proposed="true">subclause (I)</cato:entity-ref>, providing the active ingredient, the
				source of such active ingredient, the National Drug Code number, if available,
				of the source drug or bulk active ingredient, the strength of the active
				ingredient per unit, the dosage form and route of administration, the package
				description, the number of individual units produced, the National Drug Code
				number of the final product, if assigned.</text>
											</subclause>
                    </clause>
                    <clause id="id585a8607b78e4476a0577d203c939d73">
                      <enum>(ii)</enum>
                      <header>Form</header>
                      <text>Each
				report under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref> shall be prepared in such form and manner as the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may prescribe by regulation or guidance.</text>
										</clause>
                    <clause id="id8953DD0A14714917A54BFCFC25C951A7">
                      <enum>(iii)</enum>
                      <header>Confidentiality</header>
                      <text>Reports
				submitted pursuant to this subparagraph shall be exempt from inspection under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2/sp:A/cl:iii" proposed="true">subparagraph (A)(iii)</cato:entity-ref>, unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that such an exemption would
				be inconsistent with the protection of the public health.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id12fa974cab8a40f7a183ccea3767be28">
                    <enum>(C)</enum>
                    <header>Electronic registration
				and reporting</header>
                    <text>Registrations and drug reporting under this
				paragraph (including the submission of updated information) shall be submitted
				to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by electronic means unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> grants a request for
				waiver of such requirement because use of electronic means is not reasonable
				for the person requesting waiver.</text>
									</subparagraph>
                  <subparagraph id="idf94086caad924d09ae1ecbff4413895c">
                    <enum>(D)</enum>
                    <header>Risk-based inspection
				frequency</header>
										<clause id="ide56a8141242f4208a8ad4e2b4853fd57">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Compounding manufacturers shall be subject to inspection
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:704">section 704</cato:entity-ref>.</text>
										</clause>
                    <clause id="idfe374fff1fd64ac89f484e4e1b61f683">
                      <enum>(ii)</enum>
                      <header>Risk-based
				schedule</header>
                      <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through one or more officers or
				employees duly designated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, shall inspect compounding
				manufacturers described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2/sp:D/cl:i" proposed="true">clause (i)</cato:entity-ref> in accordance with a risk-based schedule
				established by the Secretary.</text>
										</clause>
                    <clause id="id272e6b267a96408e90b43cfe25035d8b">
                      <enum>(iii)</enum>
                      <header>Risk
				factors</header>
                      <text>In establishing the risk-based schedule under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2/sp:D/cl:ii" proposed="true">clause
				(ii)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall inspect compounding manufacturers according to the
				known safety risks of such compounding manufacturers, which shall be based on
				the following factors:</text>
											<subclause id="id6adb0a9ca1f645189c5d49cf171fb51c">
                        <enum>(I)</enum>
                        <text>The compliance history of
				the compounding manufacturer.</text>
											</subclause>
                      <subclause id="idcd34db1a40444826875693ec276bdfc6">
                        <enum>(II)</enum>
                        <text>The record, history, and
				nature of recalls linked to the compounding manufacturer.</text>
											</subclause>
                      <subclause id="id41f8e8795373405e9b7df430490f1a1c">
                        <enum>(III)</enum>
                        <text>The inherent risk of
				the drug compounded at the compounding manufacturer.</text>
											</subclause>
                      <subclause id="id6ed0ab7e409643f799f4a948c9a1861f">
                        <enum>(IV)</enum>
                        <text>The inspection frequency
				and history of the compounding manufacturer, including whether the compounding
				manufacturer has been inspected pursuant to section 704 within the last 4
				years.</text>
											</subclause>
                      <subclause id="id308C1E1D4F874DC89BFC9647D60A09FA">
                        <enum>(V)</enum>
                        <text>Whether the compounding
				manufacturer has registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:g/p:2" proposed="true">subsection (g)(2)</cato:entity-ref> as an entity that intends
				to compound pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:503A/ss:d/p:3/sp:A/cl:ii" proposed="true">subsection (d)(3)(A)(ii)</cato:entity-ref>.</text>
											</subclause>
                      <subclause id="id5bf233fa992345ddb0700fc574679aba">
                        <enum>(VI)</enum>
                        <text>Any other criteria
				deemed necessary and appropriate by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for purposes of allocating
				inspection resources.</text>
											</subclause>
                    </clause>
                  </subparagraph>
                </paragraph>
                <paragraph id="id7f513631d07145d282222c5e373d39fe">
                  <enum>(3)</enum>
                  <header>Adverse event
				reporting</header>
									<subparagraph id="id81292a1059cc440d9b1de0facab4df76">
                    <enum>(A)</enum>
                    <header>Definitions</header>
                    <text>In
				this paragraph:</text>
										<clause id="id28a97e7d0cfb44a9b78ffa98e4e4861a">
                      <enum>(i)</enum>
                      <header>Adverse
				event</header>
                      <text>The term <term>adverse event</term> means any
				health-related event associated with the use of a compounded drug that is
				adverse, including—</text>
											<subclause id="id468159450af44743b0a83d155ebdc677">
                        <enum>(I)</enum>
                        <text>an event occurring in the
				course of the use of the drug in professional practice;</text>
											</subclause>
                      <subclause id="idd6fe423581e64328a3b50ac50649305b">
                        <enum>(II)</enum>
                        <text>an event occurring from
				an overdose of the drug, whether accidental or intentional;</text>
											</subclause>
                      <subclause id="idfe68787d05514503b3ed2ff4debe1ee1">
                        <enum>(III)</enum>
                        <text>an event occurring from
				abuse of the drug;</text>
											</subclause>
                      <subclause id="id55d42d31df4d4312839a494d819bd186">
                        <enum>(IV)</enum>
                        <text>an event occurring from
				withdrawal of the drug; and</text>
											</subclause>
                      <subclause id="id80a98a1d6edc46adb1bbd248364d874f">
                        <enum>(V)</enum>
                        <text>any failure of expected
				pharmacological action of the drug.</text>
											</subclause>
                    </clause>
                    <clause id="id923eda2a98224e48af05d4a8d1f60de8">
                      <enum>(ii)</enum>
                      <header>Serious adverse
				event</header>
                      <text>The term <term>serious adverse event</term> means an
				adverse event that—</text>
											<subclause id="idf0511a08e2bc47868d3ad4d88e1941f0">
                        <enum>(I)</enum>
                        <text>results in—</text>
												<item id="id8333af37896343b4a532b9fbc76f2155">
                          <enum>(aa)</enum>
                          <text>death;</text>
												</item>
                        <item id="idc2c2252f28ad4486aa3ba412d4d74f62">
                          <enum>(bb)</enum>
                          <text>an adverse drug event
				that places the patient at immediate risk of death from the adverse drug event
				as it occurred (not including an adverse drug event that might have caused
				death had it occurred in a more severe form);</text>
												</item>
                        <item id="id4b6d2565ef1945d599d40da8b38ee0d0">
                          <enum>(cc)</enum>
                          <text>inpatient
				hospitalization or prolongation of existing hospitalization;</text>
												</item>
                        <item id="id2987632179c943c38384e58245d1d636">
                          <enum>(dd)</enum>
                          <text>a persistent or
				significant incapacity or substantial disruption of the ability to conduct
				normal life functions; or</text>
												</item>
                        <item id="id5323a1ecf19943848aafadc0162d8015">
                          <enum>(ee)</enum>
                          <text>a congenital anomaly or
				birth defect; or</text>
												</item>
                      </subclause>
                      <subclause id="id5410a93ba55047b096092f000389c883">
                        <enum>(II)</enum>
                        <text>based on appropriate
				medical judgment, may jeopardize the patient and may require a medical or
				surgical intervention to prevent an outcome described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:3/sp:A/cl:ii/scl:I" proposed="true">subclause (I)</cato:entity-ref>.</text>
											</subclause>
                    </clause>
                  </subparagraph>
                  <subparagraph id="id81b01225ae01462cb8c6936f3c2cbeb2">
                    <enum>(B)</enum>
                    <header>Reports</header>
										<clause id="id531395721efd4253ab12596b9aa6b7da">
                      <enum>(i)</enum>
                      <header>Adverse event reporting
				requirement</header>
											<subclause id="ide3a131298ac04333bca6764de8d1ef3a">
                        <enum>(I)</enum>
                        <header>15-day
				report</header>
                        <text>If a compounding manufacturer becomes aware of any serious
				adverse event, such manufacturer shall submit reports of each instance to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as soon as practicable, but in no case later than 15 calendar days
				after the initial receipt of the applicable information. Such manufacturer
				shall investigate and submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> followup reports for each such
				instance not later than 15 calendar days after receipt of new information or as
				requested by the Secretary. Unless and until the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> establishes the
				content and format of adverse event reports by guidance or regulation, reports
				shall be submitted in accordance with the content and format requirements under
				<external-xref legal-doc="regulation" parsable-cite="cfr/21/310.305">section 310.305</external-xref> of title 21, Code of Federal Regulations (or any successor
				regulations) or <external-xref legal-doc="regulation" parsable-cite="cfr/21/600.80">section 600.80</external-xref> of title 21, Code of Federal Regulations (or any
				successor regulations).</text>
											</subclause>
                      <subclause id="idce400218e3244a3786977df2da216f13">
                        <enum>(II)</enum>
                        <header>Annual
				report</header>
                        <text>Compounding manufacturers that report serious adverse
				events shall submit in December of each year a narrative summary of any
				analysis of each report submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:3/sp:B/cl:i/scl:I" proposed="true">subclause (I)</cato:entity-ref>, including a history of
				actions taken during the year because of each report, using the content,
				format, and manner established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by guidance or regulation.
				Until such time as the Secretary publishes such guidance or regulation, each
				compounding manufacturer shall retain such summaries as part of the records to
				be maintained in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:3/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>.</text>
											</subclause>
                    </clause>
                    <clause id="id926abd868bd6472ea151e785fa879cd9">
                      <enum>(ii)</enum>
                      <header>Product quality
				reporting requirement</header>
                      <text>Not later than 3 calendar days after the
				compounding manufacturer becomes aware of information pertaining to sterility,
				stability, or other product quality concerns that could result in serious
				adverse events, the compounding manufacturer shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a
				product quality report, in a form and manner established by the Secretary by
				guidance or regulation.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idd87a376ba44942e2ab7156ab51568172">
                    <enum>(C)</enum>
                    <header>Maintenance of
				records</header>
                    <text>A compounding manufacturer shall maintain for a period of
				10 years records of all serious adverse drug events known to the compound
				manufacturer in accordance with <external-xref legal-doc="usc" parsable-cite="usc/21/314">section 314.80(i)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulation), or as otherwise directed by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in regulations.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="idcefa210248204c5cb20403b579f5510d">
                  <enum>(4)</enum>
                  <header>Labeling of
				drugs</header>
									<subparagraph id="id24b3f5ffddf94d60a08a1a06729ed1ac">
                    <enum>(A)</enum>
                    <header>Label</header>
                    <text>The
				label of a drug compounded by a compounding manufacturer shall include—</text>
										<clause id="ide5d35ad95d314ddbbc2553f8450b1198">
                      <enum>(i)</enum>
                      <text>the statement <quote>This
				is a compounded drug.</quote> or a reasonable comparable alternative statement
				(as specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>) that prominently identifies the drug as a
				compounded drug;</text>
										</clause>
                    <clause id="id7d5295b9e78d46f898d2467f481c3b40">
                      <enum>(ii)</enum>
                      <text>the name, address, and
				phone number of the applicable compounding manufacturer; and</text>
										</clause>
                    <clause id="id6bb40f5966eb4bb793c5ef95a97c8c54">
                      <enum>(iii)</enum>
                      <text>with respect to the
				compounded drug—</text>
											<subclause id="id05cb2b6f8c8d44c28a6432603c3f6ecf">
                        <enum>(I)</enum>
                        <text>the lot or batch
				number;</text>
											</subclause>
                      <subclause id="id029b7c1356f64f33ae111648a8e321de">
                        <enum>(II)</enum>
                        <text>the established name of
				the medication;</text>
											</subclause>
                      <subclause id="idc98b6a647a0f4a2c914ff3536f878440">
                        <enum>(III)</enum>
                        <text>the dosage form and
				strength;</text>
											</subclause>
                      <subclause id="id75058c4e17524d1cb15dfe13a2fd3939">
                        <enum>(IV)</enum>
                        <text>the statement of
				quantity or volume, as appropriate;</text>
											</subclause>
                      <subclause id="idc1f6f2402af447029f5602a918ee673f">
                        <enum>(V)</enum>
                        <text>the date that the drug
				was compounded;</text>
											</subclause>
                      <subclause id="id6f80c6b7daf747e19182e2820b15d189">
                        <enum>(VI)</enum>
                        <text>the expiration
				date;</text>
											</subclause>
                      <subclause id="id3a405c3b57b747ba9a741d84a8998494">
                        <enum>(VII)</enum>
                        <text>storage and handling
				instructions;</text>
											</subclause>
                      <subclause id="iddac39d6c9ab54ae2a3052729e1f46ff1">
                        <enum>(VIII)</enum>
                        <text>the National Drug Code
				number, if available;</text>
											</subclause>
                      <subclause id="id0f9634bf852e47f393693ce37ebca988">
                        <enum>(IX)</enum>
                        <text>the <quote>not for
				resale</quote> statement as required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:f/p:3" proposed="true">subsection (f)(3)</cato:entity-ref>; and</text>
											</subclause>
                      <subclause id="id8f8e36b7bf3c4ff3b5f19f0f411430c7">
                        <enum>(X)</enum>
                        <text>subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:4/sp:B/cl:i" proposed="true">subparagraph
				(B)(i)</cato:entity-ref>, a list of active and inactive ingredients, identified by established
				name and the quantity or proportion of each ingredient.</text>
											</subclause>
                    </clause>
                  </subparagraph>
                  <subparagraph id="idaae5438c18384ebeab1d4a57eec01284">
                    <enum>(B)</enum>
                    <header>Container</header>
                    <text>The
				container from which the individual units of a drug compounded by a compounding
				manufacturer are removed for dispensing or for administration (such as a
				plastic bag containing individual product syringes) shall include—</text>
										<clause id="idb636d8a2192143e390781e55c3c41047">
                      <enum>(i)</enum>
                      <text>the information described
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:4/sp:A/cl:iii/scl:X" proposed="true">subparagraph (A)(iii)(X)</cato:entity-ref>, if there is not space on the label for such
				information;</text>
										</clause>
                    <clause id="id24e75cf8470f4ee59a9c1e8d6d4efecf">
                      <enum>(ii)</enum>
                      <text>the following
				information to facilitate adverse event reporting: www.fda.gov/medwatch and
				1–800-FDA-1088; and</text>
										</clause>
                    <clause id="idfa756a0e4aac4e6aa4321e26fc02f2d6">
                      <enum>(iii)</enum>
                      <text>the directions for use,
				including, as appropriate, dosage and administration.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id59bb8e8d68454c6e81909e6de08e0caf">
                    <enum>(C)</enum>
                    <header>Additional
				information</header>
                    <text>The label and labeling of a drug compounded by a
				compounding manufacturer shall include any other information as determined
				necessary and specified in regulations promulgated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id7087cc151e13442aa2540203186ca4a2">
                <enum>(h)</enum>
                <header>Compounding
				manufacturer establishment and reinspection fees</header>
								<paragraph id="idf06dbf92b4c04ec397a09780ab7b7f3e">
                  <enum>(1)</enum>
                  <header>Definitions</header>
                  <text>In
				this subsection—</text>
									<subparagraph id="ida30997ca601e426b93b43cc01d711c99">
                    <enum>(A)</enum>
                    <text>the term
				<term>affiliate</term> has the meaning given such term in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section
				735(11)</cato:entity-ref>;</text>
									</subparagraph>
                  <subparagraph id="idf9a4a3970ff741af82eadfe02303de41">
                    <enum>(B)</enum>
                    <text>the term <term>gross
				annual sales</term> means the total worldwide gross annual sales, in United
				States dollars, for a compounding manufacturer, including the sales of all the
				affiliates of the compounding manufacturer; and</text>
									</subparagraph>
                  <subparagraph id="id80be8f9fe43c464485367ee48b339553">
                    <enum>(C)</enum>
                    <text>the term
				<term>reinspection</term> means, with respect to a compounding manufacturer, 1
				or more inspections conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref> subsequent to an inspection
				conducted under such provision which identified noncompliance materially
				related to an applicable requirement of this Act, specifically to determine
				whether compliance has been achieved to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> satisfaction.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="idac7e73d9858e4947999b164cffb12bcc">
                  <enum>(2)</enum>
                  <header>Establishment and
				reinspection fees</header>
									<subparagraph id="idF0A0BC277E0A4469925265D712E6B1D0">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>For fiscal year 2015 and each subsequent fiscal year, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, in accordance with this subsection, assess and collect—</text>
										<clause id="id88306b62729444d985dc737adddee953">
                      <enum>(i)</enum>
                      <text>an annual establishment
				fee from each compounding manufacturer; and</text>
										</clause>
                    <clause id="idabea42da173946fda75e40ca795ba2fc">
                      <enum>(ii)</enum>
                      <text>a reinspection fee from
				each compounding manufacturer subject to a reinspection in such fiscal
				year.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id29B241CFFE8E43228EF35FAE66E7E9A0">
                    <enum>(B)</enum>
                    <header>Multiple
				reinspections</header>
                    <text>A compounding manufacturer subject to multiple
				reinspections in a fiscal year shall be subject to a reinspection fee for each
				reinspection.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id974e8036a4b047dd9307fafd481d5b1a">
                  <enum>(3)</enum>
                  <header>Establishment and
				reinspection fee setting</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish the
				establishment and reinspection fee to be collected under this subsection for
				each fiscal year, based on the methodology described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4" proposed="true">paragraph (4)</cato:entity-ref> and shall
				publish such fee in a Federal Register notice not later than 60 calendar days
				before the start of each such year.</text>
								</paragraph>
                <paragraph id="id9557988DA6C34821B84C39BECEB8BC80">
                  <enum>(4)</enum>
                  <header>Amount of establishment
				fee and reinspection fee</header>
									<subparagraph id="id5897436d9d9b4413a23781170f38e9d3">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>For each compounding manufacturer in a fiscal
				year—</text>
										<clause id="id812F4D15CDBB4A1B8ADEE6804FD60002">
                      <enum>(i)</enum>
                      <text>except as provided
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>, the amount of the annual establishment fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2" proposed="true">paragraph
				(2)</cato:entity-ref> shall be equal to the sum of—</text>
											<subclause id="id756FEA7A89B14D96B26469DE7D333269">
                        <enum>(I)</enum>
                        <text>$15,000,
				multiplied by the inflation adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>;
				plus</text>
											</subclause>
                      <subclause id="id49d8f1fcfdfa4372ac26a9805874e0b2">
                        <enum>(II)</enum>
                        <text>the small
				business adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>; and</text>
											</subclause>
                    </clause>
                    <clause id="idB6CAA63035B74ADD830F9F8AA9140262">
                      <enum>(ii)</enum>
                      <text>the amount of any
				reinspection fee (if applicable) under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2" proposed="true">paragraph (2)</cato:entity-ref> shall be equal to $15,000,
				multiplied by the inflation adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:B" proposed="true">subparagraph
				(B)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="ida18c3a0e3a564e639dec3f99c1c3583f">
                    <enum>(B)</enum>
                    <header>Inflation adjustment
				factor</header>
										<clause id="id9865dd76cf854ad3b4416c738ee346b3">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>For fiscal year 2015 and subsequent fiscal years, the fee
				amounts established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be adjusted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by
				notice, published in the Federal Register, for a fiscal year by the amount
				equal to the sum of—</text>
											<subclause id="id4ed805c038364db09ead2e88ca4994ff">
                        <enum>(I)</enum>
                        <text>one;</text>
											</subclause>
                      <subclause id="id233f6077d30a41b985dae881f55795ef">
                        <enum>(II)</enum>
                        <text>the average
				annual percent change in the cost, per full-time equivalent position of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, of all personnel compensation and benefits paid
				with respect to such positions for the first 3 years of the preceding 4 fiscal
				years, multiplied by the proportion of personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal years;
				and</text>
											</subclause>
                      <subclause id="idfad9158887a648e3aa84d3d4c7f8b25c">
                        <enum>(III)</enum>
                        <text>the average annual
				percent change that occurred in the Consumer Price Index for urban consumers
				(U.S. City Average; Not Seasonally Adjusted; All items; Annual Index) for the
				first 3 years of the preceding 4 years of available data multiplied by the
				proportion of all costs other than personnel compensation and benefits costs to
				total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal years.</text>
											</subclause>
                    </clause>
                    <clause id="id0b5e3f6477254c6fb4626b2c0e9549d2">
                      <enum>(ii)</enum>
                      <header>Compounded
				basis</header>
                      <text>The adjustment made each fiscal year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref> shall
				be added on a compounded basis to the sum of all adjustments made each fiscal
				year after fiscal year 2014 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id1f50613fbe6d4e848190d16ba9602a86">
                    <enum>(C)</enum>
                    <header>Small business
				adjustment factor</header>
                    <text>The small business adjustment factor referred
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:A/cl:i/scl:II" proposed="true">subparagraph (A)(i)(II)</cato:entity-ref> shall be an amount established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for
				each fiscal year based on the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>’s estimate of—</text>
										<clause id="idd454a93e55be4ec3895bbbb246ee46c0">
                      <enum>(i)</enum>
                      <text>the number of small
				businesses that will pay a reduced establishment fee for such fiscal year;
				and</text>
										</clause>
                    <clause id="idf0d541a4a46a4d0e97f1183e2056d251">
                      <enum>(ii)</enum>
                      <text>the adjustment to the
				establishment fee necessary to achieve total fees equaling the total fees that
				the Secretary would have collected if no entity qualified for the small
				business exception in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id9a02275438d24f51931468268f91c1fb">
                    <enum>(D)</enum>
                    <header>Exception for small
				businesses</header>
										<clause id="idc92c3ada8c204c3e874ef717421fe629">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>In the case of a compounding manufacturer with gross
				annual sales of $1,000,000 or less in the 12 months ending April 1 of the
				fiscal year immediately preceding the fiscal year in which the fees under this
				subsection are assessed, the amount of the establishment fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2" proposed="true">paragraph
				(2)</cato:entity-ref> for a fiscal year shall be equal to <fraction>1/3</fraction> of the amount
				calculated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:A/cl:i/scl:I" proposed="true">subparagraph (A)(i)(I)</cato:entity-ref> in such fiscal year.</text>
										</clause>
                    <clause id="id53495fecda514a5da4f8d3dc8bae423c">
                      <enum>(ii)</enum>
                      <header>Application</header>
                      <text>To
				qualify for the exception under this subparagraph, a small business shall
				submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such exception, in a format
				specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in guidance, certifying its gross annual sales for
				the 12 months ending April 1 of the fiscal year immediately preceding the
				fiscal year in which fees under this subsection are assessed. Any such
				application must be submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than April 30 for the
				following fiscal year. Any statement or representation made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall be subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1001">
                        <external-xref legal-doc="usc" parsable-cite="usc/18/1001">section 1001</external-xref> of title 18, United States Code</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id6f15f87ccf5040f099749f9eb31a52c0">
                    <enum>(E)</enum>
                    <header>Crediting of
				fees</header>
                    <text>In establishing the small business adjustment factor under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref> for a fiscal year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide for the
				crediting of fees from the previous year to the next year if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				overestimated the amount of the small business adjustment factor for such
				previous fiscal year, and consider the need to account for any adjustment of
				fees and such other factors as the Secretary determines appropriate.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id438d918d22fd4fceb606cfbe63da1273">
                  <enum>(5)</enum>
                  <header>Use of
				fees</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make all of the fees collected pursuant
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2/sp:A/cl:ii" proposed="true">(ii) of paragraph (2)(A)</cato:entity-ref> available solely to pay for the
				costs of oversight of compounding manufacturers.</text>
								</paragraph>
                <paragraph id="id8d56ad346cae4fa39b4e24590b0ccc1d">
                  <enum>(6)</enum>
                  <header>Supplement not
				supplant</header>
                  <text>Funds received by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> pursuant to this
				subsection shall be used to supplement and not supplant any other Federal funds
				available to carry out the activities described in this section.</text>
								</paragraph>
                <paragraph id="id6bada36eb2b54dc1b2f53878dc0b0cbc">
                  <enum>(7)</enum>
                  <header>Crediting and
				availability of fees</header>
                  <text>Fees authorized under this subsection shall
				be collected and available for obligation only to the extent and in the amount
				provided in advance in appropriations Acts. Such fees are authorized to remain
				available until expended. Such sums as may be necessary may be transferred from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> salaries and expenses appropriation account
				without fiscal year limitation to such appropriation account for salaries and
				expenses with such fiscal year limitation. The sums transferred shall be
				available solely for the purpose of paying the costs of oversight of
				compounding manufacturers.</text>
								</paragraph>
                <paragraph id="id9bf6d321983745008d2703fac3492f93">
                  <enum>(8)</enum>
                  <header>Collection of
				fees</header>
									<subparagraph id="ideccb464b15f448f68d61b1c0f6948a70">
                    <enum>(A)</enum>
                    <header>Establishment
				fee</header>
                    <text>A compounding manufacturer shall remit the establishment fee
				due under this subsection in a fiscal year when submitting a registration
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">subsection (g)</cato:entity-ref> for such fiscal year.</text>
									</subparagraph>
                  <subparagraph id="idd90c129d36604bb0a21814b9f262d153">
                    <enum>(B)</enum>
                    <header>Reinspection
				fee</header>
                    <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify in the Federal Register notice
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:3" proposed="true">paragraph (3)</cato:entity-ref> the manner in which reinspection fees assessed under
				this subsection shall be collected and the timeline for payment of such fees.
				Such a fee shall be collected after the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has conducted a reinspection
				of the compounding manufacturer involved.</text>
									</subparagraph>
                  <subparagraph id="ide4ca8af7c7db4d6fbc5b014ec507067f">
                    <enum>(C)</enum>
                    <header>Effect of failure to
				pay fees</header>
										<clause id="idead9bf1088f44aa8aeba019ac0fc9783">
                      <enum>(i)</enum>
                      <header>Registration</header>
                      <text>A
				compounding manufacturer shall not be considered registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">subsection
				(g)</cato:entity-ref> in a fiscal year until the date that the compounding manufacturer remits
				the establishment fee under this subsection for such fiscal year.</text>
										</clause>
                    <clause id="id4efc5ac806b449dfac6de098014e0bd9">
                      <enum>(ii)</enum>
                      <header>Misbranding</header>
                      <text>All
				drugs manufactured, prepared, propagated, compounded, or processed by a
				compounding manufacturer for which any establishment fee or reinspection fee
				has not been paid as required by this subsection shall be deemed misbranded
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:cc">section 502(cc)</cato:entity-ref> until the fees owed for such compounding manufacturer
				under this subsection have been paid.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id9b7e5a158bf04effba83fd19b0f3d90c">
                    <enum>(D)</enum>
                    <header>Collection of unpaid
				fees</header>
                    <text>In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not receive payment of
				a fee assessed under this subsection within 30 calendar days after it is due,
				such fee shall be treated as a claim of the United States Government subject to
				provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States
				Code</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id39e674a293bf4b9cb48371dbda5e97cf">
                  <enum>(9)</enum>
                  <header>Annual report to
				congress</header>
                  <text>Not later than 120 calendar days after each fiscal year
				in which fees are assessed and collected under this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall submit a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health Education Labor and Pensions
				of the Senate</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of
				Representatives</cato:entity-ref>, to include a description of fees assessed and collected for
				each year, a summary description of entities paying the fees, and the number of
				inspections and reinspections of such entities performed each year.</text>
								</paragraph>
                <paragraph id="iddaa332140cb4492ba1a59215dcfa53ad">
                  <enum>(10)</enum>
                  <header>Authorization of
				appropriations</header>
                  <text>
                    <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                      <cato:funds-and-year amount="indefinite" year="2015,..">For fiscal year 2015 and each subsequent fiscal
				year</cato:funds-and-year>, there is authorized to be appropriated <cato:property name="purpose">for fees under this subsection an
				amount equivalent to the total amount of fees assessed for such fiscal year
				under this subsection</cato:property>.</cato:entity>
                  </text>
								</paragraph>
              </subsection>
              <subsection id="id4d6796f1a44a46df975fa8496551a1b6">
                <enum>(i)</enum>
                <header>Action by secretary
				regarding complaints from state boards of pharmacy</header>
								<paragraph id="id19013B2BF73F45638669BB88CE84C968">
                  <enum>(1)</enum>
                  <header>Identification of
				compounding manufacturers</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall encourage States to
				identify to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> facilities that are licensed by a State as a pharmacy
				that appear to be entities that are required to be registered with the
				Secretary as a compounding manufacturer.</text>
								</paragraph>
                <paragraph id="idc5024a1e81b8470ab5bb065c86213ab8">
                  <enum>(2)</enum>
                  <header>Designation</header>
                  <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall designate a point of contact and establish a format and
				procedure for a State Board of Pharmacy to notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> if it appears
				to a State Board of Pharmacy that an entity licensed by a State as a pharmacy
				is required to be registered with the Secretary as a compounding
				manufacturer.</text>
								</paragraph>
                <paragraph id="id2f727e726f8e43fb98f0cda47e8386a8">
                  <enum>(3)</enum>
                  <header>Determination</header>
                  <text>If
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that such an entity described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:i/p:2" proposed="true">paragraph (2)</cato:entity-ref> is
				required to be registered with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as a compounding manufacturer, the
				Secretary shall transmit such determination to the State Board of Pharmacy in
				the State in which the entity is located, and to the State Board of Pharmacy in
				the notifying State, if different, within 15 calendar days of such
				determination and shall make such determination publicly available on the
				Internet Web site of the Food and Drug Administration.</text>
								</paragraph>
                <paragraph id="id31afcf63000c48619639d31afdd8591a">
                  <enum>(4)</enum>
                  <header>Effect</header>
                  <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall encourage direct communications between States regarding
				traditional compounders. Nothing in this subsection shall expand the
				Secretary’s authority over or responsibility for traditional
				compounders.</text>
								</paragraph>
              </subsection>
            </section>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</subsection>
        <subsection id="idda700afb73f547ef93f8f6f031b622f6">
          <enum>(c)</enum>
          <header>Prohibited
			 act</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301">Section 301</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
                <cato:entity-ref entity-type="uscode" value="usc/21/331">21 U.S.C. 331</cato:entity-ref>
              </external-xref>)</cato:entity> is amended—</text>
					<paragraph id="id7750ca3bb4da4f48bbe52c20aba25bc2">
            <enum>(1)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:e">subsection (e)</cato:entity-ref>, by
			 striking <quote>417, 416, 504</quote> and inserting <quote>417, 416, 503A(g),
			 504</quote>; and</text>
					</paragraph>
          <paragraph id="id51a62f1c609341d2bfe008cdaeda3b7d">
            <enum>(2)</enum>
            <text>by adding at the end the
			 following:</text>
						<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="idA77E9CEA27BB467497A1283C0E8F834B" reported-display-style="italic" style="OLC">
							<subsection commented="no" id="idB240394C7F40429D850AF85AE859C065">
                <enum>(ccc)</enum>
                <paragraph commented="no" display-inline="yes-display-inline" id="id1C516EFB10A444D9BA73C270E792FAAD">
                  <enum>(1)</enum>
                  <text>The resale of a
				compounded drug that is labeled <quote>not for resale</quote> as required by
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section 503A</cato:entity-ref>.</text>
								</paragraph>
                <paragraph changed="added" commented="no" committee-id="SSHR00" id="idBE7D41F4D2EE40359F22886AD1F8EC97" indent="up1" reported-display-style="italic">
                  <enum>(2)</enum>
                  <text>The failure to register
				in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">subsection (g) of section 503A</cato:entity-ref> or the failure to submit a
				report as required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:B" proposed="true">subsection (g)(2)(B)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:3" proposed="true">(g)(3) of such
				section</cato:entity-ref>.</text>
								</paragraph>
              </subsection>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</paragraph>
        </subsection>
        <subsection id="id8787c88655224bb1b12301108d9b8c4a">
          <enum>(d)</enum>
          <header>Report by
			 GAO</header>
          <text>Not later than November 1, 2016, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General of
			 the United States</cato:entity-ref> shall conduct a study and submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> a report on the
			 safety of animal drug compounding and the availability of safe and effective
			 drugs for animals.</text>
				</subsection>
      </section>
      <section id="idad2964bbb9084e169acf987e8c5c6734">
        <enum>103.</enum>
        <header>Other
			 requirements</header>
				<subsection id="idacfc9170a57d420199b68a040339fc21">
          <enum>(a)</enum>
          <header>Labeling</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502">Section
			 502</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
                <cato:entity-ref entity-type="uscode" value="usc/21/352">21 U.S.C. 352</cato:entity-ref>
              </external-xref>)</cato:entity> is amended by adding at the end the following:</text>
					<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id0fee8a42123b4519bfa327d8a30eb13f" reported-display-style="italic" style="OLC">
						<subsection id="id1ea2e402a2b04a83b1f0099db1a240ab">
              <enum>(bb)</enum>
              <text>If it is a compounded
				drug and the labeling does not include the information as required by
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:f/p:3" proposed="true">subsections (f)(3)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:4" proposed="true">(g)(4) of section 503A</cato:entity-ref>, as applicable.</text>
						</subsection>
            <subsection id="id316779C71B9C43CB8596820C5CE7C7F1">
              <enum>(cc)</enum>
              <text>If the advertising or
				promotion of a compounded drug is false or misleading in any particular.</text>
						</subsection>
            <subsection id="idce00a289ea9747ae9ac4730eee141556">
              <enum>(dd)</enum>
              <text>If it is a drug, and it
				was manufactured, prepared, propagated, compounded, or processed by a
				compounding manufacturer for which fees have not been paid as required by
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">section
				503A(g)</cato:entity-ref>.</text>
						</subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</subsection>
        <subsection id="idec03e494f1fe488a849df20f9dce519a">
          <enum>(b)</enum>
          <header>Application of
			 inspection requirements to compounding manufacturers</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a/p:2">Section
			 704(a)(2)</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/374">
                <cato:entity-ref entity-type="uscode" value="usc/21/374/a/2">21 U.S.C. 374(a)(2)</cato:entity-ref>
              </external-xref>)</cato:entity> is amended by adding at the end the following
			 flush text:</text>
					<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="idAC24258CBBD8411AA381B0B43C891363" reported-display-style="italic" style="OLC">
						<quoted-block-continuation-text changed="added" committee-id="SSHR00" quoted-block-continuation-text-level="section" reported-display-style="italic">The
				exemption in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a/p:2/sp:A">subparagraph (A)</cato:entity-ref> does not apply with respect to compounding
				manufacturers (as such term is defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section
				503A</cato:entity-ref>).</quoted-block-continuation-text>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</subsection>
      </section>
      <section id="ide6ee348803ae4fb8bc4c5a7c5e75897d">
        <enum>104.</enum>
        <header>Implementation</header>
				<subsection id="id8119ef23916349e78d30d0695a54b12f">
          <enum>(a)</enum>
          <header>Consultation with
			 stakeholders</header>
          <text>In implementing this title (and the amendments made
			 by this title), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref> shall consult with
			 relevant stakeholders including pharmacists, professional associations, patient
			 and public health advocacy groups, manufacturers and physicians.</text>
				</subsection>
        <subsection id="idefe7444ece3c494a9defe14f266ca5cd">
          <enum>(b)</enum>
          <header>Regulations</header>
          <text>In
			 promulgating any regulations to implement this title (and the amendments made
			 by this title), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref> shall—</text>
					<paragraph id="idf52f8c24e019477884648838d7d8eea4">
            <enum>(1)</enum>
            <text>issue a notice of
			 proposed rulemaking that includes the proposed regulation;</text>
					</paragraph>
          <paragraph id="idbfa83df662564bae9bc87292cb173183">
            <enum>(2)</enum>
            <text>provide a period of not
			 less than 60 calendar days for comments on the proposed regulation; and</text>
					</paragraph>
          <paragraph id="id86ff6839b27a475db2588b432c9eee98">
            <enum>(3)</enum>
            <text>publish the final
			 regulation not more than 18 months following publication of the proposed rule
			 and not less than 30 calendar days before the effective date of such final
			 regulation.</text>
					</paragraph>
        </subsection>
      </section>
      <section commented="no" display-inline="no-display-inline" id="id8e3448708e0a42a8a3391b881e33f907" section-type="subsequent-section">
        <enum>105.</enum>
        <header>Effective
			 date</header>
        <text display-inline="no-display-inline">This title (and the
			 amendments made by this title) shall take effect on the date that is 1 year
			 after the date of enactment of this Act.</text>
			</section>
    </title>
    <title changed="added" committee-id="SSHR00" id="idA6D5B3EFFDD347388F74014AC6650496" reported-display-style="italic">
      <enum>II</enum>
      <header>Drug Supply Chain
			 Security</header>
			<section id="id564FD637D4154F21AC4047FDB1025B55">
        <enum>201.</enum>
        <header>Short
			 title</header>
        <text display-inline="no-display-inline">This title may be cited
			 as the <quote>
            <short-title>Drug Supply Chain Security
			 Act</short-title>
          </quote>.</text>
			</section>
      <section id="id152ccba45d2d4c529aa71d3141e42f5d">
        <enum>202.</enum>
        <header>Pharmaceutical
			 distribution supply chain</header>
        <text display-inline="no-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter V</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
              <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq.</cato:entity-ref>
            </external-xref>)</cato:entity> is amended
			 by adding at the end the following:</text>
				<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id5bdb07e4de4041be82c5abe03118f8b3" reported-display-style="italic" style="OLC">
					<subchapter id="idd8202d6f2a164af786469a74f7d1d26c">
            <enum>H</enum>
            <header>Pharmaceutical
				distribution supply chain</header>
						<section id="id3a18d9b0d1dd4088a70189c2cc31802e">
              <enum>581.</enum>
              <header>Definitions</header>
              <text display-inline="no-display-inline">In this subchapter:</text>
							<paragraph id="ideef85786e6e4448a82a8fdc3a8d0cd4b">
                <enum>(1)</enum>
                <header>Authorized</header>
                <text>The
				term <term>authorized</term> means—</text>
								<subparagraph id="id5fd0b970ed59442ebd08725e85b9f2a6">
                  <enum>(A)</enum>
                  <text>in the case of a
				manufacturer or repackager, having a valid registration in accordance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="idc777bdcd84684193a11ff361923eb832">
                  <enum>(B)</enum>
                  <text>in the case of a
				wholesale distributor, having a valid license under State law or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>,
				in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:6" proposed="true">section 582(a)(6)</cato:entity-ref> and complying with the licensure reporting
				requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref>, as amended by the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>;</text>
								</subparagraph>
                <subparagraph id="idb5edff8174814ba48dbf752f38eadfe8">
                  <enum>(C)</enum>
                  <text>in the case of a
				third-party logistics provider, having a valid license under State law or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:a/p:1" proposed="true">section 584(a)(1)</cato:entity-ref>, in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:7" proposed="true">section 582(a)(7)</cato:entity-ref> and complying with the
				licensure reporting requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:b" proposed="true">section 584(b)</cato:entity-ref>; and</text>
								</subparagraph>
                <subparagraph id="id973ebb0363c24427b1fc03b88e389579">
                  <enum>(D)</enum>
                  <text>in the case of a
				dispenser, having a valid license under State law.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id0DE960C30F5D4659AF50A28B7C172896">
                <enum>(2)</enum>
                <header>Dispenser</header>
                <text>The
				term <term>dispenser</term>—</text>
								<subparagraph id="id867DB2E332B64235BDB11DF0611DDB89">
                  <enum>(A)</enum>
                  <text>means a retail pharmacy,
				hospital pharmacy, a group of chain pharmacies under common ownership and
				control that do not act as a wholesale distributor, or any other person
				authorized by law to dispense or administer prescription drugs, and the
				affiliated warehouses or distribution centers of such entities under common
				ownership and control that do not act as a wholesale distributor; and</text>
								</subparagraph>
                <subparagraph id="idF2DAD3182D2941A496F0B699068ED4A4">
                  <enum>(B)</enum>
                  <text>does not include a person
				who dispenses only products to be used in animals in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:a/p:5">section
				512(a)(5)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idda6e5010dba747a1b2d8ecdd06b68e3d">
                <enum>(3)</enum>
                <header>Disposition</header>
                <text>The
				term <term>disposition</term>, with respect to a product within the possession
				or control of an entity, means the removal of such product from the
				pharmaceutical distribution supply chain, which may include disposal or return
				of the product for disposal or other appropriate handling and other actions,
				such as retaining a sample of the product for further additional physical
				examination or laboratory analysis of the product by a manufacturer or
				regulatory or law enforcement agency.</text>
							</paragraph>
              <paragraph id="idfc8c6328ffab42028fe7be8dab64309d">
                <enum>(4)</enum>
                <header>Distribute or
				distribution</header>
                <text>The term <term>distribute</term> or
				<term>distribution</term> means the sale, purchase, trade, delivery, handling,
				storage, or receipt of a product, and does not include the dispensing of a
				product pursuant to a prescription executed in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section
				503(b)(1)</cato:entity-ref> or the dispensing of a product approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b">section 512(b)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="idA4556EC0B2CC41AF84B2BF988AE9948F">
                <enum>(5)</enum>
                <header>Exclusive
				distributor</header>
                <text>The term <term>exclusive distributor</term> means the
				wholesale distributor that directly purchased the product from the manufacturer
				and is the sole distributor of that manufacturer's product to a subsequent
				repackager, wholesale distributor, or dispenser.</text>
							</paragraph>
              <paragraph id="idB8542D170FD443EBBF73DC6D6E5D0930">
                <enum>(6)</enum>
                <header>Homogeneous
				case</header>
                <text>The term <term>homogeneous case</term> means a sealed case
				containing only product that has a single National Drug Code number belonging
				to a single lot.</text>
							</paragraph>
              <paragraph id="idcc29be85d8fb47eca661045e3e5c492a">
                <enum>(7)</enum>
                <header>Illegitimate
				product</header>
                <text>The term <term>illegitimate product</term> means a
				product for which credible evidence shows that the product—</text>
								<subparagraph id="idbdc9e75337b5485bb65e6274b048cade">
                  <enum>(A)</enum>
                  <text>is counterfeit, diverted,
				or stolen;</text>
								</subparagraph>
                <subparagraph id="idd54d466db0474169b9ccb4de2f0e0bef">
                  <enum>(B)</enum>
                  <text>is intentionally
				adulterated such that the product would result in serious adverse health
				consequences or death to humans;</text>
								</subparagraph>
                <subparagraph id="id67376b7d3cc540598383ede303182493">
                  <enum>(C)</enum>
                  <text>is the subject of a
				fraudulent transaction; or</text>
								</subparagraph>
                <subparagraph id="idb832a731104e4ee9904253db2236efa5">
                  <enum>(D)</enum>
                  <text>appears otherwise unfit
				for distribution such that the product could result in serious adverse health
				consequence or death to humans.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idb7b0012b4a0f452a87274ee277cced57">
                <enum>(8)</enum>
                <header>Licensed</header>
                <text>The
				term <term>licensed</term> means—</text>
								<subparagraph id="ida8901217a7554e20bc566672ddf65844">
                  <enum>(A)</enum>
                  <text>in the case of a
				wholesale distributor, having a valid license in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref>
				or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:6" proposed="true">section 582(a)(6)</cato:entity-ref>, as applicable;</text>
								</subparagraph>
                <subparagraph id="id8342cdba6825407eacd88c81de0a8e23">
                  <enum>(B)</enum>
                  <text>in the case of a
				third-party logistics provider, having a valid license in accordance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:a" proposed="true">section 584(a)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:7" proposed="true">section 582(a)(7)</cato:entity-ref>, as applicable; and</text>
								</subparagraph>
                <subparagraph id="id8da2ce2d40f24370874be6bc0cf7188c">
                  <enum>(C)</enum>
                  <text>in the case of a
				dispenser, having a valid license under State law.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idc2ba4fef09cd4a559c553eb6d5c67a4b">
                <enum>(9)</enum>
                <header>Manufacturer</header>
								<subparagraph id="id72745956D4AB4382BA6DD09567D01742">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The term <term>manufacturer</term> means, with respect to
				a product—</text>
									<clause id="id1978b386d1d04192967f4ad8e8517513">
                    <enum>(i)</enum>
                    <text>a
				person that holds an application approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or a license issued
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> for such product, or if such
				product is not the subject of an approved application or license, the person
				who manufactured the product;</text>
									</clause>
                  <clause id="id05f65ef9ea6e476a91c8c2ac150c3ad2">
                    <enum>(ii)</enum>
                    <text>a co-licensed partner of
				the person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:9/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> that obtains the product directly from a
				person described in this clause or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:9/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:9/sp:A/cl:iii" proposed="true">(iii)</cato:entity-ref>; or</text>
									</clause>
                  <clause id="id3268b5f273094db6aa7a4be5e495209a">
                    <enum>(iii)</enum>
                    <text>an affiliate of a
				person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:9/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:9/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> that receives the product directly from
				a person described in this clause or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:9/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:9/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id4131D0517CDE4E97936D6BB7483B4B2E">
                  <enum>(B)</enum>
                  <header>Affiliate</header>
                  <text>For
				purposes of this paragraph, the term <term>affiliate</term> means a member of
				an affiliated group, as that term is defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code/s:1504/ss:a">section 1504(a) of the Internal
				Revenue Code</cato:entity-ref>, or a member of a group of corporations that would constitute an
				affiliated group, as so defined, but for the fact that one or more members of
				the group is a corporation described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code/s:1504/ss:b/p:3">section 1504(b)(3) of the Internal
				Revenue Code</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idbebe001ab3a74f3e8df7ad497703bcb1">
                <enum>(10)</enum>
                <header>Package</header>
								<subparagraph id="id103EE59DEDC041A792BA89C1798770C5">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The term <term>package</term> means the smallest
				individual saleable unit of product for distribution by a manufacturer or
				repackager that is intended by the manufacturer for ultimate sale to the
				dispenser of such product.</text>
								</subparagraph>
                <subparagraph id="id191B8FE881A74B9790C10F1FCABEEAB6">
                  <enum>(B)</enum>
                  <header>Individual saleable
				unit</header>
                  <text>For purposes of this paragraph, an <term>individual saleable
				unit</term> is the smallest container of product introduced into commerce by
				the manufacturer or repackager that is intended by the manufacturer or
				repackager for individual sale to a dispenser.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id279715e6549647d093eaa2da91dbbb9d">
                <enum>(11)</enum>
                <header>Prescription
				drug</header>
                <text>The term <term>prescription drug</term> means a drug for
				human use subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="idf4eb5ac4cf4a4935abddcc3412b41714">
                <enum>(12)</enum>
                <header>Product</header>
                <text>The
				term <term>product</term> means a prescription drug in a finished dosage form
				for administration to a patient without substantial further manufacturing (such
				as capsules, tablets, and lyophilized products before reconstitution), but for
				purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582">section 582</cato:entity-ref>, does not include blood or blood components intended
				for transfusion, radioactive drugs or radioactive biological products (as
				defined in <external-xref legal-doc="regulation" parsable-cite="cfr/21/600.3">section 600.3(ee)</external-xref> of title 21, Code of Federal Regulations) that are
				regulated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3100">Nuclear Regulatory Commission</cato:entity-ref> or by a State pursuant to an
				agreement with such Commission under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                    <cato:entity-ref entity-type="act" value="Atomic Energy Act of 1954/s:274">section 274 of the Atomic Energy Act of
				1954</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/2021">
                      <cato:entity-ref entity-type="uscode" value="usc/42/2021">42 U.S.C. 2021</cato:entity-ref>
                    </external-xref>)</cato:entity>, an intravenous product described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:23/sp:B/cl:xiv" proposed="true">clause xiv</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:23/sp:B/cl:xv" proposed="true">xv</cato:entity-ref>, or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:23/sp:B/cl:xvi" proposed="true">xvi of paragraph (23)</cato:entity-ref>, any medical gas (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:575">section 575</cato:entity-ref>), or a drug
				compounded in compliance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section 503A</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="id1372100e9d964a47a5e04237ca567317">
                <enum>(13)</enum>
                <header>Product
				identifier</header>
                <text>The term <term>product identifier</term> means a
				standardized graphic that includes, in both human-readable form and on a
				machine-readable data carrier that conforms to the standards developed by a
				widely-recognized international standards development organization, the
				standardized numerical identifier, lot number, and expiration date of the
				product.</text>
							</paragraph>
              <paragraph id="idD8B19FBC402A4FA6A8C459D61FFF297D">
                <enum>(14)</enum>
                <header>Quarantine</header>
                <text>The
				term <term>quarantine</term> means the storage or identification of a product,
				to prevent distribution or transfer of the product, in a physically separate
				area clearly identified for such use or through other procedures.</text>
							</paragraph>
              <paragraph id="idfc1ae01e2a3e4b76b7d87951fdcf77f8">
                <enum>(15)</enum>
                <header>Repackager</header>
                <text>The
				term <term>repackager</term> means a person who owns or operates an
				establishment that repacks and relabels a product or package for further
				sale.</text>
							</paragraph>
              <paragraph id="id6e1ecf8ad846456ead6533e801b1a612">
                <enum>(16)</enum>
                <header>Return</header>
                <text>The
				term <term>return</term> means providing product to the authorized immediate
				trading partner from which such product was purchased, or to a returns
				processor or reverse logistics provider for handling of such product.</text>
							</paragraph>
              <paragraph id="id59513d18bd0a4ab4b7e19a68fe88cd80">
                <enum>(17)</enum>
                <header>Returns processor or
				reverse logistics provider</header>
                <text>The term <term>returns
				processor</term> or <term>reverse logistics provider</term> means a person who
				owns or operates an establishment that dispositions or otherwise processes
				saleable or nonsaleable product received from an authorized trading partner
				such that the product may be processed for credit to the purchaser,
				manufacturer, or seller or disposed of for no further distribution.</text>
							</paragraph>
              <paragraph id="ide2d7a0e74f584e609bfa1f628932608f">
                <enum>(18)</enum>
                <header>Specific patient
				need</header>
                <text>The term <term>specific patient need</term> refers to the
				transfer of a product from one pharmacy to another to fill a prescription for
				an identified patient. Such term does not include the transfer of a product
				from one pharmacy to another for the purpose of increasing or replenishing
				stock in anticipation of a potential need.</text>
							</paragraph>
              <paragraph id="id8b5cbdca10e24f7aa100de541ac01038">
                <enum>(19)</enum>
                <header>Standardized numerical
				identifier</header>
                <text>The term <term>standardized numerical
				identifier</term> means a set of numbers or characters used to uniquely
				identify each package or homogenous case that is composed of the National Drug
				Code that corresponds to the specific product (including the particular package
				configuration) combined with a unique alphanumeric serial number of up to 20
				characters.</text>
							</paragraph>
              <paragraph id="id7a5be6ac9c594085ab9feab1952f47a5">
                <enum>(20)</enum>
                <header>Suspect
				product</header>
                <text>The term <term>suspect product</term> means a product for
				which there is reason to believe that such product—</text>
								<subparagraph id="id7e6716ca3f6748d4ac3ada3b0b802e3b">
                  <enum>(A)</enum>
                  <text>is potentially
				counterfeit, diverted, or stolen;</text>
								</subparagraph>
                <subparagraph id="id052cc2f672554e99bd71077b78088f5c">
                  <enum>(B)</enum>
                  <text>is potentially
				intentionally adulterated such that the product would result in serious adverse
				health consequences or death to humans;</text>
								</subparagraph>
                <subparagraph id="idfcfd88f1ce4945c09267b7de46142712">
                  <enum>(C)</enum>
                  <text>is potentially the
				subject of a fraudulent transaction; or</text>
								</subparagraph>
                <subparagraph id="id96e183e271b947669efec9532068d5de">
                  <enum>(D)</enum>
                  <text>appears otherwise unfit
				for distribution such that the product would result in serious adverse health
				consequences or death to humans.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idad2a332b6e7b4d368be38907b0939cf0">
                <enum>(21)</enum>
                <header>Third-party logistics
				provider</header>
                <text>The term <term>third-party logistics provider</term>
				means an entity that provides or coordinates warehousing, or other logistics
				services of a product in interstate commerce on behalf of a manufacturer,
				wholesale distributor, or dispenser of a product, but does not take ownership
				of the product, nor have responsibility to direct the sale or disposition of
				the product.</text>
							</paragraph>
              <paragraph id="id20902c8261dd4b4b855f6743136f34b7">
                <enum>(22)</enum>
                <header>Trading
				partner</header>
                <text>The term <term>trading partner</term> means—</text>
								<subparagraph id="id75928a1a6dd748ac8fb9ea81e21491fd">
                  <enum>(A)</enum>
                  <text>a manufacturer,
				repackager, wholesale distributor, or dispenser from whom a manufacturer,
				repackager, wholesale distributor, or dispenser accepts direct ownership of a
				product or to whom a manufacturer, repackager, wholesale distributor, or
				dispenser transfers direct ownership of a product; or</text>
								</subparagraph>
                <subparagraph id="id1fb7169c63574c21afb9a8bd314338cb">
                  <enum>(B)</enum>
                  <text>a third-party logistics
				provider from whom a manufacturer, repackager, wholesale distributor, or
				dispenser accepts direct possession of a product or to whom a manufacturer,
				repackager, wholesale distributor, or dispenser transfers direct possession of
				a product.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idc351f735afc24d65bf79a47cacc7d6b5">
                <enum>(23)</enum>
                <header>Transaction</header>
								<subparagraph id="id85e1fa0df95e4fdfa8cf504c40502c8a">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The term <term>transaction</term> means the transfer of
				product between persons in which a change of ownership occurs.</text>
								</subparagraph>
                <subparagraph id="id59e38a9fcd4a4d6985d67b634959974e">
                  <enum>(B)</enum>
                  <header>Exemptions</header>
                  <text>The
				term <term>transaction</term> does not include—</text>
									<clause id="id2ef68d4493674ec9938b2695ba9a1bc6">
                    <enum>(i)</enum>
                    <text>intracompany distribution
				of any product between members of an affiliated group (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">section
				1504(a) of the Internal Revenue Code of 1986</cato:entity-ref>) or within a manufacturer;</text>
									</clause>
                  <clause id="ide2c942b3b82a4893b51633a7513ca608">
                    <enum>(ii)</enum>
                    <text>the distribution of a
				product among hospitals or other health care entities that are under common
				control;</text>
									</clause>
                  <clause id="id276e3165050941f28309435d6e25dc44">
                    <enum>(iii)</enum>
                    <text>the
				distribution of a product for emergency medical reasons including a public
				health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public Health
				Service Act</cato:entity-ref>, except that a drug shortage not caused by a public health
				emergency shall not constitute an emergency medical reason;</text>
									</clause>
                  <clause id="idfb8d47894a554d0d926e2b0a26d0440d">
                    <enum>(iv)</enum>
                    <text>the dispensing
				of a product pursuant to a valid prescription executed in accordance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>;</text>
									</clause>
                  <clause id="id4dad1453ca81467481f6587e20bb18a5">
                    <enum>(v)</enum>
                    <text>the distribution
				of product samples by a manufacturer or a licensed wholesale distributor in
				accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">section 503(d)</cato:entity-ref>;</text>
									</clause>
                  <clause id="idec7611c0f765471485047fc0ba58336e">
                    <enum>(vi)</enum>
                    <text>the distribution of
				blood or blood components intended for transfusion;</text>
									</clause>
                  <clause id="id3a415585c57d40f39f49ff11d8f7b69d">
                    <enum>(vii)</enum>
                    <text>the distribution of
				minimal quantities of product by a licensed retail pharmacy to a licensed
				practitioner for office use;</text>
									</clause>
                  <clause id="id529815ee76ff4d7082e14d52fd73e4d5">
                    <enum>(viii)</enum>
                    <text>the sale,
				purchase, or trade of a drug or an offer to sell, purchase, or trade a drug by
				a charitable organization described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1954/s:501/ss:c/p:3">section 501(c)(3) of the Internal
				Revenue Code of 1954</cato:entity-ref> to a nonprofit affiliate of the organization to the extent
				otherwise permitted by law;</text>
									</clause>
                  <clause id="ida15ad14a23864e7995409f4a74798dd9">
                    <enum>(ix)</enum>
                    <text>the distribution of a
				product pursuant to the sale or merger of a pharmacy or pharmacies or a
				wholesale distributor or wholesale distributors, except that any records
				required to be maintained for the product shall be transferred to the new owner
				of the pharmacy or pharmacies or wholesale distributor or wholesale
				distributors;</text>
									</clause>
                  <clause id="id4e6a280bfd364451b255337948958c55">
                    <enum>(x)</enum>
                    <text>the dispensing of
				a product approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b">section 512(b)</cato:entity-ref>;</text>
									</clause>
                  <clause id="idecf8e564a4c7441e89c3c3340a8bc58b">
                    <enum>(xi)</enum>
                    <text>products transferred to
				or from any facility that is licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3100">Nuclear Regulatory Commission</cato:entity-ref> or
				by a State pursuant to an agreement with such Commission under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                        <cato:entity-ref entity-type="act" value="Atomic Energy Act of 1954/s:274">section 274 of
				the Atomic Energy Act of 1954</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/2021">
                          <cato:entity-ref entity-type="uscode" value="usc/42/2021">42 U.S.C. 2021</cato:entity-ref>
                        </external-xref>)</cato:entity>;</text>
									</clause>
                  <clause id="idf7f949528f51402884ea9424109fc14a">
                    <enum>(xii)</enum>
                    <text>a combination product
				that is—</text>
										<subclause id="id856de6da470943959c08797305f7ab70">
                      <enum>(I)</enum>
                      <text>a product comprised of a
				device and 1 or more other regulated components (such as a drug/device,
				biologic/device, or drug/device/biologic) that are physically, chemically, or
				otherwise combined or mixed and produced as a single entity;</text>
										</subclause>
                    <subclause id="ide5c89ee4654d40a0aae823beb98e7628">
                      <enum>(II)</enum>
                      <text>2 or more separate
				products packaged together in a single package or as a unit and comprised of a
				drug and device or device and biological product; or</text>
										</subclause>
                    <subclause id="idad73efd1cadb4a2f8be5e7f2926a6e1e">
                      <enum>(III)</enum>
                      <text>2 or more
				finished medical devices plus one or more drug or biological products which are
				packaged together in what is referred to as a <quote>medical convenience
				kit</quote> as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:23/sp:B/cl:xiii" proposed="true">clause (xiii)</cato:entity-ref>;</text>
										</subclause>
                  </clause>
                  <clause id="idc093ab22cec54016b0dc290e53ea8c9f">
                    <enum>(xiii)</enum>
                    <text>the distribution of a
				collection of finished medical devices or a collection of finished drug or
				biological products assembled in kit form strictly for the convenience of the
				purchaser or user (to be known as a <quote>medical convenience kit</quote>)
				if—</text>
										<subclause id="id6f29a6f1b784436cba2b3894d209d21f">
                      <enum>(I)</enum>
                      <text>the medical convenience
				kit is assembled in an establishment that is registered with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref> as a device manufacturer in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:b/p:2">section
				510(b)(2)</cato:entity-ref>;</text>
										</subclause>
                    <subclause id="id21c3831654fb4067b0d6f408c19ab0e2">
                      <enum>(II)</enum>
                      <text>the person who
				manufacturers a medical convenience kit purchased the product contained in the
				medical convenience kit directly from the pharmaceutical manufacturer or from a
				wholesale distributor that purchased the product directly from the
				pharmaceutical manufacturer;</text>
										</subclause>
                    <subclause id="id50074e2e76a14725bbf37b6cb1f13c61">
                      <enum>(III)</enum>
                      <text>the person who
				manufacturers a medical convenience kit does not alter the primary container or
				label of the product as purchased from the manufacturer or wholesale
				distributor;</text>
										</subclause>
                    <subclause id="id2f76cb38f136405ba964b848b6e0e257">
                      <enum>(IV)</enum>
                      <text>the medical
				convenience kit does not contain a controlled substance that appears in a
				schedule contained in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970">Comprehensive Drug Abuse Prevention and Control Act
				of 1970</cato:entity-ref>; and</text>
										</subclause>
                    <subclause commented="no" id="id67cc18d501304120956f2a1ae44e2730">
                      <enum>(V)</enum>
                      <text>the products contained in
				the medical convenience kit are—</text>
											<item commented="no" id="id9946b07719bd491a882bc04a701012c6">
                        <enum>(aa)</enum>
                        <text>intravenous solutions
				intended for the replenishment of fluids and electrolytes;</text>
											</item>
                      <item commented="no" id="id83169e7b0dc34d0d9112dcd733481958">
                        <enum>(bb)</enum>
                        <text>products intended to
				maintain the equilibrium of water and minerals in the body;</text>
											</item>
                      <item commented="no" id="ida8a7001d46c84fd48501fbb7545b0ddf">
                        <enum>(cc)</enum>
                        <text>products intended for
				irrigation or reconstitution;</text>
											</item>
                      <item commented="no" id="id447a00837bde47fcbf3b19d7dae01d8d">
                        <enum>(dd)</enum>
                        <text>anesthetics;</text>
											</item>
                      <item commented="no" id="id4f31ae30b6c54ccfa81fb2f8829e29b8">
                        <enum>(ee)</enum>
                        <text>anticoagulants;</text>
											</item>
                      <item commented="no" id="id415e5434fcfe423aa0a2e65787aca2ca">
                        <enum>(ff)</enum>
                        <text>vasopressors; or</text>
											</item>
                      <item commented="no" id="idee2eb92470f94d32ac022d92f7f81ca1">
                        <enum>(gg)</enum>
                        <text>sympathicomimetics;</text>
											</item>
                    </subclause>
                  </clause>
                  <clause id="id69f27ef9ecb64b11adc6793ee07484d8">
                    <enum>(xiv)</enum>
                    <text>the distribution of an
				intravenous product that, by its formulation, is intended for the replenishment
				of fluids and electrolytes (such as sodium, chloride, and potassium) or
				calories (such as dextrose and amino acids);</text>
									</clause>
                  <clause id="id12530294cc164d36821772622fc376d8">
                    <enum>(xv)</enum>
                    <text>the distribution of an
				intravenous product used to maintain the equilibrium of water and minerals in
				the body, such as dialysis solutions;</text>
									</clause>
                  <clause id="id70cce742ef304264894a443073c30383">
                    <enum>(xvi)</enum>
                    <text>the distribution of a
				product that is intended for irrigation or reconstitution, or sterile water,
				whether intended for such purposes or for injection;</text>
									</clause>
                  <clause id="idf127af1045fe4ae6be819ee48bdee7f7">
                    <enum>(xvii)</enum>
                    <text>the distribution of a
				medical gas (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970/s:575">section 575</cato:entity-ref>); or</text>
									</clause>
                  <clause id="idA050B63788504E278CB043049EBD6BEE">
                    <enum>(xviii)</enum>
                    <text>the
				distribution or sale of any licensed product under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public
				Health Service Act</cato:entity-ref> that meets the definition of a device under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:201/ss:h">section
				201(h)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="id8f6a79e496e74f0a95882c4c19f97a52">
                <enum>(24)</enum>
                <header>Transaction
				history</header>
                <text>The term <term>transaction history</term> means a
				statement in paper or electronic form, including the transaction information
				for each prior transaction going back to the manufacturer of the
				product.</text>
							</paragraph>
              <paragraph id="idaa900461f34c40eb9fc14b16e596cadd">
                <enum>(25)</enum>
                <header>Transaction
				information</header>
                <text>The term <term>transaction information</term>
				means—</text>
								<subparagraph id="idca98550e56a645c7b098fe9278326569">
                  <enum>(A)</enum>
                  <text>the proprietary or
				established name or names of the product;</text>
								</subparagraph>
                <subparagraph id="id386a30da80c0403880676fa3c3e4c469">
                  <enum>(B)</enum>
                  <text>the strength and dosage
				form of the product;</text>
								</subparagraph>
                <subparagraph id="id7615f0999be64861956cf8426c3e698d">
                  <enum>(C)</enum>
                  <text>the National Drug Code
				number of the product;</text>
								</subparagraph>
                <subparagraph id="id0a077f0485af4fd6993f8de504062c45">
                  <enum>(D)</enum>
                  <text>the container
				size;</text>
								</subparagraph>
                <subparagraph id="ide94175caa17e44ce9c9c272738f14f1b">
                  <enum>(E)</enum>
                  <text>the number of
				containers;</text>
								</subparagraph>
                <subparagraph id="id82a3c8680b2b44cfacd679c332d9af65">
                  <enum>(F)</enum>
                  <text>the lot number of the
				product;</text>
								</subparagraph>
                <subparagraph id="id7efd3f6ccf5545ae834fd657660d584c">
                  <enum>(G)</enum>
                  <text>the date of the
				transaction;</text>
								</subparagraph>
                <subparagraph id="id27b76abda7c1484f98ff846bc709591f">
                  <enum>(H)</enum>
                  <text>the date of the shipment,
				if different from the date of the transaction;</text>
								</subparagraph>
                <subparagraph id="ide58569b4c2914634a89d62d17b7992ca">
                  <enum>(I)</enum>
                  <text>the business name and
				address of the person from whom ownership is being transferred; and</text>
								</subparagraph>
                <subparagraph id="id85c9627775484111bd479714c4ae17fb">
                  <enum>(J)</enum>
                  <text>the business name and
				address of the person to whom ownership is being transferred.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id356d828b4997401b934b2a5e59241792">
                <enum>(26)</enum>
                <header>Transaction
				statement</header>
                <text>The <term>transaction statement</term> is a statement,
				in paper or electronic form, that the entity transferring ownership in a
				transaction—</text>
								<subparagraph id="id18a4efa686ad445f85b79cc6c4f80097">
                  <enum>(A)</enum>
                  <text>is authorized as required
				under the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>;</text>
								</subparagraph>
                <subparagraph id="id67a0a2fb0bb14a4a9b6ffcadb77d469a">
                  <enum>(B)</enum>
                  <text>received the product from
				a person that is authorized as required under the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>;</text>
								</subparagraph>
                <subparagraph id="id02781730D561448CB810679D29C5D390">
                  <enum>(C)</enum>
                  <text>received
				transaction information and a transaction statement from the prior owner of the
				product, as required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="idcac2d913ce84400db604f862b410483c">
                  <enum>(D)</enum>
                  <text>did not knowingly ship a
				suspect or illegitimate product;</text>
								</subparagraph>
                <subparagraph id="idCDA67D75D0CF4EA4A7B1B2B5539EA460">
                  <enum>(E)</enum>
                  <text>had systems and
				processes in place to comply with verification requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section
				582</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="idea18980e94fb47b7b3a8c9f801099fbf">
                  <enum>(F)</enum>
                  <text>did not knowingly provide
				false transaction information; and</text>
								</subparagraph>
                <subparagraph id="id821bbce9d3ae4cfa969060d6c124b999">
                  <enum>(G)</enum>
                  <text>did not knowingly alter
				the transaction history.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id0fb40f67e3b04906a5268574b4d63b0b">
                <enum>(27)</enum>
                <header>Verification or
				verify</header>
                <text>The term <term>verification</term> or
				<quote>verify</quote> means determining whether the product identifier affixed
				to, or imprinted upon, a package or homogeneous case corresponds to the
				standardized numerical identifier or lot number and expiration date assigned to
				the product by the manufacturer or the repackager, as applicable in accordance
				with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>.</text>
							</paragraph>
              <paragraph commented="no" id="id1a6ab3c16a3341fbae288693e0fd2a42">
                <enum>(28)</enum>
                <header>Wholesale
				distributor</header>
                <text>The term <term>wholesale distributor</term> means a
				person (other than a manufacturer, a manufacturer's co-licensed partner, a
				third-party logistics provider, or repackager) engaged in wholesale
				distribution (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:4" proposed="true">section 503(e)(4)</cato:entity-ref>, as amended by the
				<short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                  </short-title>).</text>
							</paragraph>
            </section>
            <section id="id0e96c13b1e944d0283468014a8ff4603">
              <enum>582.</enum>
              <header>Requirements</header>
							<subsection id="idc9e4612b030e4b1980d0f0db2666aabb">
                <enum>(a)</enum>
                <header>In general</header>
								<paragraph id="idcad420f79ecc427da64d5d4f201df2f3">
                  <enum>(1)</enum>
                  <header>Other
				activities</header>
                  <text>Each manufacturer, repackager, wholesale distributor,
				third-party logistics provider, and dispenser shall comply with the
				requirements set forth in this section with respect to the role of such
				manufacturer, repackager, wholesale distributor, third-party logistics
				provider, or dispenser in a transaction involving product. If an entity meets
				the definition of more than one of the entities listed in the preceding
				sentence, such entity shall comply with all applicable requirements in this
				section, but shall not be required to duplicate requirements.</text>
								</paragraph>
                <paragraph id="id37f83c884ab54f1ab1fb5e22d634fd5f">
                  <enum>(2)</enum>
                  <header>Initial
				standards</header>
									<subparagraph id="idD874702E61B34786BA69B2EA8177F5AF">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>The Secretary shall, in consultation with other
				appropriate Federal officials, manufacturers, repackagers, wholesale
				distributors, third-party logistics providers, dispensers, and other
				pharmaceutical distribution supply chain stakeholders, issue a draft guidance
				document that establishes standards for the interoperable exchange of
				transaction information, transaction history, and transaction statements, in
				paper or electronic format, for compliance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a" proposed="true">subsections (a)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b" proposed="true">(b)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c" proposed="true">(c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d" proposed="true">(d)</cato:entity-ref>,
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e" proposed="true">(e)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f" proposed="true">(f)</cato:entity-ref>. In establishing such standards, the Secretary shall consider the
				feasibility of establishing standardized documentation to be used by members of
				the pharmaceutical distribution supply chain to convey the transaction
				information, transaction history, and transaction statement to the subsequent
				purchaser of a product and to facilitate the exchange of lot level data. The
				standards established under this paragraph shall take into consideration the
				standards established under section 505D and shall comply with a form and
				format developed by a widely recognized international standards development
				organization.</text>
									</subparagraph>
                  <subparagraph id="id74B3639C825C49B5A31BD50BB211E381">
                    <enum>(B)</enum>
                    <header>Public
				input</header>
                    <text>Prior to issuing the draft guidance under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>,
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall gather comments and information from stakeholders and
				maintain such comments and information in a public docket for at least 60 days
				prior to issuing such guidance.</text>
									</subparagraph>
                  <subparagraph id="id834853DFD1374AE0B59897AB12CD3B59">
                    <enum>(C)</enum>
                    <header>Publication</header>
                    <text>The
				Secretary shall publish the standards established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> not
				later than 1 year after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id52847607be7f4567b1224facddbf1115">
                  <enum>(3)</enum>
                  <header>Waivers, exceptions,
				and exemptions</header>
									<subparagraph id="idb4be36e379a34b86bfdfb4acd69f670e">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>Not later than 2 years after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                      </short-title>,
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, by guidance—</text>
										<clause id="id046aa406c23a458fb0e4f933f4c59e03">
                      <enum>(i)</enum>
                      <text>establish a
				process by which an authorized manufacturer, repackager, wholesale distributor,
				or dispenser may request a waiver from any of the requirements set forth in
				this section if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that such requirements would result in
				an undue economic hardship or for emergency medical reasons, including a public
				health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public Health
				Service Act</cato:entity-ref>;</text>
										</clause>
                    <clause id="id0c0475ac0bdf4d13b6f461fbbff7ec5e">
                      <enum>(ii)</enum>
                      <text>establish a
				process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines exceptions, and a process through
				which a manufacturer or repackager may request such an exception, to the
				requirements relating to product identifiers if a product is packaged in a
				container too small or otherwise unable to accommodate a label with sufficient
				space to bear the information required for compliance with this section;
				and</text>
										</clause>
                    <clause id="idd6f921d9e6cd486c963d2ee9c9b599a2">
                      <enum>(iii)</enum>
                      <text>establish a
				process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may determine other products or transactions
				that shall be exempt from the requirements of this section.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idfaceb20ff9fa402585c406c5e3cf8053">
                    <enum>(B)</enum>
                    <header>Content</header>
                    <text>The
				guidance issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall include a process for the biennial
				review and renewal of such waivers, exceptions, and exemptions, as
				applicable.</text>
									</subparagraph>
                  <subparagraph commented="no" id="idEAF57E4A3C194DF6858F8502752DE6AA">
                    <enum>(C)</enum>
                    <header>Process</header>
                    <text>In
				issuing the guidance under this paragraph, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide an
				effective date that is not later than 180 days prior to the date on which
				manufacturers are required to affix or imprint a product identifier to each
				package and homogenous case of product intended to be introduced in a
				transaction into commerce consistent with this section.</text>
									</subparagraph>
                </paragraph>
                <paragraph commented="no" id="id5e1f761a44c44712a4d5159f322481c2">
                  <enum>(4)</enum>
                  <header>Self-executing
				requirements</header>
                  <text>Except where otherwise specified, the requirements
				of this section may be enforced without further regulations or guidance from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
								</paragraph>
                <paragraph id="id73e72de97f104e46a3fe6e56a012c75b">
                  <enum>(5)</enum>
                  <header>Grandfathering
				product</header>
									<subparagraph id="id4852fe7bb9a649b3b30e516a0cd2ff63">
                    <enum>(A)</enum>
                    <header>Product
				identifier</header>
                    <text>Not later than 2 years after the date of enactment of
				the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall finalize guidance specifying whether and
				under what circumstances product that is not labeled with a product identifier
				and that is in the pharmaceutical distribution supply chain at the time of the
				effective date of the requirements of this section shall be exempted from the
				requirements of this section.</text>
									</subparagraph>
                  <subparagraph id="id83b96e7662564d708bdc0ee29e6e253c">
                    <enum>(B)</enum>
                    <header>Tracing</header>
                    <text>For
				a product that entered the pharmaceutical distribution supply chain prior to
				the date that is 1 year after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>—</text>
										<clause id="id834761bfd4c2437eb733525f32c897d0">
                      <enum>(i)</enum>
                      <text>authorized trading
				partners shall be exempt from providing transaction information as required
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:1/sp:A/cl:i" proposed="true">subsections (b)(1)(A)(i)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">(c)(1)(A)(ii)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:A/cl:ii" proposed="true">(d)(1)(A)(ii)</cato:entity-ref>, and
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:ii" proposed="true">(e)(1)(A)(ii)</cato:entity-ref>;</text>
										</clause>
                    <clause id="id08de44577164496388838409419e73de">
                      <enum>(ii)</enum>
                      <text>transaction history
				required under this section shall begin with the owner of such product on such
				date; and</text>
										</clause>
                    <clause id="id5c92353bdc27481598bcb8e51f402dbe">
                      <enum>(iii)</enum>
                      <text>the owners of such
				product on such date shall be exempt from asserting receipt of transaction
				information and transaction statement from the prior owner as required under
				this section.</text>
										</clause>
                  </subparagraph>
                </paragraph>
                <paragraph id="idf1685d0360bc4f89a6eb496387e301ae">
                  <enum>(6)</enum>
                  <header>Wholesale distributor
				licenses</header>
                  <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:8/sp:A" proposed="true">section 581(8)(A)</cato:entity-ref>, until the effective
				date of the wholesale distributor licensing regulations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>, the
				term <term>licensed</term> or <term>authorized</term>, as it relates to a
				wholesale distributor with respect to prescription drugs, shall mean a
				wholesale distributor with a valid license under State law.</text>
								</paragraph>
                <paragraph id="id8258bd50035549d59bed3326d55cec29">
                  <enum>(7)</enum>
                  <header>Third-party logistics
				provider licenses</header>
                  <text>Until the effective date of the third-party
				logistics provider licensing regulations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section 584</cato:entity-ref>, a third-party
				logistics provider shall be considered <term>licensed</term> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:8/sp:A" proposed="true">section
				581(8)(B)</cato:entity-ref> unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has made a finding that the third-party
				logistics provider does not utilize good handling and distribution practices
				and publishes notice thereof.</text>
								</paragraph>
                <paragraph id="ida561b5660ce642bc97de9c1982459ce6">
                  <enum>(8)</enum>
                  <header>Label
				changes</header>
                  <text>Changes made to package labels solely to incorporate the
				product identifier may be submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the annual report of an
				establishment, in accordance with section 314.70(d) of chapter 21, Code of
				Federal Regulations (or any successor regulation).</text>
								</paragraph>
                <paragraph id="idAFDA258E0050423DB77A637A2D87141B">
                  <enum>(9)</enum>
                  <header>Product
				identifiers</header>
                  <text>With respect to any requirement relating to product
				identifiers under this subchapter—</text>
									<subparagraph id="id41C32D7747534196A40C2C7C33E23807">
                    <enum>(A)</enum>
                    <text>unless the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> allows, through guidance, the use of other technologies for data
				instead of or in addition to the technologies described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:9/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:9/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref>, the applicable data—</text>
										<clause id="idF7130F0239B747A5B0EC19BCE899AAA2">
                      <enum>(i)</enum>
                      <text>shall be included in a
				2-dimensional data matrix barcode when affixed to, or imprinted upon, a
				package; and</text>
										</clause>
                    <clause id="id14EB58A5C8EB486DB8422EE6B2CA09EA">
                      <enum>(ii)</enum>
                      <text>shall be included in a
				linear or 2-dimensional data matrix barcode when affixed to, or imprinted upon,
				a homogeneous case; and</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idF27288400FD640368827999A6BDF61CC">
                    <enum>(B)</enum>
                    <text>verification of the
				product identifier may occur by using human-readable or machine-readable
				methods.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id553feec93e3b45b3b3734a3340de56fc">
                <enum>(b)</enum>
                <header>Manufacturer
				requirements</header>
								<paragraph id="id91fc923ed7e648498b928e6c0b49d7ce">
                  <enum>(1)</enum>
                  <header>Product
				tracing</header>
									<subparagraph id="idcf0caf84a81e432b974673aa173a68e2">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>Beginning not later than 1 year after the date of
				enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>, a manufacturer shall—</text>
										<clause id="id9e261d132f1d4b3c930003ab9b27a6dc">
                      <enum>(i)</enum>
                      <text>prior to, or at the time
				of, each transaction in which such manufacturer transfers—</text>
											<subclause id="idF5662C317DEA463DBD2ACC4B3DA7A61A">
                        <enum>(I)</enum>
                        <text>ownership of a product,
				provide the subsequent recipient with transaction history, transaction
				information, and a transaction statement, in a single document in an electronic
				or paper format; or</text>
											</subclause>
                      <subclause id="idF980054B524D4D8A9A969FD2A059EA20">
                        <enum>(II)</enum>
                        <text>possession of a product
				to a third-party logistics provider for the purpose of transferring ownership
				as part of a transaction to a subsequent recipient, provide to the third-party
				logistics provider the transaction history, transaction information, and a
				transaction statement for such transaction to a subsequent recipient;
				and</text>
											</subclause>
                    </clause>
                    <clause id="id3afc991548c148dca90a0351ec16f825">
                      <enum>(ii)</enum>
                      <text>maintain the transaction
				information, transaction history, and transaction statement for each
				transaction for not less than 6 years after the date of the transaction.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id3de29356dea54f05af5a8c31833eef14">
                    <enum>(B)</enum>
                    <header>Requests for
				information</header>
                    <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect product or an illegitimate product, a manufacturer
				shall, not later than 24 hours after receiving the request or in other such
				reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, based on the circumstances of
				the request, provide the applicable transaction information, transaction
				history, and transaction statement for the product.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id0991a0019e78419d9db94f0592982e54">
                  <enum>(2)</enum>
                  <header>Product
				identifier</header>
                  <text>Beginning not later than 4 years after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, a manufacturer shall affix or imprint a product identifier
				to each package and homogenous case of a product intended to be introduced in a
				transaction into commerce. Such manufacturer shall maintain the product
				identifier information for such product for not less than 6 years after the
				date of the transaction.</text>
								</paragraph>
                <paragraph id="id4c503ff6b1554e29bad33aa8f71512cc">
                  <enum>(3)</enum>
                  <header>Authorized trading
				partners</header>
                  <text>Beginning not later than 1 year after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, the trading partners of a manufacturer may be only
				authorized trading partners.</text>
								</paragraph>
                <paragraph id="ida135ec28306d410986c839ace0c9dac8">
                  <enum>(4)</enum>
                  <header>Verification</header>
                  <text>Beginning
				not later than 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				a manufacturer shall have systems in place to enable the manufacturer to comply
				with the following requirements:</text>
									<subparagraph id="ide4ad32a0131c45268049a3f603d722d4">
                    <enum>(A)</enum>
                    <header>Suspect
				product</header>
										<clause id="id97540dee73fd4ba6b63bc45d731ed7a2">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon making a determination that a product in the
				possession or control of the manufacturer is a suspect product, or upon
				receiving a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that has made a
				determination that a product within the possession or control of a manufacturer
				is a suspect product, a manufacturer shall—</text>
											<subclause id="idc52df06835c747ba9c5dbefc239a18cb">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the manufacturer from product intended for
				distribution until such product is cleared or dispositioned; and</text>
											</subclause>
                      <subclause id="idcd6164f025f04a789daa9a21c3aa98ea">
                        <enum>(II)</enum>
                        <text>promptly conduct an
				investigation in coordination with trading partners, as applicable, to
				determine whether the product is an illegitimate product, which shall include
				validating any applicable transaction history and transaction information in
				the possession of the manufacturer and otherwise investigating to determine
				whether the product is an illegitimate product, and, beginning 4 years after
				the date of enactment of the <short-title>
                            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply
				Chain Security Act</cato:entity-ref>
                          </short-title>, verifying the product at the package level,
				including the standardized numerical identifier.</text>
											</subclause>
                    </clause>
                    <clause id="id4ac0a4b3da8f4f1ab95bad0736a31bce">
                      <enum>(ii)</enum>
                      <header>Cleared
				product</header>
                      <text>If the manufacturer makes the determination that a
				suspect product is not an illegitimate product, the manufacturer shall promptly
				notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, if applicable, of such determination and such product may
				be further distributed.</text>
										</clause>
                    <clause id="id8d0dc3cc676242339204f009bbb45641">
                      <enum>(iii)</enum>
                      <header>Records</header>
                      <text>A
				manufacturer shall keep records of the investigation of a suspect product for
				not less than 6 years after the conclusion of the investigation.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idcf29cf9c3db041639c11f20ee933c0b8">
                    <enum>(B)</enum>
                    <header>Illegitimate
				product</header>
										<clause id="idf7b725a1c7674924a67743b1c6c5d344">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon determining that a product in the possession or
				control of a manufacturer is an illegitimate product, the manufacturer shall,
				in a manner consistent with the systems and processes of such
				manufacturer—</text>
											<subclause id="id64b0b7d268474605a465e170691fc54c">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the manufacturer from product intended for
				distribution until such product is dispositioned;</text>
											</subclause>
                      <subclause id="idd7e05f9dee2d489d91c8086cb7004fbe">
                        <enum>(II)</enum>
                        <text>disposition the
				illegitimate product within the possession or control of the
				manufacturer;</text>
											</subclause>
                      <subclause id="id1e4945baf7a248568cf7f9198fd16199">
                        <enum>(III)</enum>
                        <text>take reasonable and
				appropriate steps to assist a trading partner to disposition an illegitimate
				product not in the possession or control of the manufacturer; and</text>
											</subclause>
                      <subclause id="idC60A629998314534871225BAA7F01C81">
                        <enum>(IV)</enum>
                        <text>retain a sample
				of the product for further physical examination or laboratory analysis of the
				product by the manufacturer or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (or other appropriate Federal or State
				official) upon request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (or other appropriate Federal or State
				official), as necessary and appropriate.</text>
											</subclause>
                    </clause>
                    <clause id="idc715e2ffe9ce41cd8ce57354ce19c4da">
                      <enum>(ii)</enum>
                      <header>Making a
				notification</header>
											<subclause id="idb8c5c5991bd2411298893e2736c84152">
                        <enum>(I)</enum>
                        <header>Illegitimate
				product</header>
                        <text>Upon determining that a product in the possession or
				control of the manufacturer is an illegitimate product, the manufacturer shall
				notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and all immediate trading partners that the manufacturer
				has reason to believe may have received such illegitimate product of such
				determination not later than 24 hours after making such determination.</text>
											</subclause>
                      <subclause id="idba3b3158b0034818b19ceeb7ba05491f">
                        <enum>(II)</enum>
                        <header>High risk of
				illegitimacy</header>
                        <text>A manufacturer shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and
				immediate trading partners that the manufacturer has reason to believe may have
				in the trading partner’s possession a product manufactured by, or purported to
				be a product manufactured by, the manufacturer not later than 24 hours after
				determining or being notified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or a trading partner that there
				is a high risk that such product is an illegitimate product. For purposes of
				this subclause, a <quote>high risk</quote> may include a specific high-risk
				that could increase the likelihood that illegitimate product will enter the
				pharmaceutical distribution supply chain and other high risks as determined by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in guidance pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i" proposed="true">subsection (i)</cato:entity-ref>.</text>
											</subclause>
                    </clause>
                    <clause id="id401f856c33254aa6b8f1610eac275006">
                      <enum>(iii)</enum>
                      <header>Responding to a
				notification</header>
                      <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or a trading partner that a determination has been made that a
				product is an illegitimate product, a manufacturer shall identify all
				illegitimate product subject to such notification that is in the possession or
				control of the manufacturer, including any product that is subsequently
				received, and shall perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:4/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref>.</text>
										</clause>
                    <clause id="idF374CE6063C54F4885382FBD4295A95F">
                      <enum>(iv)</enum>
                      <header>Terminating a
				notification</header>
                      <text>Upon making a determination, in consultation with
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that a notification is no longer necessary, a manufacturer shall
				promptly notify immediate trading partners that the manufacturer notified
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:4/sp:B/cl:ii" proposed="true">clause (ii)</cato:entity-ref> that such notification has been terminated.</text>
										</clause>
                    <clause id="id5206f276e6bc4122921a1e33e101954b">
                      <enum>(v)</enum>
                      <header>Records</header>
                      <text>A
				manufacturer shall keep records of the disposition of an illegitimate product
				for not less than 6 years after the conclusion of the disposition.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idd67bae2948704c99a2907228a0dd8dad">
                    <enum>(C)</enum>
                    <header>Requests for
				verification</header>
                    <text>Beginning 4 years after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                      </short-title>,
				upon receiving a request for verification from an authorized repackager,
				wholesale distributor, or dispenser that is in possession or control of a
				product such person believes to be manufactured by such manufacturer, a
				manufacturer shall, not later than 24 hours after receiving the verification
				request or in other such reasonable time as determined by the Secretary, based
				on the circumstances of the request, notify the person making the request
				whether the product identifier, including the standardized numerical
				identifier, that is the subject of the request corresponds to the product
				identifier affixed or imprinted by the manufacturer. If a manufacturer
				responding to a verification request identifies a product identifier that does
				not correspond to that affixed or imprinted by the manufacturer, the
				manufacturer shall treat such product as suspect product and conduct an
				investigation as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>. If the manufacturer has reason
				to believe the product is an illegitimate product, the manufacturer shall
				advise the person making the request of such belief at the time such
				manufacturer responds to the verification request.</text>
									</subparagraph>
                  <subparagraph id="id0a9ae00875004171b5c5805eecd72591">
                    <enum>(D)</enum>
                    <header>Electronic
				database</header>
                    <text>A manufacturer may satisfy the requirements of this
				paragraph by developing a secure electronic database or utilizing a secure
				electronic database developed or operated by another entity. The owner of such
				database shall establish the requirements and processes to respond to requests
				and may provide for data access to other members of the pharmaceutical
				distribution supply chain, as appropriate. The development and operation of
				such a database shall not relieve a manufacturer of the requirement under this
				paragraph to respond to a verification request submitted by means other than a
				secure electronic database.</text>
									</subparagraph>
                  <subparagraph id="id1c2885b9c2804acb871a07b1c9c066eb">
                    <enum>(E)</enum>
                    <header>Saleable returned
				product</header>
                    <text>Beginning 4 years after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                      </short-title>
				(except as provided pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>), upon receipt of a returned
				product that the manufacturer intends to further distribute, before further
				distributing such product, the manufacturer shall verify the product
				identifier, including the standardized numerical identifier, for each sealed
				homogeneous case of such product or, if such product is not in a sealed
				homogeneous case, verify the product identifier, including the standardized
				numerical identifier, on each package.</text>
									</subparagraph>
                  <subparagraph id="id0ADFF47B968D485088AB7ED1B907E8B5">
                    <enum>(F)</enum>
                    <header>Nonsaleable returned
				product</header>
                    <text>A manufacturer may return a nonsaleable product to the
				manufacturer or repackager, to the wholesale distributor from whom such product
				was purchased, or to a person acting on behalf of such a person, including a
				returns processor, without providing the information described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:1/sp:A/cl:i" proposed="true">paragraph
				(1)(A)(i)</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id515e8624724141b3a829ef3727d673bc">
                <enum>(c)</enum>
                <header>Wholesale distributor
				requirements</header>
								<paragraph id="id43c44392ea4b442ba974a2c534ef6edd">
                  <enum>(1)</enum>
                  <header>Product
				tracing</header>
									<subparagraph id="iddec051a0ab3742b3af89477300dc20b4">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>Beginning not later than 1 year after the date of
				enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>, the following requirements shall apply to wholesale
				distributors:</text>
										<clause id="ida209f5a1826141bd9258aed1a349fa1d">
                      <enum>(i)</enum>
                      <text>A wholesale distributor
				shall not accept ownership of a product unless the previous owner prior to, or
				at the time of, the transaction provides the transaction history, transaction
				information, and a transaction statement for the product, as applicable under
				this subparagraph.</text>
										</clause>
                    <clause id="idec6c3f21f4ca4387b01700ab772537a6">
                      <enum>(ii)</enum>
                      <subclause commented="no" display-inline="yes-display-inline" id="idB1E29F596E504969BC8B59DEA5F0120D">
                        <enum>(I)</enum>
                        <item commented="no" display-inline="yes-display-inline" id="idA8678C37A34943248C98237F61AED7F6">
                          <enum>(aa)</enum>
                          <text>If the wholesale
				distributor purchased a product directly from the manufacturer, the exclusive
				distributor of the manufacturer, or a repackager that purchased directly from
				the manufacturer, then prior to, or at the time of, each transaction in which
				the wholesale distributor transfers ownership of a product, the wholesale
				distributor shall provide to the subsequent purchaser—</text>
													<subitem changed="added" committee-id="SSHR00" id="id144DA66C00EE42E58717A25048998D12" indent="up2" reported-display-style="italic">
                            <enum>(AA)</enum>
                            <text>a transaction statement,
				which shall state that such wholesale distributor, or a member of the
				affiliated group of such wholesale distributor, purchased the product directly
				from the manufacturer, exclusive distributor of the manufacturer, or repackager
				that purchased directly from the manufacturer; and</text>
													</subitem>
                          <subitem changed="added" committee-id="SSHR00" id="id65F2E50E265A45CFB606944619B29E19" indent="up2" reported-display-style="italic">
                            <enum>(BB)</enum>
                            <text>subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii/scl:II" proposed="true">subclause (II)</cato:entity-ref>, the
				transaction history and transaction information.</text>
													</subitem>
                        </item>
                        <item changed="added" committee-id="SSHR00" id="id7360D4E892B54DA1B697C75FC7E9BBEF" indent="up2" reported-display-style="italic">
                          <enum>(bb)</enum>
                          <text>The wholesale distributor shall provide
				the transaction history, transaction information, and transaction statement
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii/scl:I/i:aa" proposed="true">item (aa)</cato:entity-ref>—</text>
													<subitem id="idD64E034E0C534CAA8DEFA493037BE425" indent="down1">
                            <enum>(AA)</enum>
                            <text>if provided to a
				dispenser, on a single document in an electronic or paper format; and</text>
													</subitem>
                          <subitem id="id08F0F60688304FFFBB5A670F16CF10AA" indent="down1">
                            <enum>(BB)</enum>
                            <text>if provided to a
				wholesale distributor, through any combination of self-generated paper,
				electronic data, or manufacturer-provided information on the product
				package.</text>
													</subitem>
                        </item>
                      </subclause>
                      <subclause changed="added" committee-id="SSHR00" id="id639C6E5F42BF4976AEFDB972584953B3" indent="up1" reported-display-style="italic">
                        <enum>(II)</enum>
                        <text>For purposes of
				transactions described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii/scl:I" proposed="true">subclause (I)</cato:entity-ref>, transaction history and transaction
				information shall not be required to include the lot number of the product, the
				initial transaction date, or the initial shipment date from the manufacturer
				(as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:25/sp:F" proposed="true">subparagraphs (F)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:25/sp:G" proposed="true">(G)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:25/sp:H" proposed="true">(H) of section 581(25)</cato:entity-ref>).</text>
											</subclause>
                    </clause>
                    <clause id="id78906204a8674bb49c0c41d7c7f96d94">
                      <enum>(iii)</enum>
                      <text>If the wholesale
				distributor did not purchase a product directly from the manufacturer, the
				exclusive distributor of the manufacturer, or a repackager that purchased
				directly from the manufacturer, as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">clause (ii)</cato:entity-ref>, then prior to, or
				at the time of, each transaction or subsequent transaction, the wholesale
				distributor shall provide to the subsequent purchaser a transaction statement,
				transaction history, and transaction information, in a paper or electronic
				format that complies with the guidance document issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2" proposed="true">subsection
				(a)(2)</cato:entity-ref>.</text>
										</clause>
                    <clause id="idD8DF9EFF33E6440DA7B9BABF279D58F2">
                      <enum>(iv)</enum>
                      <text>For the purposes of
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:iii" proposed="true">clause (iii)</cato:entity-ref>, the transaction history supplied shall begin only with the
				wholesale distributor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii/scl:I" proposed="true">clause (ii)(I)</cato:entity-ref>, but the wholesale
				distributor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:iii" proposed="true">clause (iii)</cato:entity-ref> shall inform the subsequent purchaser
				that such wholesale distributor received a direct purchase statement from a
				wholesale distributor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:iii" proposed="true">clause (ii)(I)</cato:entity-ref>.</text>
										</clause>
                    <clause id="id51717FED6206478590FEF87F9816ED11">
                      <enum>(v)</enum>
                      <text>A
				wholesale distributor shall maintain the transaction information, transaction
				history, and transaction statement for each transaction described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:i" proposed="true">clauses
				(i)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:iii" proposed="true">(iii)</cato:entity-ref> for not less than 6 years after the date of the
				transaction.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id132c7a783e6d4227ba458a2251e4d509">
                    <enum>(B)</enum>
                    <header>Returns</header>
										<clause id="id669faaa71d4f4613842062294613bdf2">
                      <enum>(i)</enum>
                      <header>Saleable
				returns</header>
                      <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:i" proposed="true">subparagraph (A)(i)</cato:entity-ref>, the following shall
				apply:</text>
											<subclause id="id348999e394224b68ab28fb707a64da05">
                        <enum>(I)</enum>
                        <header>Requirements</header>
                        <text>Until
				the date that is 6 years after the date of enactment of the
				<short-title>
                          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                        </short-title>
				(except as provided pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>), a wholesale distributor may
				accept returned product from a dispenser pursuant to the terms and conditions
				of any agreement between the parties, and, notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">subparagraph
				(A)(ii)</cato:entity-ref>, may distribute such returned product without providing the transaction
				history. For transactions subsequent to the return, the transaction history of
				such product shall begin with the wholesale distributor that accepted the
				returned product, consistent with the requirements of this subsection.</text>
											</subclause>
                      <subclause id="id96dc345e92be455da7a8704f6b5bb3f5">
                        <enum>(II)</enum>
                        <header>Enhanced
				requirements</header>
                        <text>Beginning 6 years after the date of enactment of the
				<short-title>
                          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                        </short-title>
				(except as provided pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>), a wholesale distributor may
				accept returned product from a dispenser only if the wholesale distributor can
				associate returned product with the transaction information and transaction
				statement associated with that product. For all transactions after such date,
				the transaction history, as applicable, of such product shall begin with the
				wholesale distributor that accepted and verified the returned product. For
				purposes of this subparagraph, the transaction information and transaction
				history, as applicable, need not include transaction dates if it is not
				reasonably practicable to obtain such dates.</text>
											</subclause>
                    </clause>
                    <clause id="id69d05d5e8da443feae2276d6c5df9beb">
                      <enum>(ii)</enum>
                      <header>Nonsaleable
				returns</header>
                      <text>A wholesale distributor may return a nonsaleable
				prescription drug to the manufacturer or repackager, to the wholesale
				distributor from whom such prescription drug was purchased, or to a person
				acting on behalf of such a person, including a returns processor, without
				providing the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:i" proposed="true">subparagraph (A)(i)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idbe801327dfd54f958da4d668f45aa0d2">
                    <enum>(C)</enum>
                    <header>Requests for
				information</header>
                    <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect product or an illegitimate product a wholesale
				distributor shall, not later than 24 hours after receiving the request or in
				other such reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, based on the
				circumstances of the request, provide the applicable transaction information,
				transaction history, and transaction statement for the product.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="iddc2b9ec5d1ff4e53ad6a111a41154633">
                  <enum>(2)</enum>
                  <header>Product
				identifier</header>
                  <text>Beginning 6 years after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				a wholesale distributor may engage in transactions involving a product only if
				such product is encoded with a product identifier (except as provided pursuant
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>).</text>
								</paragraph>
                <paragraph id="id1ded1eddae5b4119ac1981427f023678">
                  <enum>(3)</enum>
                  <header>Authorized trading
				partners</header>
                  <text>Beginning not later than 1 year after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, the trading partners of a wholesale distributor may be only
				authorized trading partners.</text>
								</paragraph>
                <paragraph id="id15f43b513bdd4a52a0382293ee8a06be">
                  <enum>(4)</enum>
                  <header>Verification</header>
                  <text>Beginning
				not later than 1 year after the date of enactment of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">
                      <short-title>Drug Supply Chain Security Act</short-title>
                    </cato:entity-ref>,
				a wholesale distributor shall have systems in place to enable the wholesale
				distributor to comply with the following requirements:</text>
									<subparagraph id="idebd2595aacfb4b25b96ae8941449ac29">
                    <enum>(A)</enum>
                    <header>Suspect
				product</header>
										<clause id="id2235aa7f6a2e48948c9b52d21dad0825">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon making a determination that a product in the
				possession or control of the wholesale distributor is a suspect product, or
				upon receiving a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that has made a
				determination that a product within the possession or control of a wholesale
				distributor is a suspect product, a wholesale distributor shall—</text>
											<subclause id="idfce32860949b4ce59d36fd270c0f9f34">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the wholesale distributor from product
				intended for distribution until such product is cleared or dispositioned;
				and</text>
											</subclause>
                      <subclause id="id9573d2f936214817bdddc9fd16c6c64d">
                        <enum>(II)</enum>
                        <text>promptly conduct an
				investigation in coordination with trading partners, as applicable, to
				determine whether the product is an illegitimate product, which shall include
				validating any applicable transaction history and transaction information in
				the possession of the wholesale distributor and otherwise investigating to
				determine whether the product is an illegitimate product, and, beginning 6
				years after the date of enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">
                            <short-title>Drug
				Supply Chain Security Act</short-title>
                          </cato:entity-ref> (except as provided pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>), verifying the product at the package level, including the
				standardized numerical identifier.</text>
											</subclause>
                    </clause>
                    <clause id="idaf0676b070f94ccf9a3fd176851ec1be">
                      <enum>(ii)</enum>
                      <header>Cleared
				product</header>
                      <text>If the wholesale distributor determines that a suspect
				product is not an illegitimate product, the wholesale distributor shall
				promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, if applicable, of such determination and such
				product may be further distributed.</text>
										</clause>
                    <clause id="id3658897282b6454c9fbd90fc472d85e4">
                      <enum>(iii)</enum>
                      <header>Records</header>
                      <text>A
				wholesale distributor shall keep records of the investigation of a suspect
				product for not less than 6 years after the conclusion of the
				investigation.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id67df907e0b834a04859800ce55488aa8">
                    <enum>(B)</enum>
                    <header>Illegitimate
				product</header>
										<clause id="id64a1cf8458514a6786ff0fef01735c18">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon determining, in coordination with the manufacturer,
				that a product in the possession or control of a wholesale distributor is an
				illegitimate product, the wholesale distributor shall, in a manner that is
				consistent with the systems and processes of such wholesale distributor—</text>
											<subclause id="ida3aa78caf8174688afeb6f93c663c48d">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the wholesale distributor from product
				intended for distribution until such product is dispositioned;</text>
											</subclause>
                      <subclause id="idde02722ffc2d4c08a4e52519d4569c63">
                        <enum>(II)</enum>
                        <text>disposition the
				illegitimate product within the possession or control of the wholesale
				distributor;</text>
											</subclause>
                      <subclause id="idf44cad8df77b4e6f884252b96149cf4b">
                        <enum>(III)</enum>
                        <text>take reasonable and
				appropriate steps to assist a trading partner to disposition an illegitimate
				product not in the possession or control of the wholesale distributor;
				and</text>
											</subclause>
                      <subclause id="id763C99D2FF5A4FC698A09CE63901D343">
                        <enum>(IV)</enum>
                        <text>retain a sample of the
				product for further physical examination or laboratory analysis of the product
				by the manufacturer or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (or other appropriate Federal or State
				official) upon request by the manufacturer or Secretary (or other appropriate
				Federal or State official), as necessary and appropriate.</text>
											</subclause>
                    </clause>
                    <clause id="iddad1db1fc75e457aaca41dc6398879a0">
                      <enum>(ii)</enum>
                      <header>Making a
				notification</header>
                      <text>Upon determining that a product in the possession or
				control of the wholesale distributor is an illegitimate product, the wholesale
				distributor shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and all immediate trading partners that
				the wholesale distributor has reason to believe may have received such
				illegitimate product of such determination not later than 24 hours after making
				such determination.</text>
										</clause>
                    <clause id="id6ac7aef27c3041988054b5e5408c8e7c">
                      <enum>(iii)</enum>
                      <header>Responding to a
				notification</header>
                      <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or a trading partner that a determination has been made that a
				product is an illegitimate product, a wholesale distributor shall identify all
				illegitimate product subject to such notification that is in the possession or
				control of the wholesale distributor, including any product that is
				subsequently received, and shall perform the activities described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
										</clause>
                    <clause id="id5F1AED23A637482D9A01FB2590AD01ED">
                      <enum>(iv)</enum>
                      <header>Terminating a
				notification</header>
                      <text>Upon a determination, in consultation with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that a notification is no longer necessary, a wholesale distributor
				shall promptly notify immediate trading partners that the wholesale distributor
				notified pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:4/sp:B/cl:ii" proposed="true">clause (ii)</cato:entity-ref> that such notification has been
				terminated.</text>
										</clause>
                    <clause id="idd3b792bae90d4f928a6e47ac62e9e626">
                      <enum>(v)</enum>
                      <header>Records</header>
                      <text>A
				wholesale distributor shall keep records of the disposition of an illegitimate
				product for not less than 6 years after the conclusion of the
				disposition.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id6e71015b977f4af0b3bee4637a6b317d">
                    <enum>(C)</enum>
                    <header>Electronic
				database</header>
                    <text>A wholesale distributor may satisfy the requirements of
				this paragraph by developing a secure electronic database or utilizing a secure
				electronic database developed or operated by another entity. The owner of such
				database shall establish the requirements and processes to respond to requests
				and may provide for data access to other members of the pharmaceutical
				distribution supply chain, as appropriate. The development and operation of
				such a database shall not relieve a wholesale distributor of the requirement
				under this paragraph to respond to a verification request submitted by means
				other than a secure electronic database.</text>
									</subparagraph>
                  <subparagraph id="idcd9421d35fcb43f8b08e8a07052627dd">
                    <enum>(D)</enum>
                    <header>Verification of
				saleable returned product</header>
                    <text>Beginning 6 years after the date of
				enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>, upon receipt of a returned product that the wholesale
				distributor intends to further distribute, before further distributing such
				product, the wholesale distributor shall verify the product identifier,
				including the standardized numerical identifier, for each sealed homogeneous
				case of such product or, if such product is not in a sealed homogeneous case,
				verify the product identifier, including the standardized numerical identifier,
				on each package.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="ida57260e705a744548a196a6d29561ac7">
                <enum>(d)</enum>
                <header>Dispenser
				requirements</header>
								<paragraph id="id73543783008a4d09a69e44fec590d07b">
                  <enum>(1)</enum>
                  <header>Product
				tracing</header>
									<subparagraph id="id327026c77d7e40caa7a3eed97c1c132b">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>Beginning 1 year after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                      </short-title>,
				a dispenser—</text>
										<clause id="id1ccba8b3b5de4cc2a910252fd58b248f">
                      <enum>(i)</enum>
                      <text>shall not accept
				ownership of a product, unless the previous owner prior to, or at the time of,
				the transaction, provides transaction history, transaction information, and a
				transaction statement;</text>
										</clause>
                    <clause id="id2539a94040ca4446a49d19f18daaea37">
                      <enum>(ii)</enum>
                      <text>prior to, or at the time
				of, each transaction in which the dispenser transfers ownership of a product
				(but not including dispensing to a patient or returns) shall provide the
				subsequent owner with transaction history, transaction information, and a
				transaction statement for the product, except that the requirements of this
				clause shall not apply to sales by a dispenser to another dispenser to fulfill
				a specific patient need; and</text>
										</clause>
                    <clause id="idc6cea9bc94114ba5b955506261430749">
                      <enum>(iii)</enum>
                      <text>shall maintain
				transaction information, transaction history, and transaction statements, as
				necessary to investigate a suspect product, for not less than 6 years after the
				transaction.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="ida801182fdf8f414882033510b30ec31f">
                    <enum>(B)</enum>
                    <header>Agreements with third
				parties</header>
                    <text>A dispenser may enter into a written agreement with a
				third party, including an authorized wholesale distributor, under which the
				third party confidentially maintains the transaction information, transaction
				history, and transaction statements required to be maintained under this
				subsection on behalf of the dispenser. If a dispenser enters into such an
				agreement, the dispenser shall maintain a copy of the written agreement and
				shall not be relieved of the obligations of the dispenser under this
				subsection.</text>
									</subparagraph>
                  <subparagraph id="idddbcd6d87a6642a3bf24e3ce912f5ce7">
                    <enum>(C)</enum>
                    <header>Returns</header>
										<clause id="idaedba11005a24e8c8980d14160413784">
                      <enum>(i)</enum>
                      <header>Saleable
				returns</header>
                      <text>A dispenser may return product to the trading partner
				from which the dispenser obtained the product without providing the information
				required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
										</clause>
                    <clause id="idfb0aa4e9e7174adb80d895e636d12532">
                      <enum>(ii)</enum>
                      <header>Nonsaleable
				returns</header>
                      <text>A dispenser may return a nonsaleable product to the
				manufacturer or repackager, to the wholesale distributor from whom such product
				was purchased, to a returns processor, or to a person acting on behalf of such
				a person without providing the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:A/cl:i" proposed="true">subparagraph
				(A)(i)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id678c802e3067489b8b5598989d57bbe3">
                    <enum>(D)</enum>
                    <header>Requests for
				information</header>
                    <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect or an illegitimate product, a dispenser shall, not
				later than 2 business days after receiving the request or in another such
				reasonable time as determined by the Secretary, based on the circumstances of
				the request, provide the applicable transaction information, transaction
				statement, and transaction history which the dispenser received from the
				previous owner, which shall not include the lot number of the product, the
				initial transaction date, or the initial shipment date from the manufacturer
				unless such information was included in the transaction information,
				transaction statement, and transaction history provided by the manufacturer or
				wholesale distributor to the dispenser. The dispenser may respond to the
				request by providing the applicable information in either paper or electronic
				format.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id938da59b96a14b9e811d205b3244aaaa">
                  <enum>(2)</enum>
                  <header>Product
				identifier</header>
                  <text>Beginning not later than 7 years after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, a dispenser may engage in transactions involving a product
				only if such product is encoded with a product identifier (except as provided
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>).</text>
								</paragraph>
                <paragraph id="id2ad3a5f0820c4d3c9755cac5a12e3bb3">
                  <enum>(3)</enum>
                  <header>Authorized trading
				partners</header>
                  <text>Beginning not later than 1 year after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, the trading partners of a dispenser may be only authorized
				trading partners.</text>
								</paragraph>
                <paragraph id="id852cd707db164252b4f3c44ac483604c">
                  <enum>(4)</enum>
                  <header>Verification</header>
                  <text>Beginning
				not later than 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				a dispenser shall have systems in place to enable the dispenser to comply with
				the following requirements:</text>
									<subparagraph id="id32e298f707e24001997103b5c7105c38">
                    <enum>(A)</enum>
                    <header>Suspect
				product</header>
										<clause id="idd429fb01992d4d5db52116dcbc4a67d9">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon making a determination that a product in the
				possession or control of the dispenser is a suspect product, or upon receiving
				a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that has made a determination
				that a product within the possession or control of a dispenser is a suspect
				product, a dispenser shall—</text>
											<subclause id="idb042373d629d402e94501e5efdc3606d">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the dispenser from product intended for
				distribution until such product is cleared or dispositioned; and</text>
											</subclause>
                      <subclause id="iddb65ce0d80a54810b519bf785709a317">
                        <enum>(II)</enum>
                        <text>promptly conduct an
				investigation in coordination with trading partners, as applicable, to
				determine whether the product is an illegitimate product.</text>
											</subclause>
                    </clause>
                    <clause id="id132C92A4C06444C489593AABDCD99625">
                      <enum>(ii)</enum>
                      <header>Investigation</header>
                      <text>An
				investigation conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:4/sp:A/cl:i/scl:II" proposed="true">clause (i)(II)</cato:entity-ref> shall include—</text>
											<subclause id="idfd2c2c0dc94d48eab41d9f7d0cdb9b29">
                        <enum>(I)</enum>
                        <text>beginning 7 years after
				the date of enactment of the <short-title>
                            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply
				Chain Security Act</cato:entity-ref>
                          </short-title>, verifying whether the lot number of a suspect
				product corresponds with the lot number for such product;</text>
											</subclause>
                      <subclause id="id3fee2eeb998544e78e4fee520534ccfc">
                        <enum>(II)</enum>
                        <text>beginning 7 years after
				the date of enactment of such Act, verifying that the product identifier,
				including the standardized numerical identifier, of at least 3 packages or 10
				percent of such suspect product, whichever is greater, or all packages, if
				there are fewer than 3, corresponds with the product identifier for such
				product;</text>
											</subclause>
                      <subclause id="id84fa568e382e4b5494ae3c7712042eac">
                        <enum>(III)</enum>
                        <text>validating any
				applicable transaction history and transaction information in the possession of
				the dispenser; and</text>
											</subclause>
                      <subclause id="idb00129d26377473494a394182aea23c2">
                        <enum>(IV)</enum>
                        <text>otherwise investigating
				to determine whether the product is an illegitimate product.</text>
											</subclause>
                    </clause>
                    <clause id="id6b15e40f5f534f709156ad42621eb3c7">
                      <enum>(iii)</enum>
                      <header>Cleared
				product</header>
                      <text>If the dispenser makes the determination that a suspect
				product is not an illegitimate product, the dispenser shall promptly notify the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, if applicable, of such determination and such product may be further
				distributed or dispensed.</text>
										</clause>
                    <clause id="idf09176bdaad94a948e90192fad79060f">
                      <enum>(iv)</enum>
                      <header>Records</header>
                      <text>A
				dispenser shall keep records of the investigation of a suspect product for not
				less than 6 years after the conclusion of the investigation.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id68643f492d834cf49d0c289a88f8326c">
                    <enum>(B)</enum>
                    <header>Illegitimate
				product</header>
										<clause id="id1b5fcd8a4ed040de86153a2492e5bea3">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon determining, in coordination with the manufacturer,
				that a product in the possession or control of a dispenser is an illegitimate
				product, the dispenser shall—</text>
											<subclause id="idf118465e15de4f3a87ea1b4bb31e6f20">
                        <enum>(I)</enum>
                        <text>disposition the
				illegitimate product within the possession or control of the dispenser;</text>
											</subclause>
                      <subclause id="ide4d26696fca840ffb513d61e8e48999e">
                        <enum>(II)</enum>
                        <text>take reasonable and
				appropriate steps to assist a trading partner to disposition an illegitimate
				product not in the possession or control of the dispenser; and</text>
											</subclause>
                      <subclause id="idD83E49DA7F9C4DF38593D9EA6F61114C">
                        <enum>(III)</enum>
                        <text>retain a sample of the
				product for further physical examination or laboratory analysis of the product
				by the manufacturer or Secretary (or other appropriate Federal or State
				official) upon request by the manufacturer or Secretary (or other appropriate
				Federal or State official), as necessary and appropriate.</text>
											</subclause>
                    </clause>
                    <clause id="id68a7b2ac302a41a3bbda0b9c7c0dec85">
                      <enum>(ii)</enum>
                      <header>Making a
				notification</header>
                      <text>Upon determining that a product in the possession or
				control of the dispenser is an illegitimate product, the dispenser shall notify
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and all immediate trading partners that the dispenser has reason
				to believe may have received such illegitimate product of such determination
				not later than 24 hours after making such determination.</text>
										</clause>
                    <clause id="iddab89879fd6f43dda911d1b03502654c">
                      <enum>(iii)</enum>
                      <header>Responding to a
				notification</header>
                      <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or a trading partner that a determination has been made that a
				product is an illegitimate product, a dispenser shall identify all illegitimate
				product subject to such notification that is in the possession or control of
				the dispenser, including any product that is subsequently received, and shall
				perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
										</clause>
                    <clause id="id37792e7da08340a0880ab74e4063d70e">
                      <enum>(iv)</enum>
                      <header>Terminating a
				notification</header>
                      <text>Upon making a determination, in consultation with
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that a notification is no longer necessary, a dispenser shall
				promptly notify immediate trading partners that the dispenser notified pursuant
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:4/sp:B/cl:ii" proposed="true">clause (ii)</cato:entity-ref> that such notification has been terminated.</text>
										</clause>
                    <clause id="idAEB7D96C7A614D6EB6BEA54D9F44BE60">
                      <enum>(v)</enum>
                      <header>Records</header>
                      <text>A
				dispenser shall keep records of the disposition of an illegitimate product for
				not less than 6 years after the conclusion of the disposition.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idd3799f408f6c477688c62adc19fd2bbf">
                    <enum>(C)</enum>
                    <header>Electronic
				database</header>
                    <text>A dispenser may satisfy the requirements of this
				paragraph by developing a secure electronic database or utilizing a secure
				electronic database developed or operated by another entity.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id3d0d4b915f48401f8a0d31bee2ebdf84">
                <enum>(e)</enum>
                <header>Repackager
				requirements</header>
								<paragraph id="id763126f5ed6f41a0ba0ba536ba084bef">
                  <enum>(1)</enum>
                  <header>Product
				tracing</header>
									<subparagraph id="idbae7a878bab649929a4eed9833e738d6">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>Beginning not later than 1 year after the date of
				enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>, a repackager shall—</text>
										<clause id="ida26c87e5c5fd480ebd2aecc13f5fe88f">
                      <enum>(i)</enum>
                      <text>not accept ownership of a
				product unless the previous owner, prior to, or at the time of, the
				transaction, provides transaction history, transaction information, and a
				transaction statement for the product;</text>
										</clause>
                    <clause id="id59261e54eac2429ebd5909e58b8672ad">
                      <enum>(ii)</enum>
                      <text>prior to, or at the time
				of, each transaction in which the repackager transfers ownership of a product,
				or transfers possession of a product to a third-party logistics provider,
				provide the subsequent owner with transaction history, transaction information,
				and a transaction statement; and</text>
										</clause>
                    <clause id="idaf3774e04e1347a7bfaa1cc92d82e91e">
                      <enum>(iii)</enum>
                      <text>maintain the
				transaction information, transaction history, and transaction statement for
				each transaction described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> for not less than 6 years
				after the transaction.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="idfaeddf0a81b84c81a726fa6eecd231bb">
                    <enum>(B)</enum>
                    <header>Nonsaleable
				returns</header>
                    <text>A repackager may return a nonsaleable product to the
				manufacturer or repackager, or to the wholesale distributor from whom such
				product was purchased, or to a person acting on behalf of such a person,
				including a returns processor, without providing the information required under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="idb20f9d692bea4927b8f634d1c3b79de6">
                    <enum>(C)</enum>
                    <header>Requests for
				information</header>
                    <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect product or an illegitimate product, a repackager shall,
				not later than 24 hours after receiving the request or in other such reasonable
				time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, based on the circumstances of the request,
				provide the applicable transaction information, transaction history and
				transaction statement for the product.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="idba23fc623f2149a690645ac22e9dfced">
                  <enum>(2)</enum>
                  <header>Product
				identifier</header>
                  <text>Beginning not later than 5 years after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, a repackager—</text>
									<subparagraph id="id6817cfe581244e73966464b8c4c567fa">
                    <enum>(A)</enum>
                    <text>shall affix or imprint a
				product identifier to each package and homogenous case of product intended to
				be introduced in a transaction in commerce;</text>
									</subparagraph>
                  <subparagraph id="id8042B3A76DCF47138390E8E86B60CCD0">
                    <enum>(B)</enum>
                    <text>shall maintain the
				product identifier information for such product for not less than 6 years after
				the date of the transaction;</text>
									</subparagraph>
                  <subparagraph id="idf668b681ea954b6fb4aadca632f65dca">
                    <enum>(C)</enum>
                    <text>may engage in
				transactions involving a product only if such product is encoded with a product
				identifier (except as provided pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>); and</text>
									</subparagraph>
                  <subparagraph id="iddacde1bfa5ab4a868c13e663441e8c6d">
                    <enum>(D)</enum>
                    <text>maintain records for not
				less than 6 years to allow the repackager to associate the product identifier
				the repackager affixes or imprints with the product identifier assigned by the
				original manufacturer of the product.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id8b108646ae574d5faba5091ab3dcee5f">
                  <enum>(3)</enum>
                  <header>Authorized trading
				partners</header>
                  <text>Beginning 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				the trading partners of a repackager may be only authorized trading
				partners.</text>
								</paragraph>
                <paragraph id="idf96a8e24df5d49ee8a6c2df44c9e65c7">
                  <enum>(4)</enum>
                  <header>Verification</header>
                  <text>Beginning
				not later than 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				a repackager shall have systems in place to enable the repackager to comply
				with the following requirements:</text>
									<subparagraph id="idab7a652119ae44c3b9cd29312461f772">
                    <enum>(A)</enum>
                    <header>Suspect
				product</header>
										<clause id="id0a232a49484c430c86bdf27f55c919ef">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon making a determination that a product in the
				possession or control of the repackager is a suspect product, or upon receiving
				a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that has made a determination
				that a product within the possession or control of a repackager is a suspect
				product, a repackager shall—</text>
											<subclause id="id02d1196d2174420d9aefee00b499c025">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the repackager from product intended for
				distribution until such product is cleared or dispositioned; and</text>
											</subclause>
                      <subclause id="id69bb8fa2cd424e27b49478878043fe38">
                        <enum>(II)</enum>
                        <text>promptly conduct an
				investigation in coordination with trading partners, as applicable, to
				determine whether the product is an illegitimate product, which shall include
				validating any applicable transaction history and transaction information in
				the possession of the repackager and otherwise investigating to determine
				whether the product is an illegitimate product, and, beginning 5 years after
				the date of enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">
                            <short-title>Drug Supply
				Chain Security Act</short-title>
                          </cato:entity-ref> (except as provided pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection
				(a)(5)</cato:entity-ref>), verifying the product at the package level, including the standardized
				numerical identifier.</text>
											</subclause>
                    </clause>
                    <clause id="id2db72b73c07542df99cb486c06411687">
                      <enum>(ii)</enum>
                      <header>Cleared
				product</header>
                      <text>If the repackager makes the determination that a suspect
				product is not an illegitimate product, the repackager shall promptly notify
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, if applicable, of such determination and such product may be
				further distributed.</text>
										</clause>
                    <clause id="id9e23bbf0d5ef46978c3c479f2514aece">
                      <enum>(iii)</enum>
                      <header>Records</header>
                      <text>A
				repackager shall keep records of the investigation of a suspect product for not
				less than 6 years after the conclusion of the investigation.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id3f8fb743710d43b9a161bff3994a6b73">
                    <enum>(B)</enum>
                    <header>Illegitimate
				product</header>
										<clause id="id41878dc0ded34ca5988cafac6bafcff1">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon determining, in coordination with the manufacturer,
				that a product in the possession or control of a repackager is an illegitimate
				product, the repackager shall, in a manner that is consistent with the systems
				and processes of such repackager—</text>
											<subclause id="id6050a2cfcfde471b960373cc6300e22b">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the repackager from product intended for
				distribution until such product is dispositioned;</text>
											</subclause>
                      <subclause id="id1D54FDA248A74DB7A7789ECF7F44B600">
                        <enum>(II)</enum>
                        <text>disposition the
				illegitimate product within the possession or control of the repackager;</text>
											</subclause>
                      <subclause id="id730f085fe8764cb99a2817a85c0a90a4">
                        <enum>(III)</enum>
                        <text>take reasonable and
				appropriate steps to assist a trading partner to disposition an illegitimate
				product not in the possession or control of the repackager; and</text>
											</subclause>
                      <subclause id="id9C628FE8E956491384CA6D293B00AECE">
                        <enum>(IV)</enum>
                        <text>retain a sample of the
				product for further physical examination or laboratory analysis of the product
				by the manufacturer or Secretary (or other appropriate Federal or State
				official) upon request by the manufacturer or Secretary (or other appropriate
				Federal or State official), as necessary and appropriate.</text>
											</subclause>
                    </clause>
                    <clause id="id28d794a2dcf444ada3395d992d614a0d">
                      <enum>(ii)</enum>
                      <header>Making a
				notification</header>
                      <text>Upon determining that a product in the possession or
				control of the repackager is an illegitimate product, the repackager shall
				notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and all immediate trading partners that the repackager has
				reason to believe may have received the illegitimate product of such
				determination not later than 24 hours after making such determination.</text>
										</clause>
                    <clause id="id760720e2df0c4bc89adff1b862da8cf2">
                      <enum>(iii)</enum>
                      <header>Responding to a
				notification</header>
                      <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or a trading partner, a repackager shall identify all illegitimate
				product subject to such notification that is in the possession or control of
				the repackager, including any product that is subsequently received, and shall
				perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
										</clause>
                    <clause id="ida599d7364a4e4327b33d51324e2a9042">
                      <enum>(iv)</enum>
                      <header>Terminating a
				notification</header>
                      <text>Upon a determination, in consultation with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that a notification is no longer necessary, a repackager shall
				promptly notify immediate trading partners that the repackager notified
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:B/cl:ii" proposed="true">clause (ii)</cato:entity-ref> that such notification has been terminated.</text>
										</clause>
                    <clause id="id806B72414F144A4CAD04BF3F71EB9975">
                      <enum>(v)</enum>
                      <header>Records</header>
                      <text>A
				repackager shall keep records of the disposition of an illegitimate product for
				not less than 6 years after the conclusion of the disposition.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="ide4820ac802f64985838c89e206211e68">
                    <enum>(C)</enum>
                    <header>Requests for
				verification</header>
                    <text>Beginning 5 years after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                      </short-title>,
				upon receiving a request for verification from an authorized manufacturer,
				wholesale distributor, or dispenser that is in possession or control of a
				product they believe to be repackaged by such repackager, a repackager shall,
				not later than 24 hours after receiving the verification request or in other
				such reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, based on the circumstances
				of the request, notify the person making the request whether the product
				identifier, including the standardized numerical identifier, that is the
				subject of the request corresponds to the product identifier affixed or
				imprinted by the repackager. If a repackager responding to a verification
				request identifies a product identifier that does not correspond to that
				affixed or imprinted by the repackager, the repackager shall treat such product
				as suspect product and conduct an investigation as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref>. If the repackager has reason to believe the product is an illegitimate
				product, the repackager shall advise the person making the request of such
				belief at the time such manufacturer responds to the verification
				request.</text>
									</subparagraph>
                  <subparagraph id="idf0150b18226146198a59f5de1e43517e">
                    <enum>(D)</enum>
                    <header>Electronic
				database</header>
                    <text>A repackager may satisfy the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4" proposed="true">paragraph
				(4)</cato:entity-ref> by developing a secure electronic database or utilizing a secure electronic
				database developed or operated by another entity. The owner of such database
				shall establish the requirements and processes to respond to requests and may
				provide for data access to other members of the pharmaceutical distribution
				supply chain, as appropriate. The development and operation of such a database
				shall not relieve a repackager of the requirement under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref> to
				respond to a verification request submitted by means other than a secure
				electronic database.</text>
									</subparagraph>
                  <subparagraph id="id4234272c8c554b15ae1ac2d830bdcc11">
                    <enum>(E)</enum>
                    <header>Verification of
				saleable returned product</header>
                    <text>Beginning 5 years after the date of
				enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                      </short-title>, upon receipt of a returned product that the repackager
				intends to further distribute, before further distributing such product, the
				repackager shall verify the product identifier for each sealed homogeneous case
				of such product or, if such product is not in a sealed homogeneous case, verify
				the product identifier on each package.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id0c227a1b27574be8ac8411e9f2ea9694">
                <enum>(f)</enum>
                <header>Third-party logistics
				provider requirements</header>
								<paragraph commented="no" id="id27e979a8240045358ab1c2bd684a9be3">
                  <enum>(1)</enum>
                  <header>In
				general</header>
                  <text>Beginning not later than 1 year after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, a third-party logistics provider shall—</text>
									<subparagraph id="id1ec32f7931294f85a97669b7dafd19d1">
                    <enum>(A)</enum>
                    <text>not accept possession of
				a product unless the owner of the product provides the transaction history,
				transaction information, and a transaction statement for the product;</text>
									</subparagraph>
                  <subparagraph id="ida1cc5d39a7404fbab6e9bccff3b5e904">
                    <enum>(B)</enum>
                    <text>maintain a copy
				of the information described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> for not less than 6 years
				after the transfer of possession; and</text>
									</subparagraph>
                  <subparagraph id="id12C59C70851E4852BDBF4552103F67BB">
                    <enum>(C)</enum>
                    <text>upon a request by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate Federal or State official, in the event of a
				recall or for the purpose of investigating a suspect product or an illegitimate
				product, not later than 24 hours after receiving the request or in other such
				reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> based on the circumstances of
				the request, provide the applicable transaction information, transaction
				history, and transaction statement for the product.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="id0c8d363eb35c40d68b29f43ef76ef060">
                  <enum>(2)</enum>
                  <header>Product
				tracing</header>
                  <text>Beginning not later than 6 years after the date of
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>, a third-party logistics provider may accept possession of
				product only if such product is encoded with a product identifier (except as
				provided pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:5" proposed="true">subsection (a)(5)</cato:entity-ref>).</text>
								</paragraph>
                <paragraph id="id1f6080e38c444bbc9af385f4f0e7f9aa">
                  <enum>(3)</enum>
                  <header>Authorized trading
				partners</header>
                  <text>Beginning 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				the trading partners of a third-party logistics provider may be only authorized
				trading partners.</text>
								</paragraph>
                <paragraph id="idc80806f9a88e49e5a361ee8378bc2931">
                  <enum>(4)</enum>
                  <header>Verification</header>
                  <text>Beginning
				not later than 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				a third-party logistics provider shall have systems in place to enable the
				third-party logistics provider to comply with the following
				requirements:</text>
									<subparagraph id="idf62ceacbfa7e44a5814990b6c8e5feb0">
                    <enum>(A)</enum>
                    <header>Suspect
				product</header>
										<clause id="id3603b838fee940e1a9edce77dee7a828">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon making a determination that a product in the
				possession or control of a third-party logistics provider is a suspect product,
				a third-party logistics provider shall—</text>
											<subclause id="idebb64ace18cc433e8d70ae721022fd74">
                        <enum>(I)</enum>
                        <text>quarantine such product
				within the possession or control of the third-party logistics provider from
				product intended for distribution until such product is cleared or transferred
				to the owner of such product for disposition of the product; and</text>
											</subclause>
                      <subclause id="idf15fdf29328640b7bf283380c829de75">
                        <enum>(II)</enum>
                        <text>promptly notify the
				owner of such product of the need to conduct an investigation to determine
				whether the product is an illegitimate product.</text>
											</subclause>
                    </clause>
                    <clause id="id13d87833b00f43cd96a684cfe98653ff">
                      <enum>(ii)</enum>
                      <header>Cleared
				product</header>
                      <text>If the owner of the product notifies the third-party
				logistics provider of the determination that a suspect product is not an
				illegitimate product, such product may be further distributed.</text>
										</clause>
                    <clause id="idab3bc8c1548448f39a99df3c8a144d90">
                      <enum>(iii)</enum>
                      <header>Records</header>
                      <text>A
				third-party logistics provider shall keep records of the activities described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:4/sp:A/cl:i/scl:I" proposed="true">subclauses (I)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:4/sp:A/cl:i/scl:II" proposed="true">(II) of clause (i)</cato:entity-ref>, as such subclauses relate to a
				suspect product, for not less than 6 years after the conclusion of the
				investigation.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="id6f2ffcaf4bf0405685304411704d1b2e">
                    <enum>(B)</enum>
                    <header>Illegitimate
				product</header>
										<clause id="id388659b378ab4c458275b3e38e424f63">
                      <enum>(i)</enum>
                      <header>In
				general</header>
                      <text>Upon determining, in coordination with the manufacturer,
				that a product in the possession or control of a third-party logistics provider
				is an illegitimate product, the third-party logistics provider shall—</text>
											<subclause id="id6961fe83646e43ab887210b0c29943cf">
                        <enum>(I)</enum>
                        <text>promptly notify the owner
				of such product of the need to disposition such product; and</text>
											</subclause>
                      <subclause id="id5fa2160095354280bae515276971c81b">
                        <enum>(II)</enum>
                        <text>promptly transfer
				possession of the product to the owner of such product to disposition the
				product.</text>
											</subclause>
                    </clause>
                    <clause id="id57e786d2abe442af985937c0b78d8e84">
                      <enum>(ii)</enum>
                      <header>Making a
				notification</header>
                      <text>Upon determining that a product in the possession or
				control of the third-party logistics provider is an illegitimate product, the
				third-party logistics provider shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than 24
				hours after making such determination.</text>
										</clause>
                    <clause id="id4e98d1b0b4c94888802d9a6e80f97b13">
                      <enum>(iii)</enum>
                      <header>Responding to a
				notification</header>
                      <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, a third-party logistics provider shall identify all illegitimate
				product subject to such notification that is in the possession or control of
				the third-party logistics provider, including any product that is subsequently
				received, and shall perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:4/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref>.</text>
										</clause>
                    <clause id="ideb96820a56ff4cb39ccf3208d7d4a760">
                      <enum>(iv)</enum>
                      <header>Terminating a
				notification</header>
                      <text>Upon making a determination, in consultation with
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and the owner of such product, that a notification is no longer
				necessary, a third-party logistics provider shall promptly terminate such
				notification.</text>
										</clause>
                    <clause id="idB8557A8FF924417CBE3037ED15D696E1">
                      <enum>(v)</enum>
                      <header>Records</header>
                      <text>A
				third-party logistics provider shall keep records of the activities described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:4/sp:A/cl:i/scl:I" proposed="true">subclauses (I)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:4/sp:A/cl:i/scl:II" proposed="true">(II) of clause (i)</cato:entity-ref> as such subclauses relate to an
				illegitimate product for not less than 6 years after the conclusion of the
				disposition.</text>
										</clause>
                  </subparagraph>
                </paragraph>
              </subsection>
              <subsection id="id4a17635c488f4ba7b15ebf394bbca3b3">
                <enum>(g)</enum>
                <header>Drop shipments</header>
								<paragraph id="ida82ff6a43bbd4a41be3f660595c916f8">
                  <enum>(1)</enum>
                  <header>In
				general</header>
                  <text>A wholesale distributor that does not physically handle
				or store product shall be exempt from the provisions of this section, except
				the notification requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:4/sp:B/cl:ii" proposed="true">clauses (ii</cato:entity-ref>), <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:4/sp:B/cl:iii" proposed="true">(iii)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:4/sp:B/cl:iv" proposed="true">(iv) of subsection
				(c)(4)(B)</cato:entity-ref>, provided that the manufacturer, repackager, or other wholesale
				distributor that distributes the product to the dispenser by means of drop
				shipment for such wholesale distributor includes on the transaction information
				and transaction history to the dispenser the contact information of such
				wholesale distributor and provides the transaction information, transaction
				history, and transaction statement directly to the dispenser.</text>
								</paragraph>
                <paragraph id="id2FEB5669BC4344E381845B6977AA21FD">
                  <enum>(2)</enum>
                  <header>Clarification</header>
                  <text>For
				purposes of this subsection, providing administrative services, including
				processing of orders and payments, shall not by itself, be construed as being
				involved in the handling, distribution, or storage of a
				product.</text>
								</paragraph>
              </subsection>
            </section>
          </subchapter>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="id78139f99bfa44fd6bfe76849e3b3d206">
        <enum>203.</enum>
        <header>Enhanced drug
			 distribution security</header>
        <text display-inline="no-display-inline">
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">Section
			 582</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:202" proposed="true">section 202</cato:entity-ref>, is amended by adding at the end the
			 following:</text>
				<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id59969741af6e427a9f1cb2699dcabf62" reported-display-style="italic" style="OLC">
					<subsection id="id1cad5ecabf194b0796eb75d91991a5a3">
            <enum>(h)</enum>
            <header>Enhanced drug
				distribution security</header>
						<paragraph id="id08dca4b9ec8149499795c59ea0bcae5a">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>On the date that is 10 years after the date of enactment
				of the <short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                </short-title>, the following interoperable, electronic tracing of product
				at the package level requirements shall go into effect:</text>
							<subparagraph id="ide440bf6050e141e3b4dafd2fe94ecb62">
                <enum>(A)</enum>
                <text>The transaction
				information and the transaction statements as required under this section shall
				be exchanged in a secure, interoperable, electronic manner in accordance with
				the standards established under the guidance issued pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:3" proposed="true">paragraphs (3)</cato:entity-ref>
				and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:4" proposed="true">(4) of subsection (i)</cato:entity-ref>, including any revision of such guidance issued in
				accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:5" proposed="true">paragraph (5)</cato:entity-ref> of such subsection.</text>
							</subparagraph>
              <subparagraph id="id7a6f1d3e7254443d8e92edd0a16a4d62">
                <enum>(B)</enum>
                <text>The transaction
				information required under this section shall include the product identifier at
				the package level for each package included in the transaction.</text>
							</subparagraph>
              <subparagraph id="id6e54d5038e1b4769a88b573d3ee667e3">
                <enum>(C)</enum>
                <text>Systems and processes for
				verification of product at the package level, including the standardized
				numerical identifier, shall be required in accordance with the standards
				established under the guidance issued pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref> and the
				guidances issued pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:2" proposed="true">paragraphs (2)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:3" proposed="true">(3)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:4" proposed="true">(4) of subsection (i)</cato:entity-ref>,
				including any revision of such guidances issued in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:5" proposed="true">paragraph
				(5) of such subsection</cato:entity-ref>, which may include the use of aggregation and inference
				as necessary.</text>
							</subparagraph>
              <subparagraph id="id76ad7d97f89e48ec93e179d68166ac70">
                <enum>(D)</enum>
                <text>The systems and
				processes necessary to promptly respond with the transaction information and
				transaction statement for a product upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (or other
				appropriate Federal or State official) in the event of a recall or for the
				purposes of investigating a suspect product or an illegitimate product shall be
				required.</text>
							</subparagraph>
              <subparagraph id="id6f8d8c5d7de44124a5dd3e82dcf981ac">
                <enum>(E)</enum>
                <text>The systems and processes
				necessary to promptly facilitate gathering the information necessary to produce
				the transaction information for each transaction going back to the
				manufacturer, as applicable, shall be required—</text>
								<clause id="id2710315DC397425494812E51F4FD02AE">
                  <enum>(i)</enum>
                  <text>in the event of a
				request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (or other appropriate Federal or State official), on
				account of a recall or for the purposes of investigating a suspect product or
				an illegitimate product; or</text>
								</clause>
                <clause id="id350C7F7FEC8D4FE699ADD919E4E89EA2">
                  <enum>(ii)</enum>
                  <text>in the event of
				a request by an authorized trading partner, in a secure manner that ensures the
				protection of confidential commercial information and trade secrets, for
				purposes of investigating a suspect product or assisting the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (or
				other appropriate Federal or State official) with a request described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:1/sp:E/cl:i" proposed="true">clause
				(i)</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
              <subparagraph id="id8d04fa00a38242fab1858f96da188978">
                <enum>(F)</enum>
                <text>Each person accepting a
				saleable return shall have systems and processes in place to allow acceptance
				of such product and may accept saleable returns only if such person can
				associate the saleable return product with the transaction information and
				transaction statement associated with that product.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="ida792bc0703d44fbeae6ed2579d0537b2">
              <enum>(2)</enum>
              <header>Compliance</header>
							<subparagraph id="id9b1077ae3109408d9030e441c74fafbc">
                <enum>(A)</enum>
                <header>Information maintenance
				agreement</header>
                <text>A dispenser may enter into a written agreement with a
				third party, including an authorized wholesale distributor, under which the
				third party shall confidentially maintain any information and statements
				required to be maintained under this section. If a dispenser enters into such
				an agreement, the dispenser shall maintain a copy of the written agreement and
				shall not be relieved of the obligations of the dispenser under this
				subsection.</text>
							</subparagraph>
              <subparagraph id="id4d2220111ab34a6ca02e50455b10f7e7">
                <enum>(B)</enum>
                <header>Alternative
				methods</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, taking into consideration the assessment
				conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:3" proposed="true">paragraph (3)</cato:entity-ref>, shall provide for alternative methods of
				compliance with any of the requirements set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:1" proposed="true">paragraph (1)</cato:entity-ref>,
				including—</text>
								<clause id="id44bb2774b3c9441caec8a491986dd0a3">
                  <enum>(i)</enum>
                  <text>establishing timelines
				for compliance by small businesses (including small business dispensers with 25
				or fewer full time employees) with such requirements, in order to ensure that
				such requirements do not impose undue economic hardship for small businesses,
				including small business dispensers for whom the criteria set forth in the
				assessment under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:3" proposed="true">paragraph (3)</cato:entity-ref> is not met, if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that
				such requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:1" proposed="true">paragraph (1)</cato:entity-ref> would result in undue economic hardship;
				and</text>
								</clause>
                <clause id="ida4416b70070a4a9090fc4913ad8d5bfa">
                  <enum>(ii)</enum>
                  <text>establishing a
				process by which a dispenser may request a waiver from any of the requirements
				set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:1" proposed="true">paragraph (1)</cato:entity-ref> if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that such requirements
				would result in an undue economic hardship, which shall include a process for
				the biennial review and renewal of any such waiver.</text>
								</clause>
              </subparagraph>
            </paragraph>
            <paragraph id="idc116ed31a5b942fdafacfe142d47079b">
              <enum>(3)</enum>
              <header>Assessment</header>
							<subparagraph id="idedb3e3e9b1c24735a89cd2851b7bc001">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>Not later than the date that is 18 months after the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> issues the final guidance required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i" proposed="true">subsection (i)</cato:entity-ref>, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall enter into contract with a private, independent consulting firm
				with expertise to conduct a technology and software assessment that looks at
				the feasibility of dispensers with 25 or fewer full-time employees conducting
				interoperable, electronic tracing of products at the package level. In no case
				may such assessment commence later than 7½ years after the date of enactment of
				the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                  </short-title>.</text>
							</subparagraph>
              <subparagraph id="idAFEF47DD7337440BAB205F1175E77B97">
                <enum>(B)</enum>
                <header>Condition</header>
                <text>As
				a condition of the award of the contract under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the private,
				independent consulting firm shall agree to consult with dispensers with 25 or
				fewer full-time employees when conducting the assessment under such
				subparagraph.</text>
							</subparagraph>
              <subparagraph id="id6e98f4618f9440f49f52e39c44ce578a">
                <enum>(C)</enum>
                <header>Content</header>
                <text>The
				assessment conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall assess whether—</text>
								<clause id="idf0cc61d562df4dbda9e070035fa0930d">
                  <enum>(i)</enum>
                  <text>the necessary software
				and hardware is readily accessible to such dispensers;</text>
								</clause>
                <clause id="idf644f736b7804fd9ae31f611af38f431">
                  <enum>(ii)</enum>
                  <text>the necessary software
				and hardware is prohibitively expensive to obtain, install, and maintain for
				such dispensers; and</text>
								</clause>
                <clause id="id5e41e8847c0042ecbf2abab0e60db70c">
                  <enum>(iii)</enum>
                  <text>the necessary hardware
				and software can be integrated into business practices, such as
				interoperability with wholesale distributors, for such dispensers.</text>
								</clause>
              </subparagraph>
              <subparagraph id="idba9a9bd282004f3ba69b9c5a13a1c154">
                <enum>(D)</enum>
                <header>Publication</header>
                <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<clause id="id80519817c10a4229b39cda39c08b66e2">
                  <enum>(i)</enum>
                  <text>publish the
				statement of work for the assessment conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> for
				public comment prior to beginning the assessment;</text>
								</clause>
                <clause id="iddc52ea6ea0024666bef8fe48fa301bc9">
                  <enum>(ii)</enum>
                  <text>publish the final
				assessment for public comment not later than 30 calendar days after receiving
				such assessment; and</text>
								</clause>
                <clause id="id9a02f0fde2c247d3b898f068ce527c35">
                  <enum>(iii)</enum>
                  <text>hold a public meeting
				not later than 180 calendar days after receiving the final assessment at which
				public stakeholders may present their views on the assessment.</text>
								</clause>
              </subparagraph>
            </paragraph>
            <paragraph id="idbeb98a33f64d40caa7e73c41afc31ea6">
              <enum>(4)</enum>
              <header>Procedure</header>
              <text>Notwithstanding
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/553">
                  <external-xref legal-doc="usc" parsable-cite="usc/5/553">section 553</external-xref> of title 5, United States Code</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in promulgating any
				regulation pursuant to this section, shall—</text>
							<subparagraph id="id9729ac5b569a408fa21bd0d84e164352">
                <enum>(A)</enum>
                <text>provide appropriate
				flexibility by—</text>
								<clause id="idfb629951661b4ca587e5f37ecbe2bd66">
                  <enum>(i)</enum>
                  <text>not requiring the
				adoption of specific business systems for the maintenance and transmission of
				data;</text>
								</clause>
                <clause id="idbdb50c04292641f9a6051a5ab3af2c7e">
                  <enum>(ii)</enum>
                  <text>prescribing
				alternative methods of compliance for any of the requirements set forth in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:1" proposed="true">paragraph (1)</cato:entity-ref> or set forth in regulations implementing such requirements,
				including timelines—</text>
									<subclause id="id689b0a455432450a90e1152a96a72c00">
                    <enum>(I)</enum>
                    <text>for small
				businesses to comply with the requirements set forth in the regulations in
				order to ensure that such requirements do not impose undue economic hardship
				for small businesses (including small business dispensers for whom the criteria
				set forth in the assessment under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:3" proposed="true">paragraph (3)</cato:entity-ref> is not met), if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				determines that such requirements would result in undue economic hardship;
				and</text>
									</subclause>
                  <subclause id="id4aa1311e99d34973b83e3bf2dec1364b">
                    <enum>(II)</enum>
                    <text>which shall
				include establishing a process by which a dispenser may request a waiver from
				any of the requirements set forth in such regulations if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				determines that such requirements would result in an undue economic hardship;
				and</text>
									</subclause>
                </clause>
                <clause id="ide5d93bd691534f3a8ba3409cdf4bb942">
                  <enum>(iii)</enum>
                  <text>taking into
				consideration—</text>
									<subclause id="id9b201a779f694c889c3c1e64eb030706">
                    <enum>(I)</enum>
                    <text>the results of pilot
				projects, including pilot projects pursuant to this section;</text>
									</subclause>
                  <subclause id="id4fdbebc1a56d4cab963d943f5fcaaa59">
                    <enum>(II)</enum>
                    <text>the public meetings held
				and related guidance documents issued under this section;</text>
									</subclause>
                  <subclause id="id31e35c1ca7ce49ddb1f465fe428327d3">
                    <enum>(III)</enum>
                    <text>the public health
				benefits of any additional regulations in comparison to the cost of compliance
				with such requirements, including on entities of varying sizes and
				capabilities;</text>
									</subclause>
                  <subclause id="id5ff76dce4d2243ddba522508aa0a1dc0">
                    <enum>(IV)</enum>
                    <text>the diversity of the
				pharmaceutical distribution supply chain by providing appropriate flexibility
				for each sector, including both large and small businesses; and</text>
									</subclause>
                  <subclause id="idb0a779c890ed4bb7941bc5f5783219d0">
                    <enum>(V)</enum>
                    <text>the assessment
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:3" proposed="true">paragraph (3)</cato:entity-ref> with respect to small business dispensers, including
				related public comment and the public meeting, and requirements under this
				section;</text>
									</subclause>
                </clause>
              </subparagraph>
              <subparagraph id="id7c10a31624b044f198f728156038162a">
                <enum>(B)</enum>
                <text>issue a notice of
				proposed rulemaking that includes a copy of the proposed regulation;</text>
							</subparagraph>
              <subparagraph id="id6ca06c5183d74e5bbcabc0ef5ef9ef6c">
                <enum>(C)</enum>
                <text>provide a period of not
				less than 60 days for comments on the proposed regulation; and</text>
							</subparagraph>
              <subparagraph id="id77a9e190274545749ad17e84a100c0bd">
                <enum>(D)</enum>
                <text>publish the final
				regulation not less than 2 years prior to the effective date of the
				regulation.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="ideaac9677f4734df39a94fb252fc48e34">
            <enum>(i)</enum>
            <header>Guidance
				documents</header>
						<paragraph id="id29CA8E5838AB49DBA26AC0222B843105">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>For the purposes of facilitating the successful and
				efficient adoption of secure, interoperable product tracing at the package
				level in order to enhance drug distribution security and further protect the
				public health, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue the guidance documents as provided for
				in this subsection.</text>
						</paragraph>
            <paragraph id="id98c9539f840340358d0b85e7665567f6">
              <enum>(2)</enum>
              <header>Suspect and
				illegitimate product</header>
							<subparagraph id="id162068CC657541FEAE09F3A0659E6E00">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>Not later than 180 days after the date of enactment of
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">
                    <short-title>Drug Supply Chain Security
				Act</short-title>
                  </cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a guidance document to aid trading
				partners in the identification of a suspect product and notification
				termination. Such guidance document shall—</text>
								<clause id="id3bfbe26c01fa4ae4a3ef5298b73f3fa9">
                  <enum>(i)</enum>
                  <text>identify specific
				scenarios that could significantly increase the risk of a suspect product
				entering the pharmaceutical distribution supply chain;</text>
								</clause>
                <clause id="idd8f9962fe03745548aaa943c4e807910">
                  <enum>(ii)</enum>
                  <text>provide recommendation
				on how trading partners may identify such product and make a determination if
				the product is a suspect product as soon as practicable; and</text>
								</clause>
                <clause id="idece122f8c2f14965a8ce454e98387d3b">
                  <enum>(iii)</enum>
                  <text>set forth the process
				by which manufacturers, repackagers, wholesale distributors, dispensers, and
				third-party logistics providers shall terminate notifications in consultation
				with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> regarding illegitimate product pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:4/sp:B" proposed="true">subsections
				(b)(4)(B)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:4/sp:B" proposed="true">(c)(4)(B)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:4/sp:B" proposed="true">(d)(4)(B)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:B" proposed="true">(e)(4)(B)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:4/sp:B" proposed="true">(f)(4)(B)</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
              <subparagraph id="id296C5DBC3AFF47EE825ED36658A2A547">
                <enum>(B)</enum>
                <header>Revised
				guidance</header>
                <text>If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> revises the guidance issued under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall follow the procedure set forth in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:5" proposed="true">paragraph (5)</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id65a18a369da44f19b36fbc79ff21f09a">
              <enum>(3)</enum>
              <header>Unit level
				tracing</header>
							<subparagraph id="id855CC5F333294F4EBE9F7FE81D40286A">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>In order to enhance drug distribution security at the
				package level, not later than 18 months after conducting a public meeting on
				the system attributes necessary to enable secure tracing of product at the
				package level, including allowing for the use of verification, inference, and
				aggregation, as necessary, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a final guidance document
				that outlines and makes recommendations with respect to the system attributes
				necessary to enable secure tracing at the package level as required under the
				requirements established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h" proposed="true">subsection (h)</cato:entity-ref>. Such guidance document
				shall—</text>
								<clause id="id8afb11903c994533b90e807404f33db5">
                  <enum>(i)</enum>
                  <text>define the circumstances
				under which the sectors within the pharmaceutical distribution supply chain
				may, in the most efficient manner practicable, infer the contents of a case,
				pallet, tote, or other aggregate of individual packages or containers of
				product, from a product identifier associated with the case, pallet, tote, or
				other aggregate, without opening each case, pallet, tote, or other aggregate or
				otherwise individually scanning each package;</text>
								</clause>
                <clause id="idf158a7f65ec94948a40d7afcd4662ab7">
                  <enum>(ii)</enum>
                  <text>identify methods and
				processes to enhance secure tracing of product at the package level, such as
				secure processes to facilitate the use of inference, enhanced verification
				activities, the use of aggregation and inference, processes that utilize the
				product identifiers to enhance tracing of product at the package level,
				including the standardized numerical identifier, or package security features;
				and</text>
								</clause>
                <clause id="id47F253528FC9451A91B654F61A0BE459">
                  <enum>(iii)</enum>
                  <text>ensure the protection
				of confidential commercial information and trade secrets.</text>
								</clause>
              </subparagraph>
              <subparagraph id="idC856CB9872C54F2482A5C2C884BF881D">
                <enum>(B)</enum>
                <header>Procedure</header>
                <text>In
				issuing the guidance under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, and in revising such guidance, if
				applicable, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall follow the procedure set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:5" proposed="true">paragraph
				(5)</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id9515753a3c3b4ad0b7c79f9c35adee52">
              <enum>(4)</enum>
              <header>Standards for
				interoperable data exchange</header>
							<subparagraph id="id00C847C7AEC64014BA496C59C494F570">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>In order to enhance secure tracing of a product at the
				package level, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, not later than 18 months after conducting a
				public meeting on the interoperable standards necessary to enhance the security
				of the pharmaceutical distribution supply chain, shall update the guidance
				issued pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref>, as necessary and appropriate, and
				finalize such guidance document so that the guidance document—</text>
								<clause id="idec032e434c27483b8aa77c51a38dc8bc">
                  <enum>(i)</enum>
                  <text>identifies and makes
				recommendations with respect to the standards necessary for adoption in order
				to support the secure, interoperable electronic data exchange among the
				pharmaceutical distribution supply chain that comply with a form and format
				developed by a widely recognized international standards development
				organization;</text>
								</clause>
                <clause id="id774b670f020b407cbdf671c36a70e72c">
                  <enum>(ii)</enum>
                  <text>takes into
				consideration standards established pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505D">section
				505D</cato:entity-ref>;</text>
								</clause>
                <clause id="idf10e1522eb1b4296834d814eb8cdb412">
                  <enum>(iii)</enum>
                  <text>facilitates the
				creation of a uniform process or methodology for product tracing; and</text>
								</clause>
                <clause id="id7c368bfa92fd4939b0251ab9374fd639">
                  <enum>(iv)</enum>
                  <text>ensures the protection
				of confidential commercial information and trade secrets.</text>
								</clause>
              </subparagraph>
              <subparagraph id="id36A572DFC43C4353B233CFE18AD6F027">
                <enum>(B)</enum>
                <header>Procedure</header>
                <text>In
				issuing the guidance under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, and in revising such guidance, if
				applicable, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall follow the procedure set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:5" proposed="true">paragraph
				(5)</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id1D45A921BB7A40768F2AC70F5E71316A">
              <enum>(5)</enum>
              <header>Procedure</header>
              <text>In
				issuing or revising any guidance issued pursuant to this subsection or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h" proposed="true">subsection (h)</cato:entity-ref>, except the initial guidance issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:2/sp:A" proposed="true">paragraph (2)(A)</cato:entity-ref>, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
							<subparagraph id="id7fd9c754f0e24dbe98159ecd92932598">
                <enum>(A)</enum>
                <text>publish a notice in the
				Federal Register for a period not less than 30 days announcing that the draft
				or revised draft guidance is available;</text>
							</subparagraph>
              <subparagraph id="id62de2e5bf670443f8a64c8fc43f051f4">
                <enum>(B)</enum>
                <text>post the draft
				guidance document on the Internet Web site of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
				and make such draft guidance document available in hard copy;</text>
							</subparagraph>
              <subparagraph id="idbd9338595cca4ebb9da25eb30345b5ae">
                <enum>(C)</enum>
                <text>provide an opportunity
				for comment and review and take into consideration any comments
				received;</text>
							</subparagraph>
              <subparagraph id="id50c46d0db007425ba3d6d81e05c4ed08">
                <enum>(D)</enum>
                <text>revise the draft
				guidance, as appropriate;</text>
							</subparagraph>
              <subparagraph id="id660384bc78c84ba38bb384865abc3788">
                <enum>(E)</enum>
                <text>publish a notice in the
				Federal Register for a period not less than 30 days announcing that the final
				guidance or final revised guidance is available;</text>
							</subparagraph>
              <subparagraph id="id4c543ed1bd2544c88c065e83fb40f9e2">
                <enum>(F)</enum>
                <text>post the final guidance
				document on the Internet Website of the Food and Drug Administration and make
				such final guidance document available in hard copy; and</text>
							</subparagraph>
              <subparagraph id="id9dc9093e057e445fb408af36cb888cce">
                <enum>(G)</enum>
                <text>provide for an effective
				date of not earlier than 1 year after such guidance becomes final.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="id38121468d2b448efba1df9e6d5a83109">
            <enum>(j)</enum>
            <header>Public
				meetings</header>
						<paragraph id="id79021d74220c4ac6a0f5397aec1ee2f3">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall hold not less than 3 public meetings
				to enhance the safety and security of the pharmaceutical distribution supply
				chain and provide for comment. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may hold the first such public
				meeting not earlier than 1 year after the date of enactment of the
				<short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                </short-title>.
				In carrying out the public meetings described in this paragraph, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall—</text>
							<subparagraph id="idb154d2a9cba640f8811b29ce1887d5db">
                <enum>(A)</enum>
                <text>prioritize topics
				necessary to inform the issuance of the guidance described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:3" proposed="true">paragraphs (3)</cato:entity-ref>
				and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:4" proposed="true">(4) of subsection (i)</cato:entity-ref>; and</text>
							</subparagraph>
              <subparagraph id="id76ffe7679d8349d6a9fd5333d2f5f01a">
                <enum>(B)</enum>
                <text>take all measures
				reasonable and practicable to ensure the protection of confidential commercial
				information and trade secrets.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id2151a3ad36834631acc5d3c4665e50c5">
              <enum>(2)</enum>
              <header>Content</header>
              <text>Each
				of the following topics shall be addressed in at least one of the public
				meetings described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:j/p:1" proposed="true">paragraph (1)</cato:entity-ref>:</text>
							<subparagraph id="idc7235e5feec04bf6a2ed14e9dfc377ab">
                <enum>(A)</enum>
                <text>An assessment of
				the steps taken under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b..f" proposed="true">subsections (b) through (f)</cato:entity-ref> to build capacity for a
				unit-level system, including the impact of the requirements of such subsections
				on—</text>
								<clause id="id4e5fc9517aac4ff99049bbf69a32c2fc">
                  <enum>(i)</enum>
                  <text>the ability of the health
				care system collectively to maintain patient access to medicines;</text>
								</clause>
                <clause id="id634426b9c50040a983afed92e824982d">
                  <enum>(ii)</enum>
                  <text>the scalability of such
				requirements, including as it relates to product lines; and</text>
								</clause>
                <clause id="id866640e2bb5243d6bceef37fedb2c717">
                  <enum>(iii)</enum>
                  <text>the capability of
				different sectors and subsectors, including both large and small businesses, to
				affix and utilize the product identifier.</text>
								</clause>
              </subparagraph>
              <subparagraph id="idfb7f3fb8e5254b758b0f05e0f035c4a1">
                <enum>(B)</enum>
                <text>The system
				attributes necessary to support the requirements set forth under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h" proposed="true">subsection
				(h)</cato:entity-ref>, including the standards necessary for adoption in order to support the
				secure, interoperable electronic data exchange among sectors within the
				pharmaceutical distribution supply chain.</text>
							</subparagraph>
              <subparagraph id="id66b9ec8eb372421bafe3735a13594475">
                <enum>(C)</enum>
                <text>Best practices in each of
				the different sectors within the pharmaceutical distribution supply chain to
				implement the requirements of this section.</text>
							</subparagraph>
              <subparagraph id="idf5f5d479e03d4c95b322b74def3f2a69">
                <enum>(D)</enum>
                <text>The costs and benefits of
				the implementation of this section, including the impact on each pharmaceutical
				distribution supply chain sector and on public health.</text>
							</subparagraph>
              <subparagraph id="id06390ff276a5401a81124cfd477d73f7">
                <enum>(E)</enum>
                <text>Whether electronic
				tracing requirements, including tracing of product at the package level, are
				feasible, cost-effective, and needed to protect the public health.</text>
							</subparagraph>
              <subparagraph id="ida902ab4eb527488a84eba03a440c1a15">
                <enum>(F)</enum>
                <text>The systems and processes
				needed to utilize the product identifiers to enhance tracing of product at the
				package level, including allowing for verification, aggregation, and inference,
				as necessary.</text>
							</subparagraph>
              <subparagraph id="idbd44303ab3504387b853ffa8cdd9a95a">
                <enum>(G)</enum>
                <text>The technical
				capabilities and legal authorities, if any, needed to establish an
				interoperable, electronic system that provides for tracing of product at the
				package level.</text>
							</subparagraph>
              <subparagraph id="id0f363b55aea343239a29ee07c7730294">
                <enum>(H)</enum>
                <text>The impact that such
				additional requirements would have on patient safety, the drug supply, cost and
				regulatory burden, and timely patient access to prescription drugs.</text>
							</subparagraph>
              <subparagraph id="idc409502a5ec643a983b5737d3b6192c7">
                <enum>(I)</enum>
                <text>Other topics, as
				determined appropriate by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="idd08923eb52834771be96461a551833cb">
            <enum>(k)</enum>
            <header>Pilot projects</header>
						<paragraph id="id30a3fb82bf61462da7f199441cc50fb5">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish 1 or more pilot projects,
				in coordination with authorized manufacturers, repackagers, wholesale
				distributors, third-party logistics providers, and dispensers, to explore and
				evaluate methods to enhance the safety and security of the pharmaceutical
				distribution supply chain. Such projects shall build upon efforts, in existence
				as of the date of enactment of the <short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug
				Supply Chain Security Act</cato:entity-ref>
                </short-title>, to enhance the safety and security of
				the pharmaceutical distribution supply chain, take into consideration any pilot
				projects conducted prior to such date of enactment, and inform the draft and
				final guidance under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:3" proposed="true">paragraphs (3)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:i/p:4" proposed="true">(4) of subsection (i)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="id22b17c10577444deb230af1c3e7fb92d">
              <enum>(2)</enum>
              <header>Content</header>
							<subparagraph id="id9d5be24ee59b40d9a6b4a52e3412db6d">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall ensure that the pilot projects under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:k/p:1" proposed="true">paragraph (1)</cato:entity-ref> reflect the diversity of the pharmaceutical distribution supply
				chain and that the pilot projects, when taken as a whole, include participants
				representative of every sector, including both large and small
				businesses.</text>
							</subparagraph>
              <subparagraph id="id2de13569c5a1440b84553e674fd1e23f">
                <enum>(B)</enum>
                <header>Project
				design</header>
                <text>The pilot projects under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:k/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall be designed
				to—</text>
								<clause id="id578530bca2e54955b06bbf87a29dda82">
                  <enum>(i)</enum>
                  <text>utilize the product
				identifier for tracing of a product, which may include verification of the
				product identifier of a product, including the use of aggregation and
				inference;</text>
								</clause>
                <clause id="id55cfb481af6844fc8abb146631ff2d7a">
                  <enum>(ii)</enum>
                  <text>improve the technical
				capabilities of each sector and subsector to comply with systems and processes
				needed to utilize the product identifiers to enhance tracing of a
				product;</text>
								</clause>
                <clause id="idd3261d28fb5344edb342c5d1b7681ced">
                  <enum>(iii)</enum>
                  <text>identify system
				attributes that are necessary to implement the requirements established under
				this section; and</text>
								</clause>
                <clause id="id2f4688908a8f46f6a6b17f99658deb7a">
                  <enum>(iv)</enum>
                  <text>complete other
				activities as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="idc05159ec574444c581a497ee9fe7ba1d">
            <enum>(l)</enum>
            <header>Sunset</header>
            <text>The
				following requirements shall have no force or effect beginning on the date that
				is 10 years after the date of enactment of the
				<short-title>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
              </short-title>:</text>
						<paragraph id="id3123aa85b6b7416c8926eef466d5cfd7">
              <enum>(1)</enum>
              <text>The provision and receipt
				of transaction history under this section.</text>
						</paragraph>
            <paragraph id="id2b6e7824e0c64b6d8c4e24d59b5d252c">
              <enum>(2)</enum>
              <text>The requirements set
				forth for returns under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:4/sp:E" proposed="true">subsections (b)(4)(E)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:B/cl:i" proposed="true">(c)(1)(B)(i)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:B/cl:i" proposed="true">(d)(1)(C)(i)</cato:entity-ref>, and
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:E" proposed="true">(e)(4)(E)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="idfd9de69cdb82416382686911558ef781">
            <enum>(m)</enum>
            <header>Rule of
				construction</header>
            <text>The requirements set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h/p:4" proposed="true">subsections (h)(4)</cato:entity-ref>,
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:j" proposed="true">(j)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:k" proposed="true">(k)</cato:entity-ref> shall not be construed as a condition, prohibition, or precedent
				for precluding or delaying the provisions becoming effective pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:h" proposed="true">subsection
				(h)</cato:entity-ref>.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="id789f8b5aea394bc2b27455cbec46e78f">
        <enum>204.</enum>
        <header>National licensure
			 standards for prescription drug wholesale distributors</header>
				<subsection id="idF163EB8B15DE4D9B8C40936395CD38B0">
          <enum>(a)</enum>
          <header>Amendments</header>
					<paragraph id="idE65EFFEF2DCF4771AE87AE5BD0B752E3">
            <enum>(1)</enum>
            <header>License
			 requirement</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">Section 503(e)</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353">
                  <cato:entity-ref entity-type="uscode" value="usc/21/353/e">21 U.S.C. 353(e)</cato:entity-ref>
                </external-xref>)</cato:entity> is amended by
			 striking <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1">paragraphs (1)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:2">(2)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:3">(3)</cato:entity-ref> and inserting the following:</text>
						<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="idE59F80AE41874797A7084BC21C70C1F4" reported-display-style="italic" style="OLC">
							<paragraph id="id1f9b9420c75a410d84d4a15ee04215b9">
                <enum>(1)</enum>
                <header>License
				requirement</header>
                <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>:</text>
								<subparagraph id="id94C04F772A5F4C3194709FA7A3629F9C">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>No person may engage in wholesale distribution of a drug
				subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">subsection (b)(1)</cato:entity-ref> in any State unless such person—</text>
									<clause id="id19980E335D834395B7DA67CA87AFB525">
                    <enum>(i)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="id18E884A392924D38AF01B9C692083F05">
                      <enum>(I)</enum>
                      <text>is licensed by the
				State from which the drug is distributed; or</text>
										</subclause>
                    <subclause changed="added" committee-id="SSHR00" id="id720C82711F8042E48DAD17BAE5DE3BA2" indent="up1" reported-display-style="italic">
                      <enum>(II)</enum>
                      <text>if the State from which the drug
				distributed has not established a licensure requirement, is licensed by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>; and</text>
										</subclause>
                  </clause>
                  <clause id="id4B20BB6AF09F40479E936EFACF05A47B">
                    <enum>(ii)</enum>
                    <text>if the drug is
				distributed interstate, is licensed by the State into which the drug is
				distributed if the State into which the drug is distributed requires the
				licensure of a person that distributes drugs into the State.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id703C3BAC78C54122A834F2D51A05E904">
                  <enum>(B)</enum>
                  <header>License
				standards</header>
                  <text>Each Federal and State license described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall meet the standards, terms, and conditions established by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id226da65c15e74cb6aa56baf3b5cac42c">
                <enum>(2)</enum>
                <header>Licensure reporting and
				database</header>
								<subparagraph id="id817CB5D3D91245D195821750EF6072C2">
                  <enum>(A)</enum>
                  <header>Licensure
				reporting</header>
                  <text>Beginning 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				any person who owns or operates an establishment that engages in wholesale
				distribution shall report to the Secretary, on an annual basis pursuant to a
				schedule determined by the Secretary—</text>
									<clause id="idd24ce812c0f74aa3bfeb566978714857">
                    <enum>(i)</enum>
                    <text>each State by which the
				person is licensed and the appropriate identification number of each such
				license; and</text>
									</clause>
                  <clause id="idbde6c4431ca740c9acff78918171b271">
                    <enum>(ii)</enum>
                    <text>the name, address, and
				contact information of each facility at which, and all trade names under which,
				the person conducts business.</text>
									</clause>
                </subparagraph>
                <subparagraph id="idef744454ee784b509ecb8b22df336ca8">
                  <enum>(B)</enum>
                  <header>Database</header>
                  <text>Not
				later than 1 year after the date of enactment of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>,
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish a database of licensed wholesale distributors.
				Such database shall—</text>
									<clause id="id01499591fc1c41cca33f1a2c2e6110ae">
                    <enum>(i)</enum>
                    <text>identify each wholesale
				distributor by name, contact information, and each State where such wholesale
				distributor is appropriately licensed to engage in wholesale
				distribution;</text>
									</clause>
                  <clause id="ida913b40d8b254decbf1baac6dcc1a6b4">
                    <enum>(ii)</enum>
                    <text>be available to
				the public on the Internet Web site of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>;
				and</text>
									</clause>
                  <clause id="id2e64041c8a6846389028dd1d0e4cba5b">
                    <enum>(iii)</enum>
                    <text>be regularly
				updated on a schedule determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="id51c6f01400a64b11af086c037a589bd5">
                <enum>(3)</enum>
                <header>Costs</header>
								<subparagraph id="id34610194be604e30b19e7422402a3f1b">
                  <enum>(A)</enum>
                  <header>Authorized licensure
				fees of secretary</header>
                  <text>If a State does not establish a
				licensing program for persons engaged in the wholesale distribution of a drug
				subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b">subsection (b)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall license a person engaged in
				wholesale distribution located in such State and may collect a reasonable fee
				in such amount necessary to reimburse the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for costs associated with
				establishing and administering the licensure program and conducting periodic
				inspections under this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall adjust fee rates as needed
				on an annual basis to generate only the amount of revenue needed to perform
				this service. Fees authorized under this paragraph shall be collected and
				available for obligation only to the extent and in the amount provided in
				advance in appropriations Acts. Such fees are authorized to remain available
				until expended.</text>
								</subparagraph>
                <subparagraph id="id06e5fed979c84b34902fd983939bf7f6">
                  <enum>(B)</enum>
                  <header>State licensing
				fees</header>
                  <text>Nothing in this Act shall prohibit States from collecting
				fees from wholesale distributors in connection with State licensing of such
				distributors.</text>
								</subparagraph>
              </paragraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</paragraph>
          <paragraph id="id11009d86cc2446b78c2b292000c4eb56">
            <enum>(2)</enum>
            <header>Wholesale
			 distribution</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">Section 503(e)</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353">
                  <cato:entity-ref entity-type="uscode" value="usc/21/353/e">21 U.S.C. 353(e)</cato:entity-ref>
                </external-xref>)</cato:entity>, as amended by
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:204/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref>, is further amended by adding at the end the following:</text>
						<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="idf7f32e3dc5684e008752f21a112ceeaf" reported-display-style="italic" style="OLC">
							<paragraph id="ida478ee3d2d034bac932d45cbc6f159aa">
                <enum>(4)</enum>
                <text>For the purposes
				of this subsection and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">subsection (d)</cato:entity-ref>, the term <term>wholesale
				distribution</term> means the distribution of a drug subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b">subsection (b)</cato:entity-ref>
				to a person other than a consumer or patient, or receipt of a drug subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b">subsection (b)</cato:entity-ref> by a person other than the consumer or patient, but does not
				include—</text>
								<subparagraph id="idc79eccaff24c473a99e23975a1473af3">
                  <enum>(A)</enum>
                  <text>intracompany distribution
				of any drug between members of an affiliated group (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">section
				1504(a) of the Internal Revenue Code of 1986</cato:entity-ref>) or within a manufacturer;</text>
								</subparagraph>
                <subparagraph id="id3a39e320bef9462aafafb44b452925ce">
                  <enum>(B)</enum>
                  <text>the distribution of a
				drug, or an offer to distribute a drug among hospitals or other health care
				entities which are under common control;</text>
								</subparagraph>
                <subparagraph id="ida591e644579c405fb92add0a6ea75b05">
                  <enum>(C)</enum>
                  <text>the distribution of a
				drug or an offer to distribute a drug for emergency medical reasons, including
				a public health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public
				Health Service Act</cato:entity-ref>, except that, for purposes of this paragraph, a drug
				shortage not caused by a public health emergency shall not constitute an
				emergency medical reason;</text>
								</subparagraph>
                <subparagraph id="ide13af1043ccf436d8e0ede916a13e3a2">
                  <enum>(D)</enum>
                  <text>the dispensing of
				a drug pursuant to a valid prescription executed in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section
				503(b)(1)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="id3f82d5d180134a93943f0db938f9824b">
                  <enum>(E)</enum>
                  <text>the distribution of
				minimal quantities of drug by a licensed retail pharmacy to a licensed
				practitioner for office use;</text>
								</subparagraph>
                <subparagraph id="idd24555e2bc024c638a9dd97427b12bbb">
                  <enum>(F)</enum>
                  <text>the distribution of a
				drug or an offer to distribute a drug by a charitable organization to a
				nonprofit affiliate of the organization to the extent otherwise permitted by
				law;</text>
								</subparagraph>
                <subparagraph id="idbb2dab14f3ca4800be5dd09daf6ed2a2">
                  <enum>(G)</enum>
                  <text>the purchase or other
				acquisition by a dispenser, hospital, or other health care entity of a drug for
				use by such dispenser, hospital, or other health care entity;</text>
								</subparagraph>
                <subparagraph id="ida081e584f3054b3ba2c048d29a499cc1">
                  <enum>(H)</enum>
                  <text>the distribution of a
				drug by the manufacturer of such drug;</text>
								</subparagraph>
                <subparagraph id="id8cee228766d34455b12a16972238a725">
                  <enum>(I)</enum>
                  <text>the receipt or transfer
				of a drug by an authorized third-party logistics provider provided that such
				third-party logistics provider does not take ownership of the drug;</text>
								</subparagraph>
                <subparagraph id="id5d98b8ca500d4e748a54fb7c0c06ae6b">
                  <enum>(J)</enum>
                  <text>a common carrier that
				transports a drug, provided that the common carrier does not take ownership of
				the drug;</text>
								</subparagraph>
                <subparagraph id="id683e519ecf1d41179ecbf8bdb7286ce5">
                  <enum>(K)</enum>
                  <text>the distribution
				of a drug, or an offer to distribute a drug by an authorized repackager that
				has taken ownership or possession of the drug and repacks it in accordance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e" proposed="true">section 582(e)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="ide3877406299043c9b84a3112f49c81b2">
                  <enum>(L)</enum>
                  <text>salable drug returns when
				conducted by a dispenser;</text>
								</subparagraph>
                <subparagraph id="id11d483b11ba940538d350dc24667b70a">
                  <enum>(M)</enum>
                  <text>the distribution of a
				medical convenience kit which is a collection of finished medical devices or a
				collection of drug or biologic products assembled in kit form strictly for the
				convenience of the purchaser or user if—</text>
									<clause id="id2efebdd7fe4c4c998b4375b2c8398913">
                    <enum>(i)</enum>
                    <text>the medical convenience
				kit is assembled in an establishment that is registered with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref> as a device manufacturer in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:b/p:2">section
				510(b)(2)</cato:entity-ref>;</text>
									</clause>
                  <clause id="id437594fc280e484399e8324e9008cffa">
                    <enum>(ii)</enum>
                    <text>the person who
				manufacturers the medical convenience kit purchased the finished drug or
				biologic product contained in the medical convenience kit directly from the
				pharmaceutical manufacturer or from a wholesale distributor that purchased the
				product directly from the pharmaceutical manufacturer;</text>
									</clause>
                  <clause id="id4e2a19b0e92c4e41ad429d3a548eae98">
                    <enum>(iii)</enum>
                    <text>the person who
				manufacturers a medical convenience kit does not alter the primary container or
				label of the product as purchased from the manufacturer or wholesale
				distributor;</text>
									</clause>
                  <clause id="idf4a4d3140a21413f87d08f938789c2ad">
                    <enum>(iv)</enum>
                    <text>the medical convenience
				kit does not contain a controlled substance that appears in a schedule
				contained in the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                        <cato:entity-ref entity-type="act" value="Comprehensive Drug Abuse Prevention and Control Act of 1970">Comprehensive Drug Abuse Prevention and Control Act of 1970</cato:entity-ref>
				(<cato:entity-ref entity-type="uscode" value="usc/21/801/etseq">
                          <external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801</external-xref>, et seq</cato:entity-ref>)</cato:entity>; and</text>
									</clause>
                  <clause commented="no" id="id60b2b24f94fa449c8d79559c07de7633">
                    <enum>(v)</enum>
                    <text>the products contained in
				the medical convenience kit are—</text>
										<subclause commented="no" id="id2872581e13b74c19acf04cef0614597b">
                      <enum>(I)</enum>
                      <text>intravenous solutions
				intended for the replenishment of fluids and electrolytes;</text>
										</subclause>
                    <subclause commented="no" id="idb2b849902aaf4b64ad56cac36c26e1fc">
                      <enum>(II)</enum>
                      <text>drugs intended to
				maintain the equilibrium of water and minerals in the body;</text>
										</subclause>
                    <subclause commented="no" id="id671a02180b43452db2d06448ab53d143">
                      <enum>(III)</enum>
                      <text>drugs intended for
				irrigation or reconstitution;</text>
										</subclause>
                    <subclause commented="no" id="id79fa8a19b3a74d7f91d579112a116fae">
                      <enum>(IV)</enum>
                      <text>anesthetics;</text>
										</subclause>
                    <subclause commented="no" id="ida72d9cdd449248ebb076a9b815688da4">
                      <enum>(V)</enum>
                      <text>anticoagulants;</text>
										</subclause>
                    <subclause commented="no" id="iddaee9f8b38ce41d48ff2284062e4c285">
                      <enum>(VI)</enum>
                      <text>vasopressors; or</text>
										</subclause>
                    <subclause commented="no" id="id35ad17f23d81430d8f57e502c64109df">
                      <enum>(VII)</enum>
                      <text>sympathicomimetics;</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="ide517608bc6584d4d8031582487c0b19b">
                  <enum>(N)</enum>
                  <text>the distribution of an
				intravenous drug that, by its formulation, is intended for the replenishment of
				fluids and electrolytes (such as sodium, chloride, and potassium) or calories
				(such as dextrose and amino acids);</text>
								</subparagraph>
                <subparagraph id="idf63e9d00cf4049dead2dc378940f8aa4">
                  <enum>(O)</enum>
                  <text>the distribution of an
				intravenous drug used to maintain the equilibrium of water and minerals in the
				body, such as dialysis solutions;</text>
								</subparagraph>
                <subparagraph id="idd0860c0bac4347a4bf9969f3ae619c39">
                  <enum>(P)</enum>
                  <text>the distribution of a
				drug that is intended for irrigation or reconstitution, or sterile water,
				whether intended for such purposes or for injection;</text>
								</subparagraph>
                <subparagraph id="id4c5ffb8b688a44768d3f2d816ad36212">
                  <enum>(Q)</enum>
                  <text>the distribution of
				medical gas, as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:575">section 575</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="idc431b65261d040d88ce649191943bd06">
                  <enum>(R)</enum>
                  <text>facilitating the
				distribution of a product by providing solely administrative services,
				including processing of orders and payments; or</text>
								</subparagraph>
                <subparagraph id="idd779fc7ae9d5451eb816c8ebdeb83895">
                  <enum>(S)</enum>
                  <text>the transfer of a
				product by a hospital or other health care entity to a repackager registered
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> for the purpose of repackaging the drug for use by that
				hospital, or other health care entity and other health care entities that are
				under common control, if ownership of the drug remains with the hospital or
				other health care entity at all
				times.</text>
								</subparagraph>
              </paragraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</paragraph>
          <paragraph id="idcf5d8069c9c945e6bd30c70728fc2ee8">
            <enum>(3)</enum>
            <header>Third-party logistics
			 providers</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">Section 503(e)</cato:entity-ref>(<external-xref legal-doc="usc" parsable-cite="usc/21/353">
                  <cato:entity-ref entity-type="uscode" value="usc/21/353/e">21 U.S.C. 353(e)</cato:entity-ref>
                </external-xref>)</cato:entity>, as amended by
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:2">paragraph (2)</cato:entity-ref>, is further amended by adding at the end the following:</text>
						<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id1D5792219B93429E902772B8023A4176" reported-display-style="italic" style="OLC">
							<paragraph id="id1800c5d7a9d54898bc802568ddef8c8e">
                <enum>(5)</enum>
                <header>Third-party logistics
				providers</header>
                <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1..4">paragraphs (1) through (4)</cato:entity-ref>, each entity
				that meets the definition of a third-party logistics provider under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21" proposed="true">section
				581(21)</cato:entity-ref> shall obtain a license as a third-party logistics provider as described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:a">section 584(a)</cato:entity-ref> and is not required to obtain a license as a wholesale
				distributor if the entity never assumes an ownership interest in the product it
				handles.</text>
							</paragraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</paragraph>
          <paragraph id="id053cdf2332204a4b9e8eeeaca6a0cceb">
            <enum>(4)</enum>
            <header>Licensure
			 standards</header>
            <text>Subchapter H of chapter V, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:202" proposed="true">section 202</cato:entity-ref>, is
			 amended by adding at the end the following:</text>
						<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id516D324C4FF142E6BEFB150F62603583" reported-display-style="italic" style="OLC">
							<section id="id46e4fa2f7fd545359f0f3acd8ef6cb3d">
                <enum>583.</enum>
                <header>National licensure
				standards for prescription drug wholesale distributors</header>
								<subsection commented="no" id="id60d28eeab53c4b9aa9dcbfa88bc35ebd">
                  <enum>(a)</enum>
                  <header>In
				general</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, not later than 2 years after the
				date of enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain
				Security Act</cato:entity-ref>
                    </short-title>, establish by regulation minimum standards, terms,
				and conditions for the licensing of persons under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1">section 503(e)(1)</cato:entity-ref> (as amended
				by the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                    </short-title>), including the revocation, reissuance, and renewal of such
				license.</text>
								</subsection>
                <subsection id="idc219932a86784bbda65399a4e9ce6e5d">
                  <enum>(b)</enum>
                  <header>Content</header>
                  <text>The
				standards established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall apply to all State and Federal
				licenses described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1">section 503(e)(1)</cato:entity-ref> (as amended by the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>)
				and shall prescribe minimum requirements for the following:</text>
									<paragraph id="idc529fa56de3e49fe90858c657fbfd58d">
                    <enum>(1)</enum>
                    <text>The storage and handling
				of such drugs, including facility requirements.</text>
									</paragraph>
                  <paragraph id="idd02f48899cd047f19f45d4c3bab90e61">
                    <enum>(2)</enum>
                    <text>The establishment and
				maintenance of records of the distributions of such drugs.</text>
									</paragraph>
                  <paragraph id="id46c9dfed5c1b42479b6bd92a0d3475cd">
                    <enum>(3)</enum>
                    <text>The furnishing of a bond
				or other equivalent means of security, as follows:</text>
										<subparagraph id="id793d35dcca9f45779088afa9473ba56a">
                      <enum>(A)</enum>
                      <clause commented="no" display-inline="yes-display-inline" id="idD515B6DB957F4D1D8E4B76796B4287F0">
                        <enum>(i)</enum>
                        <text>For the issuance or
				renewal of a wholesale distributor license, an applicant that is not a
				government owned and operated wholesale distributor shall submit a surety bond
				of $100,000 or other equivalent means of security acceptable to the
				State.</text>
											</clause>
                      <clause changed="added" committee-id="SSHR00" id="idF253484AE21E43848335A341FED91106" indent="up1" reported-display-style="italic">
                        <enum>(ii)</enum>
                        <text>For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:b/p:3/sp:A/cl:i" proposed="true">clause
				(i)</cato:entity-ref>, the State or other applicable authority may accept a surety bond in the
				amount of $25,000 if the annual gross receipts of the previous tax year for the
				wholesaler is $10,000,000 or less.</text>
											</clause>
                    </subparagraph>
                    <subparagraph id="iddb48dfb4e9a740a494f458a955c32325">
                      <enum>(B)</enum>
                      <text>If a wholesale
				distributor can provide evidence that it possesses the required bond in a
				State, the requirement for a bond in another State shall be waived.</text>
										</subparagraph>
                  </paragraph>
                  <paragraph id="id461ea4d1abfb4d0b81f633194a9ed114">
                    <enum>(4)</enum>
                    <text>Mandatory background
				checks and fingerprinting of facility managers or designated
				representatives.</text>
									</paragraph>
                  <paragraph id="idc651125472124b0f9b27850ae2f81cc2">
                    <enum>(5)</enum>
                    <text>The establishment and
				implementation of qualifications for key personnel.</text>
									</paragraph>
                  <paragraph id="id65a714360dc64371940156fd7c77dd22">
                    <enum>(6)</enum>
                    <text>The mandatory physical
				inspection of any facility to be used in wholesale distribution within a
				reasonable time frame from the initial application of the facility and to be
				conducted by the licensing authority or by the State, consistent with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</text>
									</paragraph>
                  <paragraph id="id3db3f924680147a6a40d3cafe08243a8">
                    <enum>(7)</enum>
                    <text>in accordance
				with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:d" proposed="true">subsection (d)</cato:entity-ref>, the prohibition of certain persons from receiving or
				maintaining licensure for wholesale distribution.</text>
									</paragraph>
                </subsection>
                <subsection id="id2d1a7a1e8c244be399aa79a3ebc74df3">
                  <enum>(c)</enum>
                  <header>Inspections</header>
                  <text>To
				satisfy the inspection requirement under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:b/p:6" proposed="true">subsection (b)(6)</cato:entity-ref>, the Federal or
				State licensing authority may conduct the inspection or may accept an
				inspection by the State in which the facility is located, or by a third-party
				accreditation or inspection service approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or the State
				licensing such wholesale distributor.</text>
								</subsection>
                <subsection id="id738438e74edc4e0a86ab704cffb7ac39">
                  <enum>(d)</enum>
                  <header>Prohibited
				persons</header>
                  <text>The standards established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall
				include requirements to prohibit a person from receiving or maintaining
				licensure for wholesale distribution if the person—</text>
									<paragraph id="id575ea202f64d45a98ddd80db1534899c">
                    <enum>(1)</enum>
                    <text>has been
				convicted of any felony for conduct relating to wholesale distribution, any
				felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:i">subsection (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:k">(k) of section 301</cato:entity-ref>, or any felony
				violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1365">
                      <external-xref legal-doc="usc" parsable-cite="usc/18/1365">section 1365</external-xref> of title 18, United States Code</cato:entity-ref>, relating to product
				tampering; or</text>
									</paragraph>
                  <paragraph id="ide78613db1a91449cb3b3ded090f0795e">
                    <enum>(2)</enum>
                    <text>has engaged in a pattern
				of violating the requirements of this section, or State requirements for
				licensure, that presents a threat of serious adverse health consequences or
				death to humans.</text>
									</paragraph>
                </subsection>
                <subsection id="idbd61fa305be74bd097e85686bcf46e7e">
                  <enum>(e)</enum>
                  <header>Requirements</header>
                  <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in promulgating any regulation pursuant to this section, shall,
				notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/553">
                    <external-xref legal-doc="usc" parsable-cite="usc/5/553">section 553</external-xref> of title 5, United States Code</cato:entity-ref>—</text>
									<paragraph id="ide24b23c32e984958bf65d23d23dcb9ac">
                    <enum>(1)</enum>
                    <text>issue a notice of
				proposed rulemaking that includes a copy of the proposed regulation;</text>
									</paragraph>
                  <paragraph id="idb239630a230b4e7da3744ac0d6f56a93">
                    <enum>(2)</enum>
                    <text>provide a period of not
				less than 60 days for comments on the proposed regulation; and</text>
									</paragraph>
                  <paragraph id="id74c7d373bd1540ee8403c1310f6995fa">
                    <enum>(3)</enum>
                    <text>provide that the final
				regulation take effect on the date that is 2 years after the date such final
				regulation is
				published.</text>
									</paragraph>
                </subsection>
              </section>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</paragraph>
        </subsection>
        <subsection id="idEF99B87EDB714ABE9C72336D3ECEBB20">
          <enum>(b)</enum>
          <header>Authorized distributors
			 of record</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">Section 503(d)</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353">
                <cato:entity-ref entity-type="uscode" value="usc/21/353/d">21 U.S.C. 353(d)</cato:entity-ref>
              </external-xref>)</cato:entity> is amended by adding
			 at the end the following:</text>
					<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id1C868CDA936248B3B0772AFA18727B7B" reported-display-style="italic" style="OLC">
						<paragraph id="idA5C3443C928C4F0F9751F383F10CF095">
              <enum>(4)</enum>
              <text>In this subsection, the
				term <term>authorized distributors of record</term> means those distributors
				with whom a manufacturer has established an ongoing relationship to distribute
				such manufacturer's
				products.</text>
						</paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</subsection>
        <subsection id="id1630CEF5641647AFB44BB7B93F2EC745">
          <enum>(c)</enum>
          <header>Effective
			 date</header>
          <text>The amendments made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:204/ss:a" proposed="true">subsections (a)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:204/ss:b" proposed="true">(b)</cato:entity-ref> shall take
			 effect on the day that is 1 year after the date of enactment of this
			 Act.</text>
				</subsection>
      </section>
      <section id="idd67351dddf004eff9e0b4ae9d0e45e95">
        <enum>205.</enum>
        <header>National licensure
			 standards for third-party logistics providers; uniform national
			 policy</header>
        <text display-inline="no-display-inline">Subchapter H of chapter
			 V, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:204" proposed="true">section 204</cato:entity-ref>, is further amended by adding at the end the
			 following:</text>
				<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id95B0C9A968964BABA476B1E3B63FF509" reported-display-style="italic" style="OLC">
					<section id="id8b3909584f3a465e98244ef276148f3b">
            <enum>584.</enum>
            <header>National licensure
				standards for third-party logistics providers</header>
						<subsection id="idabf3370a48634d77a1cb0056f4fc2961">
              <enum>(a)</enum>
              <header>License
				requirements</header>
              <text>No third-party logistics provider in any State may
				conduct activities in any State unless each facility of such third-party
				logistics provider—</text>
							<paragraph id="idf77d0df1dc664d72aa5123cd4b0f25b9">
                <enum>(1)</enum>
                <subparagraph commented="no" display-inline="yes-display-inline" id="idC6793948DC164CD7A2D21B34B6041F51">
                  <enum>(A)</enum>
                  <text>is licensed by the
				State from which the drug is distributed by the third-party logistics provider,
				in accordance with the regulations promulgated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d" proposed="true">subsection (d)</cato:entity-ref>; or</text>
								</subparagraph>
                <subparagraph changed="added" committee-id="SSHR00" id="id827BCE792A2C48E09008467148563BB7" indent="up1" reported-display-style="italic">
                  <enum>(B)</enum>
                  <text>if the State from which the drug
				distributed by the third-party logistics provider has not established a
				licensure requirement, is licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in accordance with the
				regulations promulgated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d" proposed="true">subsection (d)</cato:entity-ref>; and</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id8AA0272AD88C4E76920056285294B21D">
                <enum>(2)</enum>
                <text>if the drug is
				distributed interstate, is licensed by the State into which the drug is
				distributed by the third-party logistics provider if such State licenses
				third-party logistics providers that distribute drugs into the State and the
				third-party logistics provider is not licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:a/p:1/sp:B" proposed="true">paragraph (1)(B)</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
            <subsection id="id6f85ec55acfa403090d05876b5abedd3">
              <enum>(b)</enum>
              <header>Licensure
				reporting</header>
              <text>Beginning 1 year after the date of enactment of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">
                  <short-title>Drug Supply Chain Security Act</short-title>
                </cato:entity-ref>,
				a facility of a third-party logistics provider shall report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>,
				on an annual basis pursuant to a schedule determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>—</text>
							<paragraph id="idea48483d4b054dafacf3a3d531c9c461">
                <enum>(1)</enum>
                <text>the State by which the
				facility is licensed and the appropriate identification number of such license;
				and</text>
							</paragraph>
              <paragraph id="id83fed44bd75f4b7293745dad14757520">
                <enum>(2)</enum>
                <text>the name and address of
				the facility, and all trade names under which, such facility conducts
				business.</text>
							</paragraph>
            </subsection>
            <subsection id="id5b9d6623c93f47c7ac7ebba0ea7884b1">
              <enum>(c)</enum>
              <header>Costs</header>
							<paragraph id="id15c78c0fba93408e8639c7e0f6c28f0c">
                <enum>(1)</enum>
                <header>Authorized licensure
				fees of secretary</header>
                <text>If a State does not establish a
				licensing program for a third-party logistics provider, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				license the third-party logistics provider located in such State and may
				collect a reasonable fee in such amount necessary to reimburse the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				for costs associated with establishing and administering the licensure program
				and conducting periodic inspections under this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				adjust fee rates as needed on an annual basis to generate only the amount of
				revenue needed to perform this service. Fees authorized under this paragraph
				shall be collected and available for obligation only to the extent and in the
				amount provided in advance in appropriations Acts. Such fees are authorized to
				remain available until expended.</text>
							</paragraph>
              <paragraph id="idbf4aba1aa306471590387a742d020722">
                <enum>(2)</enum>
                <header>State licensing
				fees</header>
								<subparagraph id="id9a058ebb69b24812adf2db1c3db474be">
                  <enum>(A)</enum>
                  <header>State established
				program</header>
                  <text>Nothing in this Act shall prohibit a State that has
				established a program to license a third-party logistics provider from
				collecting fees from a third-party logistics provider for such a
				license.</text>
								</subparagraph>
                <subparagraph id="id094123c5b38a4f72a1554b87de9fb7aa">
                  <enum>(B)</enum>
                  <header>No State established
				program</header>
                  <text>A State that does not establish a program to license a
				third-party logistics provider in accordance with this section shall be
				prohibited from collecting a State licensing fee from a third-party logistics
				provider.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="idea937351f7284d5596d7e3469b212f9f">
              <enum>(d)</enum>
              <header>License
				regulations</header>
							<paragraph id="id9fc4750319ba4209a907afd2021c2234">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Not later than 2 years after the date of enactment of the
				<short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                  </short-title>,
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue regulations regarding the minimum issuance and
				eligibility requirements for licensing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:a" proposed="true">subsection (a)</cato:entity-ref>, including the
				revocation and reissuance of such license, to third-party logistics providers
				under this section.</text>
							</paragraph>
              <paragraph id="idda3b7a60250a4185a59737d102798137">
                <enum>(2)</enum>
                <header>Content</header>
                <text>Such
				regulations shall—</text>
								<subparagraph id="ide4e079607eb244ffac29d0e077934cb3">
                  <enum>(A)</enum>
                  <text>establish a
				process by which a third-party accreditation program approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall, upon request by a third-party logistics provider, issue a license to
				each third-party logistics provider that meets the minimum requirements set
				forth in this section;</text>
								</subparagraph>
                <subparagraph id="id6b4087267ce54f518675963f13ff4c4e">
                  <enum>(B)</enum>
                  <text>establish a
				process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a license to each third-party
				logistics provider that meets the minimum requirements set forth in this
				section if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> is not able to approve a third-party accreditation
				program because no such program meets the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> requirements necessary
				for approval of such a third-party accreditation program;</text>
								</subparagraph>
                <subparagraph id="id7737451aee744d63ac5c96d74d3146b1">
                  <enum>(C)</enum>
                  <text>require that the
				entity complies with storage practices, as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for such
				facility, including—</text>
									<clause id="id80c5ea7904bd48178b916932dc47f263">
                    <enum>(i)</enum>
                    <text>maintaining access to
				warehouse space of suitable size to facilitate safe operations, including a
				suitable area to quarantine suspect product;</text>
									</clause>
                  <clause id="id5b6c5367752a4049821a7b688c7374a0">
                    <enum>(ii)</enum>
                    <text>maintaining adequate
				security; and</text>
									</clause>
                  <clause id="id191427f569954cb9b9789e2afb720775">
                    <enum>(iii)</enum>
                    <text>having written policies
				and procedures to—</text>
										<subclause id="id8b4d0a9e3522471c974c6ca284891ff7">
                      <enum>(I)</enum>
                      <text>address receipt,
				security, storage, inventory, shipment, and distribution of a product;</text>
										</subclause>
                    <subclause id="idc7600bc9717348449a7a5b6b6f907c49">
                      <enum>(II)</enum>
                      <text>identify, record, and
				report confirmed losses or thefts in the United States;</text>
										</subclause>
                    <subclause id="id33eff123ccb54a26a194d24d3b18088e">
                      <enum>(III)</enum>
                      <text>correct errors and
				inaccuracies in inventories;</text>
										</subclause>
                    <subclause id="idb9d716b2ee064d80b849c2c3bf452cb0">
                      <enum>(IV)</enum>
                      <text>provide support for
				manufacturer recalls;</text>
										</subclause>
                    <subclause id="id2a738e8a36704fd3bb3775ae003ba2cb">
                      <enum>(V)</enum>
                      <text>prepare for, protect
				against, and address any reasonably foreseeable crisis that affects security or
				operation at the facility, such as a strike, fire, or flood;</text>
										</subclause>
                    <subclause id="ida5cdf1beee304f1db1fe78ce899e2ab7">
                      <enum>(VI)</enum>
                      <text>ensure that any expired
				product is segregated from other products and returned to the manufacturer or
				re-packager or destroyed;</text>
										</subclause>
                    <subclause id="id2081a0a10c074941851e333a7583c086">
                      <enum>(VII)</enum>
                      <text>maintain the capability
				to trace the receipt and outbound distribution of a product, and supplies and
				records of inventory; and</text>
										</subclause>
                    <subclause id="id0e2b23a6f024474c85b53afce8ae0b26">
                      <enum>(VIII)</enum>
                      <text>quarantine or destroy
				a suspect product if directed to do so by the respective manufacturer,
				wholesale distributor, dispenser or an authorized government agency;</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="id34660072ae884fd8aa461d9593bb79a5">
                  <enum>(D)</enum>
                  <text>provide for
				periodic inspection by the licensing authority, as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>,
				of such facility warehouse space to ensure compliance with this section;</text>
								</subparagraph>
                <subparagraph id="id2471c4af99624b6c825040c56b4bfe14">
                  <enum>(E)</enum>
                  <text>prohibit a
				facility from having as a manager or designated representative anyone convicted
				of any felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:i">subsection (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:k">(k) of section 301</cato:entity-ref> or any
				violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1365">
                    <external-xref legal-doc="usc" parsable-cite="usc/18/1365">section 1365</external-xref> of title 18, United States Code</cato:entity-ref> relating to product
				tampering;</text>
								</subparagraph>
                <subparagraph id="id92e5dae1d6614f7b95bb735e3511ee5e">
                  <enum>(F)</enum>
                  <text>provide for mandatory
				background checks of a facility manager or a designated representative of such
				manager; and</text>
								</subparagraph>
                <subparagraph id="idad98831e5b08418999aacd836a09b043">
                  <enum>(G)</enum>
                  <text>require a
				third-party logistics provider to provide the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, upon a request by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, a list of all product manufacturers, wholesale distributors, and
				dispensers for whom the third-party logistics provider provides services at
				such facility.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id948c143b4a7641cc8886f068e3e33487">
                <enum>(3)</enum>
                <header>Procedure</header>
                <text>In
				promulgating the regulations under this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall,
				notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/553">
                  <external-xref legal-doc="usc" parsable-cite="usc/5/553">section 553</external-xref> of title 5, United States Code</cato:entity-ref>—</text>
								<subparagraph id="idc8f083c8c1994ae28b0fadf4954fadcb">
                  <enum>(A)</enum>
                  <text>issue a notice of
				proposed rulemaking that includes a copy of the proposed regulation;</text>
								</subparagraph>
                <subparagraph id="idb1a56325daff479a92d993f232b94a11">
                  <enum>(B)</enum>
                  <text>provide a period of not
				less than 60 days for comments on the proposed regulation; and</text>
								</subparagraph>
                <subparagraph id="ideff0f394b52f4b9396c53830167504dd">
                  <enum>(C)</enum>
                  <text>provide that the final
				regulation takes effect upon the expiration of 1 year after the date that such
				final regulation is issued.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="ida5ceff423dc84482803f1ba22ba5c705">
              <enum>(e)</enum>
              <header>Renewal of
				licenses</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall develop procedures for license
				renewal. Licenses issued under this section shall expire on the date that is 3
				years after issuance of the license. Such an expired license may be renewed for
				additional 3-year periods according to procedures developed by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
						</subsection>
          </section>
          <section id="idbebc2748d5ba419bbfd308593816b39f">
            <enum>585.</enum>
            <header>Uniform national
				policy</header>
						<subsection id="ida7eba37d583e40ec911f4d96541f5350">
              <enum>(a)</enum>
              <header>Product tracing and
				other requirements</header>
              <text>Beginning on the date of enactment of the
				<short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                </short-title>,
				no State or political subdivision of a State may establish or continue in
				effect any requirements for tracing products through the distribution system
				(including any requirements with respect to statements of distribution history,
				transaction history, transaction information, or transaction statement of a
				product as such product changes ownership in the supply chain, or verification,
				investigation, disposition, notification, or record-keeping relating to such
				systems, including paper or electronic pedigree systems or for tracking and
				tracing drugs throughout the distribution system) which are inconsistent with,
				more stringent than, or in addition to, any requirements applicable under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref> (as amended by such Act) or this subchapter (or regulations
				issued thereunder), or which are inconsistent with—</text>
							<paragraph id="id45F25DB9E1C7427D9196A4DD131CA19B">
                <enum>(1)</enum>
                <text>any waiver, exception, or
				exemption pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581" proposed="true">section 581</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">582</cato:entity-ref>; or</text>
							</paragraph>
              <paragraph id="idC61D41DB51CC40E196E5BDC57452811C">
                <enum>(2)</enum>
                <text>any restrictions
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
            <subsection id="idd2c1fcddf95d471ab8ebed5bf4d3f78f">
              <enum>(b)</enum>
              <header>Distribution and
				licensing standards</header>
							<paragraph id="id896cd02a95694462a77495effa35ad93">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Beginning on the date of enactment of the
				<short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                  </short-title>,
				no State or political subdivision of a State may establish or continue any
				standards, requirements, or regulations with respect to wholesale prescription
				drug distributor or third-party logistics provider licensure that are less
				stringent than the standards and requirements applicable under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref>
				(as amended by such Act), in the case of a wholesale distributor, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section
				584</cato:entity-ref>, in the case of a third-party logistics provider.</text>
							</paragraph>
              <paragraph commented="no" id="id2C49451AD5274DF197052D8CCE43ED98">
                <enum>(2)</enum>
                <header>State regulation of
				third-party logistics providers</header>
                <text>No State shall regulate
				third-party logistics providers as wholesale distributors.</text>
							</paragraph>
              <paragraph id="id506663cdf8e14cb984761638501952ca">
                <enum>(3)</enum>
                <header>Administration
				fees</header>
                <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>, a State may administer fee
				collections for effectuating the wholesale drug distributor and third-party
				logistics provider licensure requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e" proposed="true">sections 503(e)</cato:entity-ref> (as amended by
				the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security
				Act</cato:entity-ref>
                  </short-title>), <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">583</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">584</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="id2c56eca5d6784da49ae540dced9526c3">
                <enum>(4)</enum>
                <header>Enforcement,
				suspension, and revocation of licenses</header>
                <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:b/p:1" proposed="true">paragraph
				(1)</cato:entity-ref>, a State—</text>
								<subparagraph id="id578cdff0f637470dae33e88394979a58">
                  <enum>(A)</enum>
                  <text>may take administrative
				action, including fines, to enforce a licensure requirement promulgated by the
				State in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref> (as amended by the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                    </short-title>)
				or this subchapter;</text>
								</subparagraph>
                <subparagraph id="idc80c97fed838400086bff0c36330e877">
                  <enum>(B)</enum>
                  <text>may provide for the
				suspension or revocation of licenses issued by the State for violations of the
				laws of such State;</text>
								</subparagraph>
                <subparagraph id="id46b41927d3d84d47800d0f20d50b54be">
                  <enum>(C)</enum>
                  <text>upon conviction of
				violations of Federal, State, or local drug laws or regulations, may provide
				for fines, imprisonment, or civil penalties; and</text>
								</subparagraph>
                <subparagraph id="id1dde9b9e10fd4849967e8c40c4765d89">
                  <enum>(D)</enum>
                  <text>may regulate
				activities of licensed entities in a manner that is consistent with product
				tracing requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="id7613345DB5774D72A366B935E4C4861E">
              <enum>(c)</enum>
              <header>Exception</header>
              <text>Nothing
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:a" proposed="true">subsection (a)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:b" proposed="true">(b)</cato:entity-ref> shall be construed to preempt State requirements
				related to the distribution of prescription drugs if such requirements are not
				related to product tracing as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:a" proposed="true">subsection (a)</cato:entity-ref>, including any
				requirements applicable under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref> (as amended by the
				<short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Drug Supply Chain Security Act" proposed="true">Drug Supply Chain Security Act</cato:entity-ref>
                </short-title>)
				or this subchapter (or regulations issued
				thereunder).</text>
						</subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="idbc50988f765742969ebc9251bee48e0c">
        <enum>206.</enum>
        <header>Penalties</header>
				<subsection id="id50b00bdd84524b7db102dbda65bbd094">
          <enum>(a)</enum>
          <header>Prohibited
			 act</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:t">Section 301(t)</cato:entity-ref>(<external-xref legal-doc="usc" parsable-cite="usc/21/331">
                <cato:entity-ref entity-type="uscode" value="usc/21/331/t">21 U.S.C. 331(t)</cato:entity-ref>
              </external-xref>)</cato:entity>, is amended—</text>
					<paragraph id="id1a5b7cf278f24a7ba87f612855123962">
            <enum>(1)</enum>
            <text>by striking
			 <quote>or</quote> after <quote>the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">section 503(d)</cato:entity-ref>,</quote>;
			 and</text>
					</paragraph>
          <paragraph id="idf3dbe1b54b024640b82fe19de9d29fdf">
            <enum>(2)</enum>
            <text>by inserting <quote>,
			 failure to comply with the requirements under section 582, the failure to
			 comply with the requirements under section 584, as applicable,</quote> after
			 <quote>in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref>
              </quote>.</text>
					</paragraph>
        </subsection>
        <subsection id="idb7e8574f4aee4968aaf4c485d4664878">
          <enum>(b)</enum>
          <header>Misbranding</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502">Section
			 502</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
                <cato:entity-ref entity-type="uscode" value="usc/21/352">21 U.S.C. 352</cato:entity-ref>
              </external-xref>)</cato:entity>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:103" proposed="true">section 103</cato:entity-ref>, is further amended by adding at
			 the end the following:</text>
					<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id8be843ad3a314d658098b00b879d1f25" reported-display-style="italic" style="OLC">
						<subsection id="id4da15c7bfbf341c98ba1645b626804c2">
              <enum>(ee)</enum>
              <text>If it is a drug
				and it fails to bear the product identifier as required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section
				582</cato:entity-ref>.</text>
						</subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</subsection>
      </section>
      <section id="id919BAF362748462F8C1AB792EDD7E534">
        <enum>207.</enum>
        <header>Conforming
			 amendment</header>
				<subsection id="id98A5831FDA1344A58B360F70EF0223DF">
          <enum>(a)</enum>
          <header>In
			 general</header>
          <text display-inline="yes-display-inline">
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:303/ss:b/p:1/sp:D">Section
			 303(b)(1)(D)</cato:entity-ref>(<external-xref legal-doc="usc" parsable-cite="usc/21/333">
                <cato:entity-ref entity-type="uscode" value="usc/21/333/b/1/D">21 U.S.C. 333(b)(1)(D)</cato:entity-ref>
              </external-xref>)</cato:entity> is amended by striking
			 <quote>503(e)(2)(A)</quote> and inserting <quote>503(e)(1)</quote>.</text>
				</subsection>
        <subsection id="idCCF9C9EF9B2C4D1F917600A99101FA89">
          <enum>(b)</enum>
          <header>Effective
			 date</header>
          <text>The amendment made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:207/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall take effect on
			 the day that is 1 year after the date of enactment of this Act.</text>
				</subsection>
      </section>
      <section id="id5374815F273F423C980ED14B747BC243">
        <enum>208.</enum>
        <header>Savings
			 clause</header>
        <text display-inline="no-display-inline">Except as provided in
			 the amendments made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:204/ss:a/p:1" proposed="true">paragraphs (1)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:204/ss:a/p:2" proposed="true">(2)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:204/ss:a/p:3" proposed="true">(3) of section 204(a)</cato:entity-ref> and by
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Quality, Security, and Accountability Act/s:206/ss:a" proposed="true">section 206(a)</cato:entity-ref>, nothing in this title (including the amendments made by this
			 title) shall be construed as altering any authority of the Secretary of Health
			 and Human Services with respect to a drug subject to <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1) of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353">
              <cato:entity-ref entity-type="uscode" value="usc/21/353/b/1">21 U.S.C. 353(b)(1)</cato:entity-ref>
            </external-xref>)</cato:entity> under any other
			 provision of such Act or the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Public Health Service Act">Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/201/etseq">42 U.S.C. 201 et
			 seq.</cato:entity-ref>)</cato:entity>.</text>
			</section>
    </title>
  </legis-body>
  <official-title-amendment>Amend the title so as to read:
	 <quote>A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to
	 compounding drugs and the pharmaceutical distribution supply
	 chain.</quote>.</official-title-amendment>
	<endorsement>
		<action-date>June 19, 2013</action-date>
		<action-desc>Reported with an amendment and an amendment to the
		  title</action-desc>
	</endorsement>
</bill>
</doc>